,expected_information_gain
should,0.05083059680530222
be,0.03862819911547477
following,0.021062990848687124
plasma,0.02046320455420436
interact,0.02025292204170215
:,0.019742020283875616
protease,0.016667945633160097
may,0.013164932437837118
effects,0.013131058102743398
oral,0.012999876572558522
levels,0.01250580044234606
%,0.011921951381587914
",",0.011828395529154712
HIV,0.011642182605834828
thyroid,0.011619545605116244
medications,0.011407994434273983
Johns,0.011233472525997712
classified,0.011174114740980734
Contin,0.011151911705344242
include,0.011134588992619099
(,0.011003961696251063
),0.010996720674924743
inhibitors,0.01091265163264632
chloral,0.010890624020208572
MS,0.010873552921702112
steroids,0.01071940908800495
unreliable,0.010696683788576689
man,0.010587499534161604
*,0.010549836736960971
St.,0.01041782078894693
AUC,0.01037373912308015
wort,0.010338893511819602
hydrate,0.010151971785199332
ie,0.009909939345244312
concentrations,0.00977413421786233
warfarin,0.009563200215521483
is,0.009436323658445711
dietary,0.009387740229031771
hot,0.009385756054520189
vaccine,0.00937424379544649
influenza,0.00937424379544649
elements,0.009366101517992553
anabolic,0.009366101517992553
inhalation,0.009366101517992553
triclofos,0.009366101517992553
deficiencies,0.009366101517992553
oxolinic,0.009366101517992553
narcotics,0.009366101517992553
overdosage,0.009352146611632972
weather,0.009347210311532184
drugs,0.009343566103741763
acid,0.009334685444733926
;,0.009328800032453954
affecting,0.009313165599333706
nalidixic,0.009296260622593366
caution,0.00926535962503705
mefenamic,0.009258442960303093
oxidase,0.009238645535121881
monoamine,0.009221746616237758
of,0.009176120225634521
with,0.009162075635681277
determinations,0.008943354453275432
virus,0.008919270517920297
found,0.008798050793674017
response,0.008681432502377073
metabolism,0.008666829354233574
CYP3A4,0.008648187485816194
sodium,0.008631652695411773
reportedly,0.008563204389538615
hepatotoxic,0.008434968015309185
expected,0.00828614566463104
C,0.008100156434311723
CYP,0.0080881495545998
time,0.007970465720805286
long,0.007936635781535584
acting,0.00790891563404339
aminosalicylic,0.007902110559097952
ethacrynic,0.007835782640721045
trimethoprim/sulfamethoxazole,0.007799729740646133
prothrombin,0.00775122169520559
enzymes,0.007735532112139287
action,0.0076917024844118664
prolonged,0.007658557694888546
Agents,0.00757071252862529
not,0.007520335515622256
increase,0.007237897178640318
decreased,0.007224576523233606
no,0.007040920314822174
interactions,0.007036728884088683
blood,0.006882332422434523
that,0.006675087716673578
medicines,0.006640014405955963
induction,0.006554125684320233
absorption,0.006547525152964528
Caution,0.006365583195051316
clearance,0.006344820921699523
enhance,0.006329463805649027
vitamin,0.0060424005652308654
Drugs,0.005922240341498908
studies,0.005756139480868172
4,0.005703285760694898
Therefore,0.005700872501913867
supplements,0.0055002744236690715
5,0.005497038365846252
recommended,0.005483268718396661
depression,0.00535700658362015
patients,0.005356082214961755
due,0.005330686237731919
neuromuscular,0.005315376929686644
pharmacokinetics,0.0052965230043835465
blocking,0.005227375440584825
local,0.005206097759766215
receiving,0.005204707664189789
depressants,0.0051937525891149194
CNS,0.005036664311540595
by,0.004987956453136544
central,0.0048492859753132
nondepolarizing,0.004793927768070083
monitored,0.004750156399901173
Cmax,0.004732749518175483
additive,0.004653821871331898
3,0.004604602332769159
in,0.004584211291468576
other,0.004556449044163968
agents,0.004498495219937171
used,0.004474220708831189
were,0.004465578072801346
dose,0.004394726878513278
approached,0.004327277817455455
presence,0.0042917785659752905
narcotic,0.004260813159239207
decrease,0.004246388807198964
others,0.004218728552694562
salts,0.004211435514775097
interaction,0.004207774088204275
metabolized,0.004148596542214222
when,0.004100507783591167
type,0.00406594027376872
antihypertensive,0.004010354520410209
or,0.003979807808326297
colistimethate,0.003950955956058433
did,0.003907044024020978
anti-diarrhea,0.0038752949574629714
kaolin-pectin,0.0038752949574629714
absorbent-type,0.0038752949574629714
The,0.003864330173283692
are,0.0038321453162697416
bleeding,0.003823083568984087
inducers,0.003813566802443713
general,0.0037946480014163786
evaluating,0.003723214845873457
1,0.0036662370286730805
administered,0.00361839250840168
enzyme,0.003559916979999578
increased,0.003482923207937527
Type,0.003468706339518013
advised,0.0034629377798531813
Other,0.003444680503534414
1C,0.0034428980136111953
antiarrhythmics,0.0034327635771025378
concomitantly,0.0034211175953035022
chloride,0.0033253889836661887
such,0.003323587999310318
potassium,0.003319388890417274
grapefruit,0.0032627140391565668
juice,0.0032627140391565668
reported,0.0032525234889231314
was,0.0032433669875207016
estradiol,0.0032375341740209507
nervous,0.003192445140109079
including,0.0031161463493727393
excretion,0.0031095077637701696
considered,0.003082369427889642
you,0.003073524268686345
antifungals,0.0030622223429103146
tricyclic,0.0030411847175031426
mg,0.003011958426701211
KT,0.0029893546381082325
levonorgestrel/ethinyl,0.0029893546381082325
to,0.0029818277860094167
certain,0.0029652716185855077
If,0.0028976805845406517
muscle,0.0028938501660970006
relaxants,0.0028775907406555223
analgesics,0.0028690150773709178
serious,0.00283865210088019
taken,0.0028379928246057284
affect,0.002826641339411462
pharmacokinetic,0.00282134133634937
as,0.002812889759277293
tubular,0.0027646210976568497
within,0.0027599938987628025
adjustment,0.002755973212624996
effect,0.00274297079087904
half-life,0.002737633483204993
azole,0.00273298339867567
antidepressants,0.002718144146521717
therapy,0.002704018124998764
Because,0.0026864629366400994
approximately,0.0026698890435452594
MAO,0.0026423140018665414
resulted,0.0026212836597536704
No,0.0026183733934654896
narrow,0.0026176249831580956
strong,0.002610858478381606
it,0.0026043315945768475
combination,0.0025808242215387134
and,0.0025705172925705178
acetylsalicylic,0.002567323229314411
needed,0.0025603729394308994
concentration,0.0025586959362786654
metabolite,0.0025550750438072534
on,0.0025396497799556883
can,0.002539469961876817
been,0.002539466284548375
.,0.0025374305396125285
3A4,0.002533599867540426
any,0.002530017356762504
the,0.002500832821540455
thinners,0.0024947094636579292
drug,0.0024822396857993034
hours,0.002479457316868383
e.g.,0.002469431612709738
depressant,0.002462451300784707
because,0.0024505931224749755
induce,0.002450390728885976
cytochrome,0.002447638077853753
a,0.0024457055564031105
performed,0.0024409363468909095
20,0.0024380076329959532
fatal,0.002421110453155184
birth,0.0024138632784131975
syndrome,0.0023997159506752297
administering,0.0023963337624847147
produce,0.002384931653931277
false,0.002383407081468669
pancreatic,0.0023769644306982363
sunscreens,0.0023759387318444958
sulfa,0.0023759387318444958
para-aminobenzoic,0.0023759387318444958
-containing,0.0023759387318444958
block,0.002366302824939659
respectively,0.0023591999726630952
pills,0.00235826211532264
P450,0.0023561642181726405
potentiated,0.0023532800891182815
avoided,0.002342221902505548
significant,0.002336099200791142
index,0.0023127828960751717
exercised,0.002309113528228046
Based,0.002306432729650254
beta,0.0023000088952735975
bioavailability,0.0022982026274223077
Patients,0.002294189521268253
your,0.0022798023734809103
significantly,0.0022746028080873337
isoenzyme,0.0022617415540782115
risk,0.0022505514323893916
clinical,0.002239973227823322
Data,0.0021987164009410476
give,0.0021956588464094873
care,0.0021896457271607384
vitro,0.0021858400840355507
retinyl,0.0021736603938677934
reduce,0.0021664132141760994
doctor,0.0021478628277505907
before,0.0021448677698538976
healthy,0.0021158559462118864
excessive,0.0020987502162367333
reports,0.0020957261050329468
contraindicated,0.0020618722079974727
ergot-type,0.0020415336899362035
potential,0.0020158182226531762
daily,0.001994610336446434
exposure,0.00197465036507416
theoretical,0.001964499972990419
blurred,0.0019570551850541795
vision,0.0019570551850541795
suggest,0.0019438852102563464
ergotamine-containing,0.0019425674696524897
proliferation,0.0019414337018156536
binding,0.0019243377962007147
control,0.0019181636157394877
have,0.0019145516926519779
pain,0.0018838741163025308
active,0.0018825099887154195
if,0.0018688645628719414
dosage,0.0018659088252963585
potent,0.0018604532902531945
cause,0.0018572698477244964
result,0.00185070839219581
hepatic,0.0018503336887571997
nicotinic,0.00184765512848295
dry,0.0018383333238757293
adrenergic,0.0018363928700781962
skeletal,0.001832133845588002
co-administration,0.0018218499054153403
taking,0.001821285004760198
reactions,0.001819896840786206
possible,0.0018180889850811788
associated,0.0018078681708617594
hyperpyrexia,0.0017963668652996034
occurring,0.0017895614184375574
chboramphenicol,0.0017895614184375574
evidence,0.0017891645655060406
sedative,0.001785340774269617
colistemethate,0.0017836006478476607
hypotension,0.0017765636466771095
mouth,0.001770786054418494
diminish,0.0017698728826665011
use,0.0017522182566919176
carefully,0.001751770287887311
period,0.001751550005132163
treatment,0.001746989139434496
selegiline,0.0017365492666313598
Since,0.00173259638316825
sleeping,0.0017314261084320215
30,0.0017290186112327577
B1,0.0017290113828505316
substances,0.0017183870352466268
pressor,0.001711863481706155
causing,0.0017111024607292524
temperature,0.0017093833702415129
secretion,0.0016991956148026954
mean,0.0016970341942667
sedation,0.0016887185395233484
least,0.0016810370330659907
Consequently,0.001674987313368459
serotoninergic,0.001668287187061912
substrates,0.0016681831836318217
study,0.001666076672849237
e.,0.001665252418448504
end,0.0016605585809359447
will,0.0016586344396665176
closely,0.0016529539229281909
angiotensin-converting,0.0016434128735756115
humidity,0.0016366203377385924
dental,0.0016366203377385924
g.,0.0016137649029946965
CYP2D6,0.0016073459524450495
adrenocortical,0.0015994986091725227
agonist,0.001591490174580934
nonsteroidal,0.0015820921749538641
known,0.0015796197642885534
antagonized,0.0015765482896562544
Depressants,0.0015709531530456733
Nervous,0.0015709531530456733
prothrom-bin,0.0015696139442755719
preparations,0.0015668611325049264
Loop,0.0015644522245360504
System,0.0015627801664193086
under-dosage,0.0015503317399030436
diet,0.0015503317399030436
-,0.0015494745049311476
In,0.001549380567128611
being,0.001542180295800999
Antidepressants,0.0015421489725195858
antiparkinsonian,0.0015383789481865362
reuptake,0.0015214493739049706
Tell,0.0015192867895603701
intraconazole,0.0015192867895603701
shown,0.001508314957931356
coma,0.0015053405494555028
cautiously,0.0015039922756056034
nonselective,0.001503592967054268
basic,0.0015027189605480995
acidic,0.0015027189605480995
observation,0.001499133273909159
blockers,0.0014957862533542254
severe,0.0014941833888454381
exposed,0.0014823047491502317
epithelium,0.0014800141517383736
required,0.0014737250230031362
activity,0.0014643547065440465
had,0.001461426861831261
serotonin,0.0014614207095775544
B,0.0014475072195270222
who,0.0014473014692882868
test,0.0014430511569337723
an,0.0014355308863213123
modest,0.0014350846395405625
warranted,0.0014347563606492697
adverse,0.001430793638843797
psychotropic,0.001428737572571892
hypoglycemic,0.0014252512815381424
potentiate,0.0014241523557433355
agonists,0.001420013896352601
initiated,0.0014178810822018661
serum,0.0014167957717735602
which,0.0014160116910429954
undertaken,0.0014052927020131722
intake,0.001404156438804094
Tricyclic,0.0013999407431068978
sinus,0.0013939374712242936
decongestant,0.0013939374712242936
allergy,0.0013939374712242936
3A,0.0013918464548986487
necessary,0.0013916619220347703
incidence,0.0013886458355458764
appropriate,0.0013747701691959602
does,0.0013718974968713882
psychotic,0.001370212630359413
many,0.0013671327147877221
NOT,0.0013661864805977197
sedating,0.001359807535530666
inhibit,0.0013582434646525199
administration,0.0013554038382008748
patient,0.001342092479170387
Central,0.0013356095864164308
i.e.,0.0013343801494967167
systemic,0.0013285455399230095
effectiveness,0.0013262057461816967
2,0.001324362796654488
drug-drug,0.0013215275837092921
folic,0.0013176998212732771
cold,0.001309724051146599
delay,0.0013021116730238536
episodes,0.001296784348067903
extensively,0.0012955991426116809
like,0.0012917290679831384
gastrointestinal,0.0012909824724485208
more,0.0012870776300137887
at,0.001285349274169123
inhibits,0.0012812727288282755
volunteers,0.0012774074567942773
antipsychotic,0.0012768608671981374
24,0.0012709216880590901
conducted,0.0012675641851077613
Coadministration,0.0012648478435882682
examples,0.0012627436331887898
Diuretics,0.0012526402722945473
decreases,0.0012489361159739865
hydrochloride,0.001248284251915921
tell,0.0012436039462583315
Before,0.0012436039462583315
has,0.0012421226639094396
Agonist/Antagonist,0.0012420243669327702
Analgesics,0.0012420243669327702
Opioid,0.0012420243669327702
Mixed,0.0012420243669327702
Agonist/antagonist,0.0012420243669327702
substrate,0.0012410861109146687
results,0.0012394482350500668
],0.0012383105852540321
[,0.0012383105852540321
secondary,0.0012374425975534287
clinically,0.0012367702021426341
interfere,0.0012346981321975647
death,0.0012320824272020747
therefore,0.0012239512380144424
related,0.0012236759854107326
referred,0.0012205253130164184
make,0.0012205253130164184
exceed,0.0012192113714531994
course,0.0012147702272817806
multiple,0.0012140156636237798
avoid,0.0012138835135915294
CYP3A,0.0012120023748918296
ovarian,0.0012083108574401091
below,0.001207020449338847
women,0.0012056560760606017
antianxiety,0.0012036378025243044
system,0.0011975708932125961
complications,0.0011957498674430855
therapeutic,0.0011919793305795734
choline,0.0011908966713469749
magnesium/choline,0.0011908966713469749
anti-infectives,0.0011906723823149612
synthetase,0.0011906723823149612
calcium-channel,0.0011906723823149612
a-blockers,0.0011906723823149612
Certain,0.0011894266534091535
dose-dependent,0.0011888754726172568
listed,0.0011872331354370047
concurrently,0.0011850125888236418
increases,0.0011847718402431262
antagonize,0.0011830389462748059
dopamine,0.0011821259249109595
alone,0.0011811906529405336
range,0.0011781495879513715
sympathomimetic,0.001175301123679251
during,0.001173158040979616
renal,0.0011685587318519541
mg/day,0.0011646709347732376
thiazide,0.0011589623645766878
anticipated,0.0011588583124929608
containing,0.001157010541884107
blood-glucose-lowering,0.0011569628317362746
must,0.0011550187499237419
resulting,0.0011541820286041782
opioid,0.0011534740682680455
K,0.0011483502506710597
single,0.001146716948480453
produced,0.0011425888021356911
inducer,0.0011423295953092438
most,0.0011386304974992933
require,0.0011355209441844538
sometimes,0.001123960364297294
exhibit,0.0011233942921202722
retard,0.0011230940236753861
trials,0.0011210167893963563
than,0.001117906958009618
function,0.0011167616532503644
each,0.0011151262437713028
for,0.0011127500334624507
polymyxin,0.0011110851777903497
amphotericin,0.0011054186675545363
acute,0.0011046652289306014
pH,0.0011027751466895497
loop,0.0011011673440967096
treated,0.001095717211386349
CNS-depressant,0.0010933756957181018
80,0.001085458552396057
magnesium,0.0010851418904874732
These,0.001083623965683067
using,0.001081170934258635
extreme,0.0010804097844208105
monitoring,0.0010801220630789476
showed,0.0010798827330483762
glaucoma,0.001075004756829312
ergot,0.0010739674644048014
rarely,0.0010721074680486442
extent,0.0010719130050955705
lower,0.0010708499509762825
veratrum,0.0010663070273408959
60,0.0010599256915976296
reduced,0.001055173499703077
profound,0.0010540571853702163
bismuth,0.0010510464500939065
subsalicylate,0.0010510464500939065
eg,0.0010472878061633661
natriuretic,0.001045562992333715
induced,0.0010452234393990567
between,0.0010435776832442567
sleep,0.001041470952202861
aid,0.001041470952202861
anti-depressants/anti-anxiety,0.001041470952202861
phenothiazine,0.001041470952202861
overactive,0.001041470952202861
drowsy,0.001041470952202861
drowsiness-causing,0.001041470952202861
For,0.001040137797510221
weakness,0.001036238258812272
hyperreflexia,0.001036238258812272
incoordination,0.001036238258812272
macrolide,0.0010352207049078022
experience,0.0010344294607903537
medicine,0.0010340445526554332
initiating,0.0010327301835373337
ethyl,0.0010312206937784785
max,0.0010292232255117995
dosing,0.0010273729449057356
anticholinergic,0.0010272242618193372
some,0.00102567864843639
Concurrent,0.0010254404957651397
etc,0.0010251373777908634
discontinued,0.0010248526314319273
AUC0-,0.0010233304600966164
doubled,0.0010233304600966164
le,0.0010233304600966164
cations,0.0010108551396746934
ACE,0.0010088059170676456
actions,0.0010049145669175363
Available,0.001004102739318169
coadministration,0.001003478151924475
elimination,0.0010008570465820377
10,0.0010001503116309207
It,0.0009989045270539787
stable,0.0009985455756214012
steady-state,0.0009964063320879735
together,0.00099610626767066
blockade,0.0009906209101833152
50,0.0009905258550957363
respiratory,0.0009850079748295881
investigated,0.0009818531931101715
reacts,0.0009817478127576162
neutral,0.0009817478127576162
medication,0.0009794036637542636
analgesic,0.0009748482915105106
platelet,0.0009709765797999426
Additive,0.0009683708309285999
received,0.0009662195075426094
combined,0.0009645907425616107
diabetic,0.0009637433803714179
prostaglandin,0.0009632700021929841
infusion,0.0009593051795659946
either,0.0009591474079547746
--,0.000955234983108455
commonly,0.0009550869389700622
Use,0.0009527832505207279
occur,0.0009483668296670356
influence,0.0009440241704898877
transdermal,0.0009436400688109803
generally,0.0009388612309584321
Human,0.0009380063434584196
Interactions,0.0009379303385401716
calcium,0.0009358614622203554
adjusted,0.0009355957321774966
analog,0.0009321234790554689
conjugated,0.0009321234790554689
possibility,0.000931750026772038
danger,0.0009315265589819877
diuretics,0.0009285726349086421
protein,0.000926693643026888
cholinesterase,0.0009235380016966444
faster,0.0009212524315140858
Nephrotoxic,0.0009205620076295773
LA,0.0009205620076295773
DETROL,0.0009205620076295773
interval,0.0009173717657999791
hypotensive,0.0009157451141679207
until,0.0009143752173301767
once,0.0009135725123917693
CYP2C9,0.0009132536026900118
potentiating,0.0009104223835019187
expect,0.0009031074643249815
begins,0.0009031074643249815
reasonable,0.0009031074643249815
dinitrate,0.0009023112577591919
transcriptase,0.0009023112577591919
glyceryl,0.0009023112577591919
Example,0.0009023112577591919
trinitrate,0.0009023112577591919
Examples,0.0009023112577591919
acidifying,0.0009020176382769085
hypertension,0.000898544639636234
latter,0.0008920256188937881
ferrous,0.0008905425369133413
Avoid,0.0008893323367551442
specific,0.0008876400165289677
altered,0.0008846280205550006
conduction,0.0008836411817084722
acetate,0.0008801978464129112
nitrous,0.0008756191626677623
state,0.000875300589864958
well,0.0008744831070304215
2D6,0.0008744307199805013
elapse,0.0008739602722532824
diuretic,0.0008709993352472578
titrated,0.0008709215193996034
When,0.0008701746702631796
enhanced,0.0008699116654236061
injectable,0.000868549950866937
intravenous,0.0008680136339875855
alcohol,0.0008679972275079662
antidiabetic,0.0008674719719307111
chewable/buffered,0.000858841169800173
powder,0.000858841169800173
evaluated,0.0008553234328405601
centrally,0.0008523376370749292
might,0.0008486937621018376
myocardium,0.0008481163206235376
media,0.0008467885255462049
s,0.0008440169207126758
another,0.0008392739149256645
inhibition,0.0008335913768511283
levothyroxine,0.000832765758668419
penicillin,0.0008282623561199909
G,0.0008282623561199909
isozyme,0.0008274659561432474
close,0.0008268340866444124
intensify,0.0008230890581847339
inhibitor,0.000822084970764636
total,0.0008207196241515335
500,0.0008194726371357763
maleate,0.0008191187232874375
channel,0.0008181968698722786
duration,0.0008163683061862548
sulfate,0.00081467160509896
Absorption,0.0008107793799079221
initial,0.0008092909237654711
indicated,0.0008084867001374452
modification,0.0008057778672905247
themselves,0.0008057778672905247
regulate,0.0008057778672905247
prostate,0.0008057778672905247
through,0.0008046505621996936
antiarrhythmic,0.0008034903773769253
since,0.0008031221856156234
steady,0.0008029424450015643
multivitamin,0.000802347296264605
metal,0.000802347296264605
its,0.0007997216511088645
solution,0.000799548811006412
classes,0.0007986213179465018
myocardial,0.0007984449976203845
these,0.0007969214801228919
Close,0.0007924584229650478
pressure,0.0007919667562651389
biloba,0.000790589237169792
Ginkgo,0.000790589237169792
Allium,0.000790589237169792
herbs,0.000790589237169792
sativum,0.000790589237169792
garlic,0.000790589237169792
subjects,0.0007892442735867311
see,0.0007889562104941295
this,0.0007885302442567355
Selective,0.0007872480337867138
initiation,0.0007869912895179798
antineoplastic,0.0007838135528148715
Concomitant,0.0007835232776485235
inotropic,0.0007830741627210536
days,0.0007816121340380455
H2,0.0007810984310185898
fold,0.0007806028671384357
hydrocarbon,0.0007793105579556592
halogenated,0.0007793105579556592
involving,0.0007787037649262807
divalproex,0.0007773025047983495
15,0.0007766528637501713
toxicity,0.0007754092554205227
enhances,0.0007734755078179223
M,0.0007734755078179223
hydroxychloroquine,0.0007731735409641782
Sj,0.0007731735409641782
estrogens,0.0007731735409641782
grens,0.0007731735409641782
artificial,0.0007731735409641782
tears,0.0007731735409641782
14,0.0007705040821870401
potentiates,0.0007703748510587971
Urinary,0.0007690323552391742
determinant,0.0007690323552391742
esters,0.0007690323552391742
irrational,0.0007674914780931852
hallucinations,0.0007674914780931852
antidepressants.When,0.0007674914780931852
without,0.0007669895227323531
increasing,0.0007663768939956128
alkaloids,0.000765850484387931
but,0.0007645481938224341
Potential,0.00075996596824357
non-steroidal,0.0007595965090887447
urinary,0.0007593919427445472
then,0.0007569493565319219
pharmacodynamics,0.0007565342608013559
40,0.0007545521582685843
formal,0.0007528751166296921
intestinal,0.0007493763898231975
potassium-sparing,0.0007473281002212673
gastric,0.0007468840039088764
convulsions,0.0007450248870739529
desired,0.0007426952515832141
ordinarily,0.0007418240199748016
high,0.0007415850851233419
effective,0.0007412173477799877
liver,0.0007392612963301737
markedly,0.0007389821769052674
prostatic,0.0007388854749474927
similarly,0.0007380825531094759
amines,0.000734351640257147
Nevertheless,0.0007320876888334826
treat,0.0007316815554330169
isosorbide,0.0007309426132915409
Administration,0.0007271976191126628
there,0.0007261644426171943
's,0.0007261451032091193
onset,0.0007258915604232419
18,0.0007250682573222145
frequently,0.0007244489959410405
led,0.0007225136090287521
adrenocorticoids,0.0007216937457329431
cortisone-like,0.0007216937457329431
antidepressant,0.0007193281228916604
Co-administration,0.0007178242029695081
from,0.0007176798758694591
ethinyl,0.0007154064475606292
hydroxide,0.000713211486670029
reduction,0.0007128604262375271
multivalent,0.0007127490411403814
separate,0.0007124529555653236
experienced,0.0007096749247967882
autonomic,0.0007092948403912835
only,0.0007078014634770424
compared,0.0007074532469953931
oxide,0.0007067109254583759
area,0.0007027516941700007
behavior,0.0007024985195348554
synergistic,0.0007024985195348554
non-selective,0.0006992293985237374
primary,0.0006992186350532892
sites,0.0006979688340900125
capsule,0.0006972311324220382
Injection,0.0006954579849299813
whose,0.0006948591237353474
succinate,0.0006920805263166407
iron-containing,0.0006915726221004004
constipation,0.0006909676591630998
augment,0.0006909676591630998
hormones,0.0006899688243398039
200,0.0006896256890949193
displacement,0.0006883088632418932
limited,0.0006880447902165576
advisable,0.0006861636959126782
AV,0.00068567510981421
curve,0.0006849082356321645
monitor,0.000684836389446053
shortness,0.0006815390203466221
Radiation,0.0006815390203466221
Live,0.0006815390203466221
Bone,0.0006815390203466221
dyscrasia,0.0006815390203466221
myelotoxicity,0.0006815390203466221
Killed,0.0006815390203466221
Neurotoxic,0.0006815390203466221
13,0.0006813852478072535
anesthesia,0.0006811802136383882
43,0.0006805197315948863
analyses,0.0006803850004392098
coadministering,0.0006795957144081211
#,0.0006795957144081211
href=,0.0006795957144081211
doxorubicin,0.0006794066776557584
HCL,0.0006785731829723751
Products,0.0006785164242130159
develop,0.0006783462731657641
peak,0.0006771825137179555
Ophthalmic,0.0006766606228576499
species,0.000676418541667001
basis,0.0006763703986027991
neurologic,0.0006745497007749623
nephrotoxic,0.0006743771222827988
change,0.0006728560939897044
breath,0.0006722837993993203
placebo-controlled,0.0006713853950783832
different,0.0006676977507368287
values,0.0006660825062092535
..,0.0006643436549405024
one,0.0006632357734522865
normal,0.0006618909566395992
anesthetics,0.0006605063984452819
beta-adrenergic-blocking,0.0006596727467454988
importance,0.0006596559705536187
John,0.0006581616430610948
termed,0.0006567570375869414
augmented,0.0006567570375869414
constellation,0.0006567570375869414
Synergism,0.0006567570375869414
sumatriptan,0.0006567570375869414
Perhexiline,0.0006557045945143614
medical,0.000655339664514254
stopping,0.000655339664514254
switching,0.000655339664514254
Inducers,0.0006540721337040534
cough,0.0006540394939277272
channel-blocking,0.0006540394939277272
vasodilators,0.0006540394939277272
antigout,0.0006540394939277272
motion,0.0006540394939277272
sickness,0.0006540394939277272
majority,0.0006540394939277272
parentheses,0.0006540394939277272
115,0.0006540394939277272
CONTRAINDICATIONS,0.0006538785949163906
unless,0.0006538785949163906
depress,0.0006538785949163906
several,0.0006530650240530456
benzodiazepine,0.0006528990145360236
angina,0.0006522508915163261
Magnesium-,0.0006507401709969773
cholinergic,0.0006506037580109592
digitalis,0.0006498977923296012
antinociceptive,0.0006495963134789395
particularly,0.0006493616629660304
supervision,0.0006482076269225256
assessed,0.0006480087239508769
Drug,0.0006479871114446478
rare,0.000647669608258683
usually,0.0006469350202931157
bound,0.0006465448128559759
predictable,0.0006463070422881856
Tablets,0.0006457691705519242
counteract,0.000642711447076505
vascular,0.0006413711007823286
dopaminergic,0.0006412187089760435
IIb/IIIa,0.0006412187089760435
6,0.0006409779779010805
exhibits,0.0006405839510145173
important,0.0006404698827457977
vaccines,0.0006403083736030712
users,0.0006401445384751625
twice,0.000640120962732027
aluminum-containing,0.0006399004262147567
bradycardia,0.0006323942167787422
rate,0.000632171956325922
abnormalities,0.0006310848945296765
25,0.0006300626875528348
medroxyprogesterone,0.0006296795949296552
about,0.0006283145165039139
products,0.0006260777495714631
Population,0.0006244923853313544
mycophenolate,0.0006242664728295377
approximate,0.0006233911708442008
seizures,0.0006226711169614596
prevented,0.000622563930623321
Day,0.0006211150206901772
5-HT1,0.000620519953080656
categories,0.0006199968078102192
side,0.0006195587701514071
22,0.0006174688804752027
catecholamines,0.0006159582505160799
Monoamine,0.0006154029710796483
Hg,0.0006151226067923066
Solution,0.0006105822123808613
starting,0.0006099702051144407
BID,0.0006075439902694102
thereby,0.0006069696721971996
electrolyte,0.0006068038904625261
initiates,0.0006056782601007171
discontinues,0.0006056782601007171
impair,0.0006045964125854786
do,0.0006031263295547262
QTc,0.000602302351702444
Macrolide,0.0006015969547549238
P-450,0.0006015084154157302
vaccination,0.0006006287905702123
replication,0.0006006287905702123
bronchospasm,0.0006006287905702123
interferes,0.0006003461480823535
sensitize,0.0006000982734922777
reverse,0.000599631807446932
anti-inflammatory,0.000598090745063673
pure,0.0005977387484130681
adversely,0.0005976307356463373
similar,0.0005976020118240166
window,0.0005964408243669395
cheese,0.0005964408243669395
amine,0.0005964408243669395
imipramine,0.0005964408243669395
bananas,0.0005964408243669395
yogurt,0.0005964408243669395
wine,0.0005964408243669395
ripe,0.0005964408243669395
exposures,0.0005957956224218464
topical,0.0005957643528045065
Vitamin,0.0005953553192161731
and/or,0.0005952962642682413
PK,0.0005944976456255802
influenced,0.0005944976456255802
mofetil,0.0005944976456255802
0.5,0.0005937794622288273
aluminum,0.0005922148864304644
evaluate,0.0005917136495192654
Pharmacodynamic,0.0005916231444237363
hypnotics,0.0005916231444237363
thioxanthene,0.0005916231444237363
nonbarbiturate,0.0005916231444237363
phenothiazines,0.0005916231444237363
butyrophenone,0.0005916231444237363
salt,0.0005914106671760511
mm,0.0005905756880886237
particular,0.0005904837414245634
sustained,0.0005893571271656795
potentially,0.0005891982788625016
need,0.0005891566584070862
partially,0.0005888036019837672
caused,0.0005885198007951065
1.25,0.0005874630718392115
very,0.0005868799944154235
ileus,0.0005868799944154235
prescribed,0.0005865691476243384
chronic,0.0005850883727438472
produces,0.000584488292503238
Cmin,0.0005840171972608665
tail-flick,0.00058306799661767
depresses,0.00058306799661767
content,0.0005820405104852711
thus,0.0005813439049126012
nefazadone,0.0005807742589307718
amount,0.0005804319516071743
prolongation,0.0005799953412582992
400,0.0005797467029853287
serotonergic,0.0005782525619427714
nitroprusside,0.0005775681156798829
coumarin,0.0005772629736526813
arrhythmias,0.0005749092278669599
profile,0.0005746540901803154
selective,0.000574426713063847
dose-related,0.0005742611420007648
Plasma,0.0005739413948749883
Hormonal,0.0005708061710567591
lowered,0.0005703252860020935
discontinuing,0.0005699712856889194
likely,0.0005661994023921091
Isozymes,0.0005655152762725768
elevated,0.0005614203528385708
marrow,0.0005613441745628833
inhibited,0.0005612954051976704
Previous,0.0005605510189866658
Blood,0.0005598704922253894
PT,0.000558348730424596
21,0.0005578815945403992
Accordingly,0.0005578779464615602
23,0.0005576302682146483
Days,0.0005558287203396572
susceptibility,0.0005548123978109665
sulfonylurea,0.0005548123978109665
St,0.0005548123978109665
tromethamine,0.0005515803254094731
antiinflammatory,0.000548841945723133
52,0.0005477280009773544
chance,0.0005477280009773544
cardiovascular,0.0005472148648767439
mitogenic,0.0005466485389267195
two,0.0005457625350109296
Serious,0.0005449140241599038
Catecholamine-depleting,0.0005449140241599038
sulfonamide,0.0005448922501706255
somatostatin,0.0005448922501706255
Secretion,0.0005448603519740969
Active,0.0005448603519740969
Tubular,0.0005448603519740969
Eliminated,0.0005448603519740969
doses,0.0005439305126493377
125,0.0005435162307381169
principal,0.0005425601109407818
ability,0.0005414781720982642
post-marketing,0.0005400466539173809
reductions,0.0005394995014560422
29,0.0005386651083725269
possibly,0.0005386305270977942
Given,0.0005380512201114129
hydrogen,0.0005380512201114129
tablets,0.0005360896013000271
35,0.0005358721526829147
delirium,0.0005343421916110813
metabolic,0.0005338207841104614
antimycotic,0.0005337589867490111
considerably,0.0005337589867490111
causal,0.000533733040316231
aminoglycoside,0.000533733040316231
vivo,0.0005336438202721006
cmax,0.0005336048143441685
2-fold,0.0005334092884876629
contain,0.0005324433904807524
proof,0.0005324433904807524
vitamins,0.0005299432573054874
pharmacodynamic,0.0005294092450005561
elevation,0.0005279559481551344
weeks,0.0005273112376593669
38,0.000527043198248478
whereas,0.0005262309491566031
protein-bound,0.0005236304325940688
displaced,0.0005210920805258645
hormone,0.0005206276076028526
Using,0.0005206276076028526
Chloral,0.000520120769230692
migraine,0.0005198645489901121
maintained,0.0005183566677435802
standing,0.0005180050134148129
systolic,0.0005180050134148129
shorter,0.0005180050134148129
D2-antagonists,0.0005138168630065554
Seizure,0.0005138168630065554
Lower,0.0005138168630065554
antimycotics,0.0005138168630065554
circulatory,0.0005138168630065554
Threshold,0.0005138168630065554
frova_od.htm,0.0005138168630065554
pediatric,0.0005128994489773664
A.C.,0.0005128829801702706
27,0.0005128829801702706
Substances,0.0005105246845730216
studied,0.0005095365253973139
foods,0.0005087231561786698
Important,0.0005084368971822739
VERSED,0.0005077741166121807
Syrup,0.0005077741166121807
accentuated,0.0005077741166121807
higher,0.0005060049724757709
analysis,0.0005052163155476741
identified,0.0005050889348134913
coadministered,0.0005030345460270702
103,0.0005026288273727308
beta-adrenergic,0.0005020250017025996
diabetes,0.0005018331537880449
organ,0.0005001623852571857
There,0.0004989759147129291
INR,0.0004988517503872192
depend,0.0004981642584926949
70,0.0004978554659590406
Gastrointestinal,0.0004976823149058784
cells,0.0004971988232953528
discontinuation,0.0004970501498272606
events,0.0004969744876640592
usual,0.0004968112506325006
E,0.0004964364744647343
begin,0.0004964364744647343
Alveolar,0.0004964364744647343
reversible,0.0004964364744647343
Minimum,0.0004964364744647343
pharmacologic,0.0004957850491623672
permeation,0.0004952984956574369
Dopamine,0.0004948182945151425
safety,0.0004946748992601391
Elevated,0.0004939131661810814
displace,0.0004939131661810814
started,0.0004938376684944235
physician,0.0004937761605685598
number,0.0004927192664166968
even,0.0004912727741901435
male,0.0004893635554535924
frequency,0.000489352802022669
cyclosporine,0.0004886286583046795
Oral,0.00048714622318746237
completely,0.000486812475037679
unlikely,0.0004853811411861253
ketorolac,0.0004853811411861253
pharmacologically,0.00048421659141806295
contribute,0.0004832928302067607
elevations,0.0004832007451668341
fat,0.0004806119271311138
antiplatelet,0.0004796049291417859
estrogen/progesterone,0.0004792782015617947
suppression,0.0004786096733964129
previously,0.00047843091029875495
120,0.0004775468893774004
metabolize,0.00047742754906321405
especially,0.00047723106478947397
Magnesium-containing,0.000476996278387376
hypermagnesemia,0.000476996278387376
problems,0.0004768985694796335
exacerbated,0.0004757900915879354
characteristics,0.0004757900915879354
efficacy,0.0004755625372262484
Contraceptives,0.00047546425208955245
Interfere,0.00047546425208955245
reaction,0.0004751918959430279
rats,0.00047485479840336797
Resistance,0.0004746502400789776
34,0.0004744320116474299
TID,0.0004736845232159448
great,0.0004727119814241787
lengthened,0.0004727119814241787
durations,0.0004727119814241787
brand,0.0004727119814241787
EGF-,0.0004727119814241787
nicotine-induced,0.0004727119814241787
irritability,0.0004727119814241787
ALT,0.0004727119814241787
s.c.,0.0004727119814241787
insulin-induced,0.0004727119814241787
stimulate,0.0004727119814241787
toxicities,0.0004727119814241787
oxytocic,0.0004727119814241787
up,0.0004726451457039982
Due,0.00047151020188462844
b-lactam,0.00047014735664951957
RA,0.0004691824552047752
thrombocytopenia,0.0004691824552047752
coronary,0.0004691824552047752
eliminated,0.0004671710132660989
incompatible,0.00046570469547657645
Bromocriptine,0.00046570469547657645
prolong,0.00046568551790016066
24-hour,0.000465386505608123
abuse,0.00046527503141402526
bicarbonate,0.0004646518946215261
inhibiting,0.00046436169345898115
trough,0.0004641698518951243
31,0.00046378622230180966
bone,0.00046221832026849263
seizure,0.0004615366645024377
slight,0.00046100662522197133
altering,0.0004600995209786962
release,0.00045952826604978014
mg/kg,0.0004589889892319121
day,0.00045895022665887186
average,0.0004587163206081213
Furthermore,0.0004586256714853576
Concentration,0.000457489241879272
sparing,0.00045707242623549416
antagonists,0.00045699322478087723
database,0.00045563186984654003
herbal,0.00045563186984654003
orally,0.00045451748572378214
level,0.00045449186155166466
withdrawn,0.0004538451304358926
alkalinizing,0.0004537139645471866
PHARMACOLOGY,0.00045229068035435027
assess,0.0004522817811417612
Cytochrome,0.0004519194770473689
1200,0.0004518037259828578
form,0.00045125308328719527
hypokalemia,0.0004509883134663495
micrograms,0.0004507381138840749
neutropenia,0.0004507381138840749
Although,0.0004501737403693751
human,0.0004490178340563755
That,0.00044861087414749257
experiments,0.00044861087414749257
glycosides,0.0004482956465494681
valproic,0.00044793214015004246
8,0.0004470484910291672
observed,0.0004462794003221582
n=79,0.00044571637661250385
Antiacid,0.00044571637661250385
Non-Thalidomide,0.00044571637661250385
HIV-protease,0.00044571637661250385
sympathomimet-ics,0.00044571637661250385
phe-nothiazines,0.00044571637661250385
n=70,0.00044571637661250385
n=177,0.00044571637661250385
n=21,0.00044571637661250385
n=15,0.00044571637661250385
n=77,0.00044571637661250385
n=35,0.00044571637661250385
n=72,0.00044571637661250385
625,0.00044571637661250385
Indanavir,0.00044571637661250385
n=75,0.00044571637661250385
Phenobarbitol,0.00044571637661250385
Ritanovir,0.00044571637661250385
hemorrhage,0.0004447455011907797
consideration,0.00044421878086908784
slower,0.0004429504065868173
protein-binding,0.0004428976445838284
fat-soluble,0.0004428976445838284
history,0.00044208425024561127
As,0.0004419012753417162
occasionally,0.00044119429514255515
antagonist,0.00044119429514255515
soluble,0.000440687938412454
resins,0.00044056121018809513
management,0.00044056121018809513
anion-exchange,0.00044056121018809513
While,0.0004405516647851826
significance,0.0004405190949011706
analogues,0.00044011171506219693
relationship,0.00043972463162011977
Animal,0.0004397065237480291
ranging,0.0004393112405274291
adjusting,0.00043845455794999655
medicinal,0.0004384545336755252
48,0.00043747454539877495
against,0.0004369241283197489
disturbances,0.00043680616923025273
adjunctive,0.00043680616923025273
continue,0.00043680616923025273
stopped,0.00043680616923025273
Wait,0.00043680616923025273
take,0.00043677100422867543
kind,0.0004357772595736664
H1-blocking,0.0004357772595736664
Topical,0.0004357772595736664
LEVULAN,0.0004357772595736664
photosensitivity,0.0004357772595736664
photosensitizing,0.0004357772595736664
tendency,0.0004357772595736664
platelets,0.0004357772595736664
actinic,0.0004357772595736664
KERASTICK,0.0004357772595736664
keratoses,0.0004357772595736664
under,0.00043519500325728266
suggests,0.0004350249028558517
gluconate,0.0004350249028558517
TNF,0.0004327820016625239
exists,0.0004311583821580145
causes,0.0004306973901729849
equivalent,0.00042955436098712774
molecule,0.00042955436098712774
relevant,0.0004291919259610255
Thus,0.0004287589501545952
26,0.0004280479893451483
careful,0.0004280257361536366
observations,0.000426635301304934
Diuretic,0.00042652764430761714
pulse,0.0004257989676852425
gold,0.0004257989676852425
ophthalmic,0.0004257989676852425
CAUTION,0.0004257989676852425
SSRI,0.0004257989676852425
supraventricular,0.0004257989676852425
methylergonovine,0.0004257989676852425
better,0.0004257989676852425
obstipation,0.0004257989676852425
appropriately,0.0004257989676852425
combining,0.0004257989676852425
Particularly,0.0004257989676852425
Exert,0.0004257989676852425
phosphorylation,0.0004250209943921224
presumably,0.00042471968999269194
7.5,0.0004246519812347582
Dose,0.0004244167291591605
risks,0.00042423369295097046
Medications,0.00042408560125073436
concern,0.00042408560125073436
inflammation,0.00042408560125073436
folate,0.00042408560125073436
Crohns,0.00042408560125073436
ulcerative,0.00042408560125073436
sugar,0.00042408560125073436
utilization,0.00042408560125073436
colitis,0.00042408560125073436
mcg,0.0004227484689088845
susceptible,0.00042268564701053446
analgesia,0.00042268564701053446
attenuates,0.00042268564701053446
X,0.00042268564701053446
cross-resistance,0.00042268564701053446
available,0.0004224099289420469
CLINICAL,0.000421810717926685
CYP2B6,0.0004218051715736415
minor,0.00042121897405023034
contractility,0.00041954122277776396
life-threatening,0.00041923595889914456
while,0.0004189330266732849
aminosalicylate,0.00041866328747897086
Reciprocal,0.00041866328747897086
TPMT,0.00041866328747897086
multiple-dose,0.0004159726879342518
therapies,0.0004135854887892254
fruit,0.000413430115177027
19,0.000413430115177027
regression,0.000413430115177027
Acidifying,0.000413430115177027
juices,0.000413430115177027
apparent,0.000413430115177027
glutamic,0.000413430115177027
ascorbic,0.000413430115177027
QD,0.000413430115177027
substantially,0.0004129474197676064
periodic,0.0004110342147591872
Beta-adrenergic,0.00040922656132047486
elderly,0.0004084075232404505
threshold,0.000408407272375233
accordingly,0.000408407272375233
vary,0.00040605905523716235
D3,0.00040594353794354276
receptor,0.0004048384881520928
render,0.0004030386549498388
Severe,0.0004030386549498388
cardiac,0.00040261927981355417
myelotoxic,0.00040189110146260365
possessing,0.00040189110146260365
oxide/oxygen,0.00040189110146260365
cardiotoxic,0.00040189110146260365
3-fold,0.00040104035396115734
anesthetic,0.00039987879327618714
concomitant,0.0003991641325440387
Protein,0.00039862258504097525
reduces,0.00039861180342248836
Hypersensitivity,0.00039856670161420027
minutes,0.0003980583334283194
ototoxicity,0.00039695364478986583
thereafter,0.00039695364478986583
bromocriptine,0.0003968405517194018
included,0.00039614588756531344
alternative,0.00039560807979688306
urine,0.0003954150332678985
unpredictable,0.0003947266154844531
family,0.0003946703720615341
ingested,0.0003940640383547356
loss,0.00039393479472560333
parent,0.00039389700724212773
Extended,0.00039194838778422447
hyperthermia,0.00039114174574195193
crisis,0.00039114174574195193
anticoagulation,0.00039114174574195193
sedative/hypnotics,0.0003909506035272292
addition,0.00039083957309693496
Anticholinergic,0.00038928628802059606
elevating,0.00038928628802059606
demonstrates,0.00038928628802059606
Blunting,0.00038786197284312873
beta-adrenoceptor,0.00038786197284312873
-8,0.00038786197284312873
stimulated,0.00038786197284312873
rigidity,0.00038786197284312873
states,0.00038786197284312873
rise,0.00038786197284312873
protection,0.00038786197284312873
exaggerate,0.00038786197284312873
SGPT,0.00038786197284312873
Rhabdomyolysis,0.00038786197284312873
hypoglycemia,0.00038730923058838407
anticonvulsant,0.0003871551723847455
B12,0.00038654788196734735
given,0.0003863440053969436
moieties,0.00038623318487474023
octapeptide,0.00038623318487474023
affinity,0.00038623318487474023
cholecystokinin,0.00038623318487474023
three,0.00038567010309520366
Tosylate,0.0003849035503463716
Bretylium,0.0003849035503463716
44,0.00038482117907867597
co,0.000384631440870864
recently,0.00038406884096064964
live,0.00038406884096064964
chelation,0.0003840653463179633
shortened,0.0003838278226463432
Eproxindine,0.0003832794351005253
33,0.00038184270285968047
PTH,0.0003817591261137121
frequent,0.0003817591261137121
endogenous,0.0003816868152104469
95,0.00038141436977690013
reductase,0.0003812676110324098
800,0.0003804849141570976
model,0.00037910389299267155
unchanged,0.0003790236627401189
tablet,0.0003790236627401189
hypercalcemia,0.00037880478675544893
meaningful,0.0003771201349380693
divalent,0.0003768213558914546
trivalent,0.0003768213558914546
atropine,0.0003763632237894221
Diphenoxylate,0.0003763632237894221
diphenoxylate,0.0003763632237894221
mice,0.00037633081433252613
peptide,0.00037632094712169994
safely,0.00037632094712169994
formulations,0.00037610850854619127
complexes,0.00037610850854619127
tract,0.00037567548440597953
Inhibitors,0.00037497389983032203
benefits,0.0003749224138267504
resistance,0.0003749224138267504
long-term,0.00037485825073291235
Some,0.0003743554629294099
parenteral,0.00037332484953178646
Pharmacokinetic,0.00037249868955890886
0.25,0.00037221770808704147
tachycardia,0.00037135315281389136
leading,0.0003713424097573359
IIIA4,0.0003709554999731246
600,0.00037051688352174317
concurrent,0.00037030007389760033
degree,0.00036965361741669867
concentration-time,0.00036767453936503713
Diphenhydramine,0.0003675832238428933
potassium-containing,0.0003675832238428933
GP,0.0003675832238428933
inotropes,0.0003675832238428933
substitutes,0.0003675832238428933
hypokalemic,0.0003675832238428933
longer,0.0003675089993642189
carbonate,0.0003674166855284211
pump,0.00036691442809788644
proton,0.00036691442809788644
amitriptyline,0.0003664153462348274
incompatibility,0.0003664091742621167
enhancement,0.000365814429619582
profiles,0.0003656624683601173
100,0.0003651500238150973
CI,0.00036453480633524826
however,0.0003642142991832076
simultaneous,0.0003628532439781118
CYP1A2,0.00036090271005440044
prior,0.00036079219130802365
stimulants,0.000360167055082794
contraception,0.000360167055082794
quinolone,0.00035857014725870773
bactericidal,0.00035814695645963734
hyperkalemia,0.0003577059718662401
outweigh,0.00035763005050004626
downward,0.00035763005050004626
pharmacokinetics/pharmacodynamics,0.00035649786625302493
pharmacist,0.00035649786625302493
structures,0.00035649786625302493
white,0.00035649786625302493
frontal,0.00035649786625302493
subcortical,0.00035649786625302493
fondaparinux,0.00035649786625302493
MIC,0.00035649786625302493
ampicillin/flucoxacillin,0.00035649786625302493
minimum,0.00035649786625302493
nonprescription,0.00035649786625302493
forebrain,0.00035649786625302493
cortex,0.00035649786625302493
Stimulation,0.00035649786625302493
dialysis,0.00035634983429078115
4-fold,0.0003556471827832475
Binding,0.0003556471827832475
tissue,0.0003550586070213413
nucleus,0.0003550586070213413
non-,0.0003550586070213413
accumbens,0.0003550586070213413
TNF-blocking,0.0003550586070213413
developing,0.0003550586070213413
H2-receptor,0.0003544765004318551
triazolo-benzodiazepines,0.0003544765004318551
ED50,0.0003544765004318551
heavy,0.0003544765004318551
para-aminosalicylic,0.0003544765004318551
malabsorption,0.0003544765004318551
plasmaconcentration,0.0003544765004318551
fresh,0.0003544765004318551
therapeutically,0.0003544765004318551
ionized,0.0003544765004318551
lasting,0.0003544765004318551
ammonium,0.0003544765004318551
phosphate,0.0003544765004318551
P450IIIA4,0.0003544765004318551
biotransformation,0.0003544765004318551
their,0.00035324411491943764
hospitalization,0.0003531829099612249
nasal,0.0003521633182138606
signs,0.0003514901280596838
inhaled,0.00035094705118010605
small,0.0003507731680193471
report,0.00035063000476054373
determined,0.00035055578262244147
obtained,0.00034951703628327557
=,0.0003495061496380236
minimized,0.000349471134961421
animal,0.0003491160565778362
less,0.000349068313924894
85,0.00034902875941267286
tests,0.0003481494374079075
salicylate,0.00034799062598189767
alfa,0.00034741031627549823
noted,0.00034741031627549823
-agonists,0.00034741031627549823
dornase,0.00034741031627549823
anti-pseudomonal,0.00034741031627549823
Genentech,0.00034741031627549823
whole,0.00034741031627549823
Pretreatment,0.00034704088554304846
complete,0.00034704088554304846
purpose,0.0003465870230503487
groups,0.00034641663191048444
Interaction,0.00034585762846073287
mechanism,0.00034574855010682803
Intestinal,0.0003454076346605106
carbohydrate-splitting,0.0003454076346605106
1.4-,0.0003454076346605106
digestive,0.0003454076346605106
adsorbents,0.0003454076346605106
2.0-,0.0003454076346605106
2.9-,0.0003454076346605106
1.6-,0.0003454076346605106
Potentially,0.0003454076346605106
elc,0.0003454076346605106
contained,0.0003454031309066963
crises,0.0003454031309066963
attributed,0.0003454031309066963
hyperuricemic,0.0003454031309066963
-5,0.0003454031309066963
thiosulfate,0.0003454031309066963
paralytic,0.0003454031309066963
believed,0.0003454031309066963
synergism,0.0003454031309066963
pregnancies,0.0003454031309066963
hypoparathyroid,0.0003454031309066963
ectopic,0.0003454031309066963
ANC,0.0003454031309066963
HIV-positive,0.0003454031309066963
AST,0.0003454031309066963
109/L,0.0003454031309066963
ewes,0.0003454031309066963
alpha-adrenergic,0.0003454031309066963
prevents,0.0003454031309066963
food,0.0003453282471910235
HMG-CoA,0.000344070191785395
gradual,0.0003438349533844143
e.g,0.0003435929853333741
involved,0.00034234312210779105
administrations,0.0003420791524884059
maximum,0.0003416002279337249
norepinephrine,0.00034055894102247297
OR,0.00034055894102247297
specifically,0.00034055894102247297
beta-blocking,0.00034030667149531624
lowering,0.00034022032668989954
epilepsy,0.0003399471832690182
greater,0.0003369068893905869
naproxen,0.00033668420154864265
Hepatic,0.00033668420154864265
Substrates,0.00033668420154864265
minimally,0.00033668420154864265
Those,0.0003366766446104563
Capsules,0.0003362937477302541
pose,0.0003358599705507448
Additionally,0.00033545875058360597
achieve,0.00033461575190874004
-NANM,0.0003345150205258385
requires,0.000333869410425347
oxidation,0.0003334155972885
under-digitalization,0.0003332277504034531
over-,0.0003332277504034531
elevate,0.0003328767814825273
coumarin-like,0.00033215614017911843
where,0.00033194888405030376
1000,0.00033141996304597576
infections,0.00033123386448707937
compounds,0.00033092137302515034
1.73,0.0003308242499163727
1.64,0.0003308242499163727
1.47,0.0003308242499163727
organophosphate,0.0003308242499163727
Iodide,0.0003308242499163727
1.02-2.11,0.0003308242499163727
steroidal,0.0003308242499163727
responsiveness,0.0003308242499163727
structural,0.0003308242499163727
Spontaneous,0.0003308242499163727
1.25-2.38,0.0003308242499163727
1.27-2.12,0.0003308242499163727
antimuscarinic,0.0003308242499163727
Cardiac,0.0003308242499163727
antiparkinson,0.0003308242499163727
carbamate,0.0003308242499163727
1.11-2.38,0.0003308242499163727
Sympathomimetic,0.0003308242499163727
1.63,0.0003308242499163727
postmarketing,0.0003308242499163727
Phospholine,0.0003308242499163727
odds,0.0003308242499163727
weaken,0.0003308242499163727
SSRI-TCA,0.000330781884592124
sequential,0.000330372252865474
laboratory,0.00032978171555664293
MAC,0.00032956346480483845
morphine-induced,0.00032946691530710837
CONCLUSIONS,0.000329263153631687
class,0.00032883113163184596
Kip1,0.0003282120466506777
curves,0.0003282120466506777
aggregation,0.0003282120466506777
diarrhea,0.0003282120466506777
manner,0.0003282120466506777
p27,0.0003282120466506777
arrhythmia,0.00032804501553806986
ototoxic,0.00032804501553806986
few,0.00032804501553806986
HCl,0.00032786917887484
inhaler,0.00032768348466682973
Whose,0.00032768348466682973
Level,0.00032768348466682973
surgical,0.00032768348466682973
metaproterenol,0.00032768348466682973
EXTREME,0.00032768348466682973
vertigo,0.00032768348466682973
Acidity,0.00032768348466682973
wait,0.00032768348466682973
Be,0.00032768348466682973
Can,0.00032768348466682973
advice,0.00032768348466682973
nortriptyline,0.00032768348466682973
cisplatin.1,0.00032768348466682973
Physicians,0.00032768348466682973
lopinavir/ritonavir,0.00032768348466682973
concentrate,0.00032768348466682973
Combination,0.00032768348466682973
Wyeth-Ayerst,0.00032768348466682973
EL,0.00032768348466682973
Cremophor,0.00032768348466682973
start,0.00032768348466682973
isrecommended,0.00032768348466682973
533/133,0.00032768348466682973
act,0.00032768348466682973
warned,0.00032768348466682973
Stomach,0.00032768348466682973
Affected,0.00032768348466682973
28,0.0003268018338541401
requirements,0.0003264436307546248
eight-fold,0.0003256311775364784
motility,0.0003253793282771422
Several,0.0003253793282771422
after,0.0003241341582677082
prescribing,0.00032376578202375494
titration,0.00032376578202375494
isoenzymes,0.00032376578202375494
240,0.0003229732422131981
anticoagulant,0.0003222719109190475
cases,0.00032206535448175977
data,0.00032090204055790217
racemic,0.0003208512874358638
established,0.0003198351863383797
regimens,0.00031900994083366996
population,0.00031900994083366996
metabolites,0.00031817938207190366
54,0.00031767508705571323
angiotensin,0.00031686472348313455
differences,0.0003168572818443849
microsomal,0.00031567605384963393
severity,0.000315116221397016
antagonistic,0.000315116221397016
catecholamine-depleting,0.0003144422684772108
imidazole,0.0003144422684772108
early,0.0003144422684772108
Co-medications,0.0003132536968476485
chemotherapy,0.00031290281030305067
C.P.A,0.00031279174440246305
stabilized,0.00031279174440246305
corresponding,0.00031264717387313734
poorly,0.00031264717387313734
remedies,0.00031264717387313734
converting,0.000312090284429245
To,0.00031135738885945674
insecticides,0.0003107835474782661
neurons,0.0003107835474782661
CYP2C19,0.0003107587883497409
transplant,0.0003106164068562567
intracellular,0.0003104366588604357
m,0.00031019969358814237
anaesthetised,0.00031011327433572156
2-,0.0003096130706558009
41,0.0003096130706558009
physicians,0.0003091249389132189
whether,0.0003087168395417006
72,0.00030716002748132354
those,0.0003071345944094528
brain,0.0003069599016153335
adequate,0.00030694829743060925
deficiency,0.00030694829743060925
current,0.00030463781735623474
individual,0.00030463781735623474
smaller,0.00030463781735623474
suffering,0.00030463781735623474
Careful,0.00030463781735623474
insufficient,0.00030463781735623474
minipill,0.00030463781735623474
enhancing,0.00030436218335871956
appears,0.00030432958151871414
animals,0.00030432958151871414
calcitriol/ergocalcitriol,0.0003043007698700917
ventricular,0.00030361130403433467
ECG,0.0003035857899568173
irreversibly,0.0003035857899568173
Please,0.0003035857899568173
anti-infective,0.0003035857899568173
note,0.0003035857899568173
simultaneously,0.00030275398086776484
responsible,0.00030184323047921513
Phenytoin/Phenobarbital,0.0003017358242946022
accelerating,0.0003017358242946022
employed,0.0003014814889782391
salicylic,0.00030092288224492503
formulation,0.0003004545042691875
b.i.d,0.00030035784970827706
Potassium-sparing,0.00029703977760509037
effectively,0.00029703977760509037
36,0.00029636683511202744
suggested,0.0002961426993266514
would,0.000295002878972106
exacerbate,0.00029400366529719335
6-fold,0.00029359553011854
anticoagulants,0.00029227918317031865
moderate,0.0002917880675421536
indicate,0.0002917347583473173
breast,0.00029117911108866856
nor,0.0002908630427579384
steroid,0.0002893437625167694
mL,0.0002892940425383017
17,0.0002890461319307036
N-acetyltransferase,0.0002886245087276862
potassium-,0.0002886245087276862
glycoprotein,0.0002886245087276862
PTCA/PCI,0.0002886245087276862
hydrobromide,0.0002886245087276862
dipotassium,0.0002886245087276862
dextromethorphan,0.0002886245087276862
clorazepate,0.0002886245087276862
Nephrotoxicity,0.0002886245087276862
Noncardioselective,0.0002886245087276862
rebound,0.0002886245087276862
porpranolol,0.0002886245087276862
anti-malarial,0.0002886245087276862
Folic,0.0002886245087276862
suppress,0.0002886245087276862
beta-blockers,0.0002886245087276862
nitric,0.0002886245087276862
methemoglobinemia,0.0002886245087276862
donor,0.0002886245087276862
agitation,0.0002886245087276862
information,0.0002882357866835772
failure,0.0002879503195278854
implications,0.00028727954712681747
anecdotal,0.00028727954712681747
phentermine,0.00028727954712681747
phenytoin,0.00028713172232397444
bovine,0.00028713172232397444
quantities,0.00028713172232397444
unknown,0.00028636133835258093
ss,0.00028630758324676986
oil,0.00028630758324676986
55,0.00028630758324676986
Mineral,0.00028630758324676986
3-4,0.00028630758324676986
Cholinesterase,0.0002861726677012566
tested,0.0002860326526492596
We,0.0002850509633909315
Drug/Laboratory,0.0002841034638387807
Test,0.0002841034638387807
rates,0.00028378396076367274
Laboratories,0.00028378396076367274
findings,0.00028378396076367274
according,0.00028378396076367274
changing,0.00028378396076367274
ganglion,0.00028378396076367274
reason,0.00028378396076367274
cell,0.00028372102752216577
appear,0.0002835386207780122
"2-methyl-1,3-thiazol-4-yl",0.00028183392055813883
sensitivity,0.00028183392055813883
demonstrated,0.0002810285005862001
proteins,0.00028098274936350087
organic,0.0002808920689764127
SR,0.00028016360345706204
indanyl,0.00028016360345706204
Calan,0.00028016360345706204
carbenicillin,0.00028016360345706204
valproate,0.00028016360345706204
vaiproic,0.00028016360345706204
indigestion,0.00028016360345706204
fluoxetine,0.00028016360345706204
intense,0.00028016360345706204
13.3-fold,0.00028016360345706204
q12h,0.00028016360345706204
2.93-fold,0.00028016360345706204
net,0.00028016360345706204
CyP450,0.00028016360345706204
1.5-2.5,0.00028016360345706204
modifies,0.00028016360345706204
non-ionized,0.00028016360345706204
RPMI1640,0.00027983550180232797
Non-steroidal,0.00027983550180232797
modify,0.00027983550180232797
hypertensive,0.00027983550180232797
Anti-inflammatory,0.00027983550180232797
Adrenergic,0.00027983550180232797
intraventricular,0.0002781195196966957
quart,0.0002772241315436297
sulfa-based,0.0002772241315436297
carboxymethylcellulose,0.0002772241315436297
numerous,0.0002772241315436297
iodine-containing,0.0002772241315436297
sulfamethoxazole-trimethoprim,0.0002772241315436297
conjugates,0.0002772241315436297
NYHA,0.0002772241315436297
cilexetil,0.0002772241315436297
andtolbutamide,0.0002772241315436297
Large,0.0002772241315436297
fluorescein,0.0002772241315436297
7-10/interaction,0.0002772241315436297
Cephalosporins-Cephalosporins,0.0002772241315436297
sheep,0.0002772241315436297
chains,0.0002772241315436297
methylthiadiazole,0.0002772241315436297
N-methylthiotetrazole,0.0002772241315436297
candesartan,0.0002772241315436297
At,0.00027640550879670656
Also,0.00027610596104077345
ethynyl,0.00027497685385835524
parameters,0.0002730166820277269
striking,0.0002725124861311379
Reuptake,0.0002723597196807592
here,0.0002723597196807592
Serotonin,0.0002723597196807592
ingestion,0.0002716199104245698
16,0.0002710305701962845
11,0.00027085134738558114
mg/kg/day,0.0002702403968350975
slightly,0.0002700701305401454
chronically,0.00026874898333295594
low,0.0002678604425793152
experiences,0.00026780814522064933
5-HT3,0.00026731700522053536
large,0.00026587656812360194
theoretically,0.00026585860005479134
exceeded,0.00026548686725569315
vessels,0.00026443502261797036
placental,0.00026443502261797036
blocks,0.00026375192865035757
A,0.00026358072522947307
On,0.00026306461680014603
II,0.000262718928237371
replacement,0.0002624388668541755
hypoprothrombinemia,0.00026159755866450585
III,0.00026112186605931065
Reactions,0.0002609295909674625
malignant,0.0002609295909674625
currently,0.00026021219517435856
epileptic,0.0002601520170656402
fibrillation,0.0002597791858323095
locomotor,0.0002597791858323095
consequences,0.0002597791858323095
made,0.000258854997494784
reversed,0.00025756859709791247
Hallucinations,0.00025756859709791247
psychoactive,0.00025756859709791247
Bacteriostatic,0.00025756859709791247
Psychoactive,0.00025756859709791247
Taking,0.00025756859709791247
Antiplatelet,0.00025756859709791247
labeling,0.0002574103433109487
chromaffin,0.0002574103433109487
intravenously,0.0002571498768466629
transient,0.0002570931999019699
clotting,0.0002567485393840663
regardless,0.0002567485393840663
vasodilator,0.0002567485393840663
toxic,0.00025639257578158325
Effect,0.0002563133595818723
added,0.00025598682174310383
percent,0.00025581343345448815
spray,0.00025581343345448815
affected,0.00025573661136135684
consider,0.00025479234228453773
inflammatory,0.00025479234228453773
congestive,0.00025479234228453773
undergoing,0.0002545128296346233
plus,0.0002544336370718936
changes,0.00025365317281289546
competitively,0.00025299724768079734
decreasing,0.0002524433147703675
competes,0.0002524433147703675
Enzyme,0.0002513617611984431
insufficiency,0.0002510583848340797
recovery,0.0002510583848340797
Therapeutic,0.0002507814863637048
bacteriostatic,0.00024900125013793684
similarity,0.0002488451639861555
cerebral,0.0002488451639861555
concluded,0.0002488451639861555
controlled,0.0002486410408000239
also,0.00024848250440345776
pharmacology,0.0002480040709436082
omega-conotoxin,0.00024750414577145996
P-type,0.00024750414577145996
N-type,0.00024750414577145996
1.5,0.00024750414577145996
omega-agatoxin,0.00024750414577145996
impaired,0.0002469291400089002
metabolizers,0.0002467390350402443
Reports,0.00024670907442958523
major,0.00024577293996719263
39,0.0002452176086830127
two-fold,0.0002452176086830127
53,0.0002452176086830127
bind,0.0002452176086830127
anticholinesterase,0.00024462759598697925
lead,0.00024458488223921826
case,0.0002445367490957473
An,0.00024385384705560842
males,0.00024329379326659684
prescription,0.000242557534965826
ganglionic,0.00024142411606897785
solutions,0.00024142411606897785
heart,0.00024127318306532697
mouse,0.00024020123568935237
2.5,0.00024012392719996445
twofold,0.0002394363210963535
5-fold,0.0002394363210963535
compete,0.0002394363210963535
12,0.00023938058964456665
directly,0.00023917832905318015
body,0.00023847525938258674
antibiotics,0.00023842566013976274
Amphotericin,0.00023834201297945334
dantrolene,0.00023834201297945334
becausedecreases,0.00023834201297945334
beadministered,0.00023834201297945334
potassium-depleting,0.00023834201297945334
plasmaconcentrations,0.00023834201297945334
interfering,0.00023834201297945334
judgment,0.00023834201297945334
functioning,0.00023834201297945334
curare-like,0.00023834201297945334
antibody,0.0002377479548693051
gravis,0.0002377479548693051
myasthenia,0.0002377479548693051
apnea,0.0002377479548693051
ADL,0.0002377479548693051
developed,0.0002377479548693051
8-2698,0.0002377479548693051
blocked,0.0002377479548693051
monotherapy,0.00023759841255777125
carried,0.00023759841255777125
g/mL,0.0002371147955042563
3900,0.0002371147955042563
renin,0.0002366722271691657
prevent,0.00023655163525504452
fluctuations,0.00023628044634316225
P3,0.00023628044634316225
instability,0.00023628044634316225
myeloproliferative,0.00023628044634316225
progressing,0.00023628044634316225
mumol/liter,0.00023628044634316225
N1,0.00023628044634316225
P1,0.00023628044634316225
equally,0.00023628044634316225
depression-producing,0.00023628044634316225
status,0.00023628044634316225
Pharmacologic,0.00023628044634316225
0.3,0.00023628044634316225
renin-angiotensin,0.00023628044634316225
cephalosporin,0.00023628044634316225
-6,0.00023628044634316225
blunted,0.00023628044634316225
sodation,0.00023628044634316225
broad-spectrum,0.00023628044634316225
diminishes,0.00023628044634316225
Prolonged,0.00023628044634316225
trazodone,0.00023628044634316225
Non-Steroidal,0.00023628044634316225
-9,0.00023628044634316225
ANTABUSE-like,0.00023628044634316225
ip,0.00023628044634316225
peroxidation,0.00023628044634316225
TBARS,0.00023628044634316225
levamisole,0.00023628044634316225
aware,0.00023628044634316225
Epidemiological,0.00023628044634316225
myoclonus,0.00023628044634316225
beta-lactam,0.00023628044634316225
necessitated,0.00023628044634316225
partly,0.00023628044634316225
Bcl-2,0.00023628044634316225
Cdk1,0.00023628044634316225
rhabdomyolysis,0.00023628044634316225
retention,0.00023628044634316225
One,0.00023628044634316225
Cypermethrin-induced,0.00023628044634316225
radical-mediated,0.00023628044634316225
kill,0.00023628044634316225
ig,0.00023628044634316225
4th,0.00023628044634316225
parts,0.00023628044634316225
immunosuppressive,0.00023628044634316225
bacilli,0.00023628044634316225
-7,0.00023628044634316225
Consider,0.00023628044634316225
prolactin,0.00023628044634316225
-10,0.00023628044634316225
confusional,0.00023628044634316225
vasoconstricting,0.00023628044634316225
anti-glaucoma,0.00023628044634316225
TNFa-blocking,0.00023628044634316225
microM,0.00023628044634316225
AAV2-mediated,0.00023628044634316225
attenuated,0.00023628044634316225
parental,0.00023628044634316225
fall,0.00023628044634316225
augments,0.00023628044634316225
continuously,0.00023628044634316225
Seizures,0.00023628044634316225
non-depolarising,0.00023628044634316225
Higher,0.00023628044634316225
Systemic,0.00023626407955401607
nonabsorbable,0.00023626407955401607
10-20,0.00023626407955401607
688,0.00023626407955401607
subtherapeutic,0.00023626407955401607
beneficial,0.00023618361844390812
injection,0.00023551893454887285
capable,0.00023529989964288234
coagulation,0.0002349635592067134
accumulation,0.0002348736537435281
Clomipramine,0.0002348736537435281
all,0.00023483530528767282
terminal,0.00023441736179208306
show,0.00023438085624405414
add,0.0002324648466995871
place,0.00023208426807208582
ischemic,0.00023208426807208582
adult,0.000232009156770685
n,0.00023139955844553306
Presence,0.00023135314165312337
strongly,0.00023135314165312337
Levels,0.00023135314165312337
four,0.0002305148434080806
fever,0.0002304496865984662
example,0.00023024263858029137
During,0.00023024263858029137
adults,0.0002299143450175123
ratio,0.0002298360494932261
Anticoagulants,0.0002298360494932261
-induced,0.0002298360494932261
provided,0.00022921331179615034
regimen,0.0002282810635607646
t.i.d,0.00022816026181482485
indicating,0.00022769314362691695
disposition,0.00022769314362691695
months,0.00022769314362691695
Increased,0.00022749411845324197
systems,0.00022733091646665038
category,0.00022690302099759307
includes,0.0002262541259590023
difference,0.0002262541259590023
trial,0.0002262357335660603
1.7-fold,0.0002258031020122564
2.2-fold,0.0002258031020122564
Evidence,0.00022524755578512412
transmission,0.00022524755578512412
giving,0.00022524755578512412
peripheral,0.00022457288337074388
vasoconstrictive,0.0002241629443523463
conjunction,0.00022340074176030456
alter,0.0002230710196592378
However,0.00022262093578495623
Compounds,0.0002223606560254332
they,0.00022192507308560483
low-dose,0.00022177403309331378
Long-term,0.00022177403309331378
antituberculosis,0.00022177403309331378
Blockers/Proton,0.00022177403309331378
Nonsteroidal,0.00022172897746108866
nephrotoxicity,0.0002207597171851594
deterioration,0.00022045559154260097
interleukin-1,0.00022045559154260097
amounts,0.00022045559154260097
1.2,0.00022045559154260097
Diuretic-induced,0.00022045559154260097
emerge,0.00022045559154260097
May,0.00021982366674466736
3-,0.00021910873635144767
confusion,0.00021883318233606452
occurrence,0.00021883318233606452
Especially,0.00021835965730165885
upward,0.00021835965730165885
thrombus,0.00021835965730165885
know,0.00021835965730165885
professional,0.00021835965730165885
prudent,0.00021835965730165885
2-week,0.00021835965730165885
T.A,0.00021835965730165885
dictates,0.00021835965730165885
vasospastic,0.00021835965730165885
immunomodulating,0.00021835965730165885
lethargy,0.00021835965730165885
allowed,0.00021835965730165885
usedas,0.00021835965730165885
hormonalmethods,0.00021835965730165885
cautious,0.00021835965730165885
ensure,0.00021835965730165885
Nonetheless,0.00021835965730165885
assure,0.00021835965730165885
selecting,0.00021835965730165885
myasthenic,0.00021835965730165885
initiate,0.00021835965730165885
PCP,0.00021835965730165885
Special,0.00021835965730165885
iPTH,0.00021835965730165885
leprosy-associated,0.00021835965730165885
definitely,0.00021835965730165885
still,0.00021835965730165885
comedication,0.00021835965730165885
INJECTION,0.00021835965730165885
FOR,0.00021835965730165885
Prothrombin,0.00021835965730165885
consumption,0.00021835965730165885
bupropz_od.htm,0.00021835965730165885
checked,0.00021835965730165885
compensatory,0.00021835965730165885
insure,0.00021835965730165885
conservatively,0.00021835965730165885
boric,0.00021835965730165885
5-mg,0.00021835965730165885
Refer,0.00021835965730165885
intranasal,0.00021835965730165885
72-hour,0.00021835965730165885
travelers,0.00021835965730165885
departure,0.00021835965730165885
Routine,0.00021835965730165885
deferred,0.00021835965730165885
carbonic,0.00021835965730165885
TCAtreatment,0.00021835965730165885
beta-blockade,0.00021835965730165885
finding,0.00021835965730165885
oxi-dase,0.00021835965730165885
anhydrase,0.00021835965730165885
anorexia,0.00021835965730165885
tachypnea,0.00021835965730165885
weighed,0.00021835965730165885
hyperlipidemia,0.00021835965730165885
Appropriate,0.00021835965730165885
parenterally,0.00021835965730165885
back-up,0.00021835965730165885
inwomen,0.00021835965730165885
nevirapinemay,0.00021835965730165885
thesemedications,0.00021835965730165885
awareness,0.00021835965730165885
bear,0.00021835965730165885
precautions,0.00021835965730165885
considering,0.00021835965730165885
warfarin-type,0.00021835965730165885
syncope/presyncope,0.00021835965730165885
sole,0.00021835965730165885
depletors,0.00021835965730165885
Microdosed,0.00021835965730165885
Eye,0.00021835965730165885
essential,0.00021835965730165885
releases,0.00021835965730165885
timing,0.00021835965730165885
intestines,0.00021835965730165885
interrupted,0.00021835965730165885
pre-existing,0.00021835965730165885
out,0.00021818025610320646
baseline,0.0002177883389349322
ACEI/ARB,0.0002177883389349322
Infarction,0.0002177883389349322
Failure,0.0002177883389349322
common,0.000217326515018601
Studies,0.00021663384322190282
vasospasm,0.00021652314579623244
dyspnea,0.00021652314579623244
monkeys,0.00021646173230738253
magnesium-containing,0.00021624160982225415
aluminum-,0.00021624160982225415
except,0.0002161429160059125
spontaneous,0.0002161429160059125
non-potassium,0.0002161429160059125
procedures,0.00021576890482044586
half-lives,0.00021576890482044586
45,0.00021574558070081018
woman,0.00021520480436165723
lipid,0.00021520480436165723
sympathetic,0.00021520480436165723
co-administered,0.00021518492904482045
Pump,0.00021478471352143202
creatinine,0.00021474241941277228
gland,0.00021469317712041747
coumarin-type,0.00021439248581323067
every,0.00021407767745484918
Ingestion,0.00021340970975780582
likelihood,0.00021340970975780582
one-fourth,0.00021316642232438454
300-600,0.00021316642232438454
responses,0.00021282439586300939
Immediate,0.00021265974514972363
progestin-only,0.00021251881214578994
x,0.00021225115587752974
although,0.00021212553303340265
Release,0.00021178977097224827
suggesting,0.00021109671495533888
F2alpha,0.00021077090405174914
horses,0.00021077090405174914
After,0.00021059644764798158
weight,0.0002103543584102141
association,0.0002103543584102141
peritoneal,0.0002101624235539834
suitable,0.0002100530371090814
prostaglandins,0.0002096681745969997
2/3,0.00020922865817452063
histamine,0.00020904988963676985
sudden,0.00020891580148330036
aerosol,0.00020891580148330036
relevance,0.00020891580148330036
receive,0.00020891580148330036
Results,0.0002084141295317643
Drug-Drug,0.0002084141295317643
well-controlled,0.00020840291548740453
resin,0.00020821140761717594
90,0.000208047471937034
five,0.0002079487126609436
measurement,0.0002078839984387404
EPHESUS,0.0002078839984387404
screening,0.0002078839984387404
sali-cylates,0.0002078839984387404
N=8,0.0002078839984387404
Crohn,0.0002078839984387404
uniformity,0.0002078839984387404
Heart,0.0002078839984387404
m/v,0.0002078839984387404
Less,0.0002078839984387404
3020,0.0002078839984387404
vehicle,0.0002078839984387404
162.5,0.0002078839984387404
variety,0.0002078839984387404
Post-Myocardial,0.0002078839984387404
activities,0.0002078839984387404
g/kg/min,0.0002078839984387404
Aspirin/Acetaminophen,0.0002078839984387404
antiemetics,0.0002078839984387404
Congestive,0.0002078839984387404
91,0.0002078839984387404
mEq,0.0002078839984387404
channels,0.0002078839984387404
premedications,0.0002078839984387404
40-mg,0.0002078839984387404
Multiple,0.0002078839984387404
Wort,0.00020670619731455453
worsened,0.00020666049442708
acutely,0.00020666049442708
instituted,0.00020666049442708
Sporadic,0.00020666049442708
indirect-acting,0.00020666049442708
vasodilation,0.00020666049442708
hypersensitivity,0.00020651712326846816
rat,0.00020638175025411432
dihydropyridine,0.00020536861031639209
first,0.0002041168203058552
hypervitaminosis,0.00020405794167854818
estrogen-containing,0.00020405794167854818
play,0.00020405794167854818
isomer,0.00020405794167854818
self-administration,0.00020375304901576463
withdrawal,0.00020357749634980493
relative,0.00020287709872290893
though,0.00020236993239242107
neither,0.0002022997470205734
requirement,0.00020173413302448928
300,0.00020155170474089878
antitumor,0.0002010930919972287
hemostasis,0.00020076865249885056
lowest,0.00020076865249885056
Both,0.0002006405706250769
D2,0.0002002734716290977
benefit,0.00019936303382472875
hepatotoxicity,0.00019936303382472875
larger,0.00019874540367259552
irritation,0.0001983016134319282
weekly,0.0001981248569754568
aminosalicylates,0.00019798012209426563
regarding,0.0001977657665801491
complex,0.00019702605426863418
+,0.00019688610238044468
Limited,0.00019642592069823994
flushing,0.00019555702929974217
exhibited,0.00019555702929974217
twitch,0.00019555702929974217
mucosa,0.00019461390892194785
mg/L,0.00019461390892194785
DSM-IV-diagnosed,0.00019461390892194785
17-28,0.00019461390892194785
350,0.00019461390892194785
Alkalinizing,0.00019461390892194785
Co-treatment,0.00019461390892194785
anionic-binding,0.00019461390892194785
Pre-treatment,0.00019461390892194785
845,0.00019461390892194785
dehydrogenase,0.00019461390892194785
gm,0.00019461390892194785
describes,0.00019461390892194785
accelerated,0.00019461390892194785
Women,0.00019461390892194785
coat-core,0.00019461390892194785
648,0.00019461390892194785
cimetidine,0.00019461390892194785
accumulated,0.00019461390892194785
195,0.00019461390892194785
99m-TcO-4-injection,0.00019461390892194785
accelerates,0.00019461390892194785
equivocally,0.00019461390892194785
turn,0.00019461390892194785
P-450IIE1,0.00019461390892194785
Multiple-dose,0.00019461390892194785
Milk,0.00019461390892194785
2002,0.00019461390892194785
chloride-induced,0.00019461390892194785
lesions,0.00019461390892194785
permits,0.00019461390892194785
wax,0.00019461390892194785
abnormal,0.00019461390892194785
firmly,0.00019461390892194785
enzyme-inducer,0.00019461390892194785
bipolar,0.00019461390892194785
tubularly,0.00019461390892194785
secreted,0.00019461390892194785
raise,0.00019461390892194785
displaces,0.00019461390892194785
1.6-g,0.00019461390892194785
sharing,0.00019461390892194785
400-mg,0.00019461390892194785
chicks,0.00019461390892194785
glutathione-S-transferase,0.00019461390892194785
AUCs,0.00019461390892194785
extends,0.00019461390892194785
anion,0.00019461390892194785
dissolving,0.00019461390892194785
indices,0.00019461390892194785
variation,0.00019461390892194785
mg/week,0.00019461390892194785
isoform,0.00019461390892194785
TCAmetabolism,0.00019461390892194785
minimizes,0.00019461390892194785
Separating,0.00019461390892194785
cime-tidine,0.00019461390892194785
DISCUSSION,0.00019461390892194785
fluctuate,0.00019461390892194785
deleted,0.00019461390892194785
higher-than,0.00019461390892194785
marker,0.00019461390892194785
3.6,0.00019461390892194785
56.9,0.00019461390892194785
ingesting,0.00019461390892194785
plasma-level,0.00019461390892194785
cationic,0.00019461390892194785
ultimate,0.00019461390892194785
Variability,0.00019461390892194785
Withdrawal,0.00019461390892194785
56,0.00019461390892194785
im,0.00019461390892194785
5-6,0.00019461390892194785
calcium-rich,0.00019461390892194785
mg/d,0.00019461390892194785
arise,0.00019461390892194785
serosal,0.00019461390892194785
rachitic,0.00019461390892194785
Chronic,0.00019461390892194785
leukopenic,0.00019461390892194785
reddish,0.00019461390892194785
Following,0.00019421617720549733
substantial,0.0001931406813988623
pivoxil,0.00019298539332490705
500-mg,0.00019298072198703498
1.7-gram,0.00019298072198703498
Protease,0.00019298072198703498
n=6,0.00019298072198703498
Angiotensin,0.00019246429148678246
g/kg,0.00019246429148678246
case-control,0.0001923809224402273
design,0.0001923809224402273
embryos,0.0001923809224402273
oxidative,0.0001923809224402273
expression,0.0001923809224402273
Intraventricular,0.0001923809224402273
noradrenaline,0.0001923809224402273
locus,0.0001923809224402273
co-injection,0.0001923809224402273
compromised,0.0001923809224402273
cytotoxicity,0.0001923809224402273
h,0.0001923809224402273
P2,0.0001923809224402273
elemental,0.00019231679140174762
components,0.00019150972571280178
transit,0.0001914590559818352
Preliminary,0.0001914590559818352
glucose,0.00019116834197330235
hour,0.00019090348905570487
undetectable,0.00019082213176979668
promote,0.00019082213176979668
catabolic,0.00019082213176979668
2.5-fold,0.00019082213176979668
42,0.00019082213176979668
128,0.00019082213176979668
sustained-release,0.00019082213176979668
67,0.00019082213176979668
145mg,0.00019082213176979668
t1/2,0.00019082213176979668
261,0.00019082213176979668
potently,0.00019082213176979668
314,0.00019082213176979668
MAOI,0.00019082213176979668
145,0.00019082213176979668
321,0.00019082213176979668
didanosine-placebo,0.00019082213176979668
H2antagonists,0.00019082213176979668
110,0.00019082213176979668
phosphorylated,0.00019082213176979668
-hydroxy-iso-pravastatin,0.00019082213176979668
mediated,0.00019082213176979668
84,0.00019082213176979668
agent,0.0001907338476045961
upon,0.0001904944673298825
75,0.00018845331452577163
fumarate,0.0001880767098580982
standard,0.0001880767098580982
water,0.0001880767098580982
distribution,0.0001880767098580982
decarboxylase,0.0001880767098580982
levodopa/dopa,0.0001880767098580982
assay,0.0001880767098580982
exist,0.0001880519282988491
antithrombotic,0.0001880519282988491
typical,0.0001880519282988491
definitively,0.0001880519282988491
SSRI-TCAinteractions,0.0001880519282988491
order,0.0001880512800126466
negative,0.00018754968102263625
xanthine,0.0001866642394026119
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated",0.00018659132306630966
mesenteric,0.00018659132306630966
pyridine-treated,0.00018659132306630966
toxoids,0.00018635948146639159
clinicians,0.00018635948146639159
route,0.00018635948146639159
0.4,0.00018553284499800426
capsules,0.0001851081469638194
systematically,0.0001850136660251911
69,0.00018456438686242915
Quinolone,0.00018382682693840469
slow,0.00018382682693840469
Combined,0.00018259361380201788
infusions,0.00018195281018962284
Phase,0.00018195281018962284
nicardipine,0.00018165871420838808
antiepileptic,0.00018128029366137888
Clinical,0.00018101874609499635
marketing,0.00018069505578910405
myopathy/rhabdomyolysis,0.0001793656169788438
Myopathy/Rhabdomyolysis,0.0001793656169788438
tyrosine,0.0001793656169788438
WARNINGS,0.0001793656169788438
behavioral,0.00017872628923554235
treatments,0.00017817376168638432
regard,0.00017817376168638432
51,0.0001779080414137102
bowel,0.0001779080414137102
stomach,0.0001779080414137102
R,0.0001778798084687283
CYP2C8,0.00017772767457546745
impact,0.00017772767457546745
unbound,0.00017772767457546745
Significant,0.00017772767457546745
58,0.00017772767457546745
32,0.00017772767457546745
enzyme-inducing,0.00017715993081202086
isolated,0.00017389170917758712
predominantly,0.00017380580090797793
alterations,0.00017380580090797793
absence,0.00017360320255643824
damage,0.0001735843293921846
46,0.00017355364334248335
consequence,0.00017354811222780597
highly,0.00017314644197419238
dasatinib-mediated,0.00017268140558379663
combine,0.00017268140558379663
contrary,0.00017268140558379663
abrupt,0.00017268140558379663
true,0.00017268140558379663
anaphylactoid,0.00017268140558379663
histamine-like,0.00017268140558379663
Imipramine,0.00017268140558379663
nonbenzodiazepine,0.00017268140558379663
intrinsic,0.00017268140558379663
exerts,0.00017268140558379663
term,0.00017268140558379663
worsen,0.00017268140558379663
nitrite,0.00017268140558379663
evidently,0.00017268140558379663
Reduction,0.00017268140558379663
A5,0.00017268140558379663
intrathecally,0.00017268140558379663
sodium/kg,0.00017268140558379663
AChE,0.00017268140558379663
acetylcholinesterase,0.00017268140558379663
accumbal,0.00017268140558379663
appreciated,0.00017268140558379663
COPD,0.00017268140558379663
bad,0.00017268140558379663
strongyloidiasis,0.00017268140558379663
amyl,0.00017268140558379663
disorientation,0.00017268140558379663
antiseptic,0.00017268140558379663
calculus,0.00017268140558379663
raising,0.00017268140558379663
supine,0.00017268140558379663
CAS,0.00017268140558379663
hemodynamic,0.00017268140558379663
Profound,0.00017268140558379663
systolic/diastolic,0.00017268140558379663
botulinum,0.00017268140558379663
Excessive,0.00017268140558379663
Marked,0.00017268140558379663
resolution,0.00017268140558379663
mononitrate,0.00017268140558379663
unrecognized,0.00017268140558379663
6/5,0.00017268140558379663
contortrostatin-induced,0.00017268140558379663
node,0.00017268140558379663
Dose-response,0.00017268140558379663
powders,0.00017268140558379663
Klebsiella,0.00017268140558379663
subtilis,0.00017268140558379663
Bacillus,0.00017268140558379663
oxytoca,0.00017268140558379663
MDA-MB-435,0.00017268140558379663
T24,0.00017268140558379663
dose-dependently,0.00017268140558379663
SGOT,0.00017268140558379663
triglycerides,0.00017268140558379663
Vasospastic,0.00017268140558379663
Hypertensive,0.00017268140558379663
microdosed,0.00017268140558379663
A-V,0.00017268140558379663
nodal,0.00017268140558379663
succinylcholine,0.00017268140558379663
hydroxymethylglutaryl,0.00017268140558379663
aggravated,0.00017268140558379663
wedge,0.00017268140558379663
b-blocking,0.00017268140558379663
PROSTIN,0.00017268140558379663
previous,0.00017268140558379663
nitrates,0.00017268140558379663
5-7.5,0.00017268140558379663
1.30-2.35,0.00017268140558379663
1.75,0.00017268140558379663
Impaired,0.00017268140558379663
described,0.00017268140558379663
graft-versus-host,0.00017268140558379663
antihypertensives,0.00017268140558379663
conditioned,0.00017268140558379663
Exogenous,0.00017268140558379663
conductivity,0.00017268140558379663
dilation,0.00017268140558379663
synergy,0.00017268140558379663
hepatoxicity,0.00017268140558379663
environmental,0.00017268140558379663
automaticity,0.00017268140558379663
biological,0.00017268140558379663
counteracted,0.00017268140558379663
Exacerbation,0.00017268140558379663
glomerulonephritis,0.00017268140558379663
IgA,0.00017268140558379663
crescentic,0.00017268140558379663
colonies,0.00017268140558379663
stimulating,0.00017268140558379663
oculo-bulbar,0.00017268140558379663
autoimmune,0.00017268140558379663
erythrocyte,0.00017268140558379663
hyperuricemia,0.00017268140558379663
proprietary,0.00017268140558379663
Exaggerated,0.00017268140558379663
incremental,0.00017268140558379663
blunt,0.00017268140558379663
Tinnitus,0.00017268140558379663
Europe,0.00017268140558379663
morphological,0.00017268140558379663
markers,0.00017268140558379663
chromatin,0.00017268140558379663
condensation,0.00017268140558379663
drying,0.00017268140558379663
Edema,0.00017268140558379663
implantable,0.00017268140558379663
within14,0.00017268140558379663
epidural,0.00017268140558379663
rauwolfia,0.00017268140558379663
invasion,0.00017268140558379663
Disease,0.00017268140558379663
anti-resorptive,0.00017268140558379663
Paget,0.00017268140558379663
Calcitonin,0.00017268140558379663
primates,0.00017268140558379663
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced",0.00017268140558379663
Causing,0.00017268140558379663
Stevens-Johnson,0.00017268140558379663
myocarditis,0.00017268140558379663
nuclear,0.00017268140558379663
reliable,0.00017268140558379663
anti-cancer,0.00017268140558379663
ganglionic-blocking,0.00017268140558379663
inoculated,0.00017268140558379663
alkalizing,0.00017268140558379663
lymphatic,0.00017268140558379663
thyroiditis,0.00017268140558379663
pemphigoid,0.00017268140558379663
bullous,0.00017268140558379663
diphosphonate,0.00017268140558379663
-gentamicin,0.00017268140558379663
99mTc-methylene,0.00017268140558379663
PTX-induced,0.00017268140558379663
reexacerbation,0.00017268140558379663
non-depolarizing,0.00017268140558379663
ureidopenicillins,0.00017268140558379663
Antagonism,0.00017268140558379663
triazolopyridazines,0.00017268140558379663
air,0.00017268140558379663
allows,0.00017268140558379663
passages,0.00017268140558379663
3.1,0.00017268140558379663
3.9,0.00017268140558379663
dehydration,0.00017268140558379663
Deaths,0.00017268140558379663
salmon,0.00017268140558379663
mTOR,0.00017268140558379663
normalized,0.00017268140558379663
anticholinergic-like,0.00017268140558379663
somnolence,0.00017268140558379663
month,0.00017268140558379663
hypokinesia,0.00017268140558379663
Mild,0.00017268140558379663
.005,0.00017268140558379663
anitagonism,0.00017268140558379663
.004,0.00017268140558379663
piperidine,0.00017268140558379663
enlargement,0.00017268140558379663
Transient,0.00017268140558379663
3-hydroxyphenyl,0.00017268140558379663
"trans-3,4-dimethyl-4-",0.00017268140558379663
MM,0.00017268140558379663
represents,0.00017268140558379663
Exposure,0.00017268140558379663
misuse,0.00017268140558379663
thiazide-type,0.00017268140558379663
Increasing,0.00017268140558379663
anticholinergic-type,0.00017268140558379663
Paralytic,0.00017268140558379663
neutralizing,0.00017268140558379663
Sodium,0.00017268140558379663
High-dose,0.00017268140558379663
interesting,0.00017268140558379663
occasions,0.00017268140558379663
tubal,0.00017268140558379663
special,0.00017268140558379663
antituberculous,0.00017268140558379663
vecuronium-induced,0.00017268140558379663
hyperlocomotion,0.00017268140558379663
intubating,0.00017268140558379663
ED95,0.00017268140558379663
0.1-mg/kg,0.00017268140558379663
coumaphos/kg/day,0.00017268140558379663
Potassium,0.00017268140558379663
protects,0.00017268140558379663
forced,0.00017268140558379663
siRNAs,0.00017268140558379663
dasatinib-enhanced,0.00017268140558379663
regulating,0.00017268140558379663
2.5-6,0.00017268140558379663
6-10,0.00017268140558379663
disc,0.00017268140558379663
typhoid,0.00017268140558379663
adding,0.00017268140558379663
MDP,0.00017268140558379663
A7,0.00017268140558379663
dopamine-induced,0.00017268140558379663
two-second,0.00017268140558379663
modulates,0.00017268140558379663
opposite,0.00017268140558379663
way,0.00017268140558379663
enkephalinergic,0.00017268140558379663
dangerous,0.00017268140558379663
100-500,0.00017268140558379663
Administering,0.00017268140558379663
erythema,0.00017268140558379663
stupor,0.00017268140558379663
muscular,0.00017268140558379663
coeruleus,0.00017268140558379663
adjoining,0.00017268140558379663
12-120,0.00017268140558379663
tranquilizers,0.00017268140558379663
Prostaglandin,0.00017268140558379663
Endogenous,0.00017268140558379663
Synthesis,0.00017268140558379663
Renin,0.00017268140558379663
pacemaker,0.00017268140558379663
diminished,0.00017247926351848797
Similarly,0.00017230188513950306
matrix,0.00017176938441298972
immediate,0.00017176938441298972
towards,0.00017176938441298972
proposed,0.00017176938441298972
Blockers,0.00017126280380019843
Antiepileptic,0.00017126280380019843
fluoroquinolone,0.00017075970444602184
apart,0.00017047042882578634
qd,0.00017047042882578634
Antiepilepsy,0.00017047042882578634
Receptor,0.0001701945203409494
supplemented,0.00016945805126500346
single-dose,0.00016945805126500346
binds,0.00016945805126500346
Chewable/Dispersible,0.00016902166203947022
Powder,0.00016902166203947022
FR,0.00016902166203947022
inactivated,0.00016902166203947022
Two,0.00016902166203947022
Buffered,0.00016902166203947022
indicates,0.00016902166203947022
relaxant,0.00016902166203947022
leukemia,0.0001685653700880252
injections,0.0001682712775354922
cancers,0.0001682712775354922
chemotherapeutic,0.0001682712775354922
analyzed,0.0001682712775354922
female,0.0001682712775354922
Steady-state,0.0001682490236107892
Mean,0.0001682490236107892
1A2,0.0001682490236107892
Oxidase,0.0001682490236107892
proportion,0.0001682490236107892
already,0.00016818478467384157
Racemic,0.0001678219149700011
Foods,0.00016564654111461685
Fortified,0.00016564654111461685
100-mg,0.00016564654111461685
synthetic,0.00016564654111461685
FeSO4,0.00016564654111461685
extensive,0.00016564654111461685
125mg,0.00016564654111461685
enzyme-,0.00016564654111461685
Coumarin,0.00016550114994884346
FI,0.00016550114994884346
+/-,0.00016550114994884346
MAO-A,0.0001654395137248299
rashes,0.00016534550106073187
cecectomized,0.00016534550106073187
gram-negative,0.00016534550106073187
infection,0.00016534550106073187
chick,0.00016534550106073187
LDL-C,0.00016534550106073187
stress,0.00016534550106073187
crossover,0.000165201164557649
IV,0.00016513905381720928
alert,0.0001647022498659778
REMERON,0.00016325924761706467
beginning,0.00016325924761706467
SolTab,0.00016325924761706467
interference,0.0001631654747633604
coumarin-derivative,0.00016292796562544787
mEq/L,0.00016288221632876354
Enhanced,0.00016261373308656957
uptake,0.00016261373308656957
statistically,0.00016253315589942474
placebo,0.00016218101335274682
antimicrobial,0.00016192827729211157
prolongs,0.00016144912195004135
1.5-fold,0.0001613959202736437
postdose,0.0001613959202736437
recent,0.0001613959202736437
3.6-fold,0.0001613959202736437
eight,0.0001613959202736437
electrocardiographic,0.0001610510292935352
responding,0.00016092600253303502
additional,0.00016050145554136197
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-",0.0001599511103080875
pretreatment,0.00015942452892225845
PROLEUKIN-induced,0.00015942452892225845
hyperbilirubinemia,0.00015942452892225845
Therapy,0.00015939371333795194
TC,0.0001589972420588115
300-mg,0.0001589972420588115
isozymes,0.0001589972420588115
alkaloid,0.00015893564901836577
derivatives,0.00015840632041430602
fractional,0.00015836925736256724
objective,0.00015836925736256724
disoproxil,0.00015836925736256724
investigate,0.00015836925736256724
strain,0.00015836925736256724
fibrosis,0.00015836925736256724
carbidopa-levodopa,0.00015836925736256724
tenofovir,0.00015836925736256724
whom,0.0001581120002696057
motor,0.0001577361547758782
one-third,0.00015654585568836143
Reversible,0.00015653806046889152
122,0.00015653806046889152
tubule,0.00015653806046889152
half,0.00015653806046889152
metabolised,0.00015653806046889152
pointe,0.00015653806046889152
antibacterials,0.00015653806046889152
typically,0.00015653806046889152
arrythmias,0.00015653806046889152
uricosuric,0.00015653806046889152
doubling,0.00015653806046889152
impairing,0.00015653806046889152
intestine,0.00015653806046889152
49,0.00015653806046889152
tmax,0.00015653806046889152
bronchodilators,0.00015639488015339875
N=12,0.00015623316780610796
beta-1a,0.00015623316780610796
IM,0.00015623316780610796
-receptor,0.00015623316780610796
H,0.00015623316780610796
interferon,0.00015623316780610796
D,0.00015609155789053641
blocker,0.0001559739945711236
phenobarbital,0.00015594730513079913
confidence,0.00015594730513079913
antibiotic,0.00015541428924481515
maximal,0.0001553691580071792
3-day,0.00015528861487124068
present,0.00015525101871960434
de,0.00015390312519225624
beyond,0.00015366211450007494
procaine,0.0001529250955624173
P,0.00015235367212684814
Maalox,0.00015206333442918663
suspension,0.00015206333442918663
Single,0.00015206333442918663
life,0.00015206333442918663
hearing,0.00015161560888976577
ARE,0.00015161560888976577
Antiretroviral,0.00015122552246293886
week,0.00015094776779900343
enzymatic,0.00015078173222216051
HIV-infected,0.00015078173222216051
6-thiouric,0.00015078173222216051
perindopril/perindoprilat,0.00015078173222216051
Mercaptopurine/Azathioprine,0.00015078173222216051
canine,0.00015078173222216051
disintegrating,0.00015078173222216051
formation,0.00015069374243137368
bid,0.00015024588537049244
q.d,0.00015024588537049244
Upon,0.00015024588537049244
torsades,0.00015024588537049244
six,0.00015024588537049244
ng/mL,0.00015024588537049244
delayed,0.00015014147855407778
comparable,0.00015007269698741332
diltiazem,0.0001498290697266036
so,0.00014890627200037088
circulation,0.00014890627200037088
undergo,0.00014890627200037088
neurotoxic,0.00014853792548774614
extended,0.00014853792548774614
rifamipicin,0.0001484677011236446
myopathy,0.0001484677011236446
Q-type,0.0001484677011236446
GVIA-sensitive,0.0001484677011236446
several-,0.0001484677011236446
hypo-prothrombinemic,0.0001484677011236446
premedicated,0.0001484677011236446
insulin-dependent,0.0001484677011236446
lymphoma,0.0001484677011236446
pill,0.0001484677011236446
sclerosis,0.0001484677011236446
glatiramer,0.0001484677011236446
inconclusive,0.0001484677011236446
lomefloxacin,0.0001484677011236446
hydroxide-containing,0.0001484677011236446
hydroxide-,0.0001484677011236446
Pharmacokinetics,0.0001484677011236446
diphen-hydramine,0.0001484677011236446
organophosphorous,0.0001484677011236446
ventilation,0.0001484677011236446
Being,0.0001484677011236446
multi,0.0001484677011236446
Dolasetron,0.0001484677011236446
models,0.0001484677011236446
murine,0.0001484677011236446
high-frequency,0.0001484677011236446
anti-arrhythmic,0.0001484677011236446
5-HTv,0.0001484677011236446
worse,0.0001484677011236446
fibric,0.0001484677011236446
coupled,0.0001484677011236446
behave,0.0001484677011236446
IVA-sensitive,0.0001484677011236446
calcium-channel-blocking,0.0001484677011236446
Like,0.0001484677011236446
minerals,0.0001484677011236446
presumptive,0.0001484677011236446
cystic,0.0001484677011236446
3000,0.0001484677011236446
refractory,0.0001484677011236446
Between,0.0001484677011236446
And,0.0001484677011236446
VIA-resistant,0.0001484677011236446
Wistar,0.0001484677011236446
Have,0.0001484677011236446
opiate,0.0001484677011236446
condition,0.0001484677011236446
non-opioid,0.0001484677011236446
compound,0.0001484677011236446
coincide,0.0001484677011236446
cavity,0.0001484677011236446
FICI,0.0001484677011236446
BACKGROUND,0.0001484677011236446
kinds,0.0001484677011236446
checkerboard,0.0001484677011236446
nimodipine/omega-conotoxin,0.0001484677011236446
GVIA/omega-agatoxin,0.0001484677011236446
0,0.00014843363428784784
among,0.00014807890564805248
high-dose,0.000147035887176572
electrolytes,0.00014693897465600791
vital,0.00014693897465600791
proceed,0.00014693897465600791
theophylline-related,0.00014693897465600791
Intrathecal,0.00014693897465600791
retinal,0.00014693897465600791
concealed,0.00014693897465600791
describing,0.00014693897465600791
neoplastic,0.00014693897465600791
i,0.00014693897465600791
Converting,0.00014693897465600791
Cytotoxic,0.00014693897465600791
inefficacy,0.00014693897465600791
rises,0.00014693897465600791
vasoconstrictors,0.00014693897465600791
losses,0.00014693897465600791
Recovery,0.00014693897465600791
HDAC,0.00014693897465600791
fibrate,0.00014693897465600791
separated,0.00014693897465600791
artery,0.00014693897465600791
alertness,0.00014693897465600791
enteric,0.00014693897465600791
transduction,0.00014693897465600791
stereoisomer,0.00014693897465600791
intermediate,0.00014693897465600791
culture,0.00014693897465600791
nonfailing,0.00014693897465600791
Curariform,0.00014693897465600791
addicts,0.00014693897465600791
fade,0.00014693897465600791
curariform,0.00014693897465600791
could,0.00014674080718246607
precipitate,0.0001458894116319609
role,0.0001458894116319609
via,0.00014554847784942204
antagonism,0.00014502556099460495
changed,0.00014375531578481038
S,0.0001437054156196993
potentiation,0.00014274937093983198
immediately,0.00014205625431018554
99.5,0.00014197406199745188
reach,0.00014197406199745188
filtrated,0.00014197406199745188
hazard,0.00014197406199745188
discontinuance,0.00014197406199745188
schizophrenia,0.00014197406199745188
to10,0.00014197406199745188
99.3,0.00014197406199745188
rheumatoid,0.00014197406199745188
Transdermal,0.00014197406199745188
Including,0.00014197406199745188
Implantable,0.00014197406199745188
Injectable,0.00014197406199745188
Do,0.00014185101422659052
precipitated,0.00014185101422659052
enough,0.00014185101422659052
throughout,0.00014185101422659052
syncope,0.00014185101422659052
Alternatives,0.00014185101422659052
method,0.00014185101422659052
watched,0.00014185101422659052
Simultaneous,0.00014185101422659052
occurs,0.00014185101422659052
delivery,0.00014185101422659052
catecholamine,0.00014185101422659052
Particular,0.0001413267442791355
revealed,0.00014123297142520919
intensity,0.00014123297142520919
Chemotherapy,0.00014123297142520919
development,0.00014087045232769047
cognitive,0.00014020379741108702
returned,0.00014016113139669883
production,0.00013965159201023702
product,0.00013965159201023702
Normalized,0.00013918221724562585
Ratio,0.00013918221724562585
enterohepatic,0.00013902882283589602
functional,0.0001387180283287659
pigeons,0.00013861604962350782
intraperitoneally,0.00013861604962350782
corrected,0.00013856660877475946
examine,0.00013856660877475946
versus,0.00013856660877475946
examined,0.00013856660877475946
improves,0.00013856660877475946
having,0.00013846224730629242
same,0.00013814778243115278
7,0.00013759781396815995
Antibiotics,0.0001356181565769221
examining,0.00013519088550539848
group,0.00013519088550539848
symptoms,0.0001349829179634332
pre-Mexitil,0.00013479507568425753
point,0.00013479507568425753
disease,0.0001346634774525013
determine,0.00013461335235032124
supplement,0.00013452580606121423
I,0.00013404149123297238
-erythro-fluorocitrate,0.00013404149123297238
conclude,0.00013384451746156767
hoof,0.00013384451746156767
output,0.00013384451746156767
AUGMENTIN,0.00013384451746156767
enterocolitis,0.00013384451746156767
XR,0.00013384451746156767
BP,0.00013384451746156767
dysesthesia,0.00013384451746156767
Hypotension,0.00013384451746156767
drinking,0.00013384451746156767
characterized,0.00013384451746156767
fosinopril,0.00013384451746156767
fluid,0.00013384451746156767
rapid,0.00013384451746156767
cardioactive,0.0001336505715978653
various,0.00013334939066222962
counts,0.00013324079006105105
adjustments,0.00013323108477258927
cancer,0.00013249956885319492
Beta,0.00013172961116192372
individuals,0.00013150712161269507
instances,0.00013144569545719964
inducing,0.00013138945528079482
fluvoxamine,0.00012985716608582276
unaffected,0.0001296902407896816
occurred,0.00012915981210248617
indication,0.0001286659802730572
procedure,0.0001286659802730572
spinal,0.0001286659802730572
Study,0.0001286659802730572
endorphinergic,0.0001286659802730572
R=,0.0001286659802730572
placebo-treated,0.0001286659802730572
Inhibit,0.00012857240203389964
arthritis,0.00012837391142439536
cycling,0.00012810616444336453
diffusion,0.00012786986050994376
we,0.0001269737686624417
escalating,0.0001269737686624417
min,0.00012654088031394117
vasoconstriction,0.00012564788477176236
apoptosis,0.00012557489415132572
depressed,0.00012491973776040943
cholesterol,0.0001245801875101593
Of,0.0001245801875101593
cytotoxic,0.0001243658664968894
Our,0.0001243658664968894
fewer,0.0001243658664968894
member,0.00012382062978399944
unusually,0.00012329013879686102
took,0.00012329013879686102
free,0.00012314278939318246
alteration,0.00012246787704250917
target,0.00012213732493382423
transport,0.0001221368860053751
primarily,0.0001221368860053751
temporarily,0.00012184841953610803
both,0.00012182255378734297
working,0.00012176338400082809
properly,0.00012176338400082809
into,0.00012176338400082809
QT,0.00012131785780211679
breakdown,0.0001203422303298618
arterial,0.00012014408204907845
mg/m2,0.00012004155865941168
"tramadol.4,5",0.00012004155865941168
388,0.00012004155865941168
"drugs.1,3",0.00012004155865941168
Tumor,0.00012004155865941168
health,0.00011978323941108648
IN,0.00011913203847369047
ANTICOAGULANTS,0.00011913203847369047
COUMARIN,0.00011913203847369047
CONJUNCTION,0.00011913203847369047
EXERCISED,0.00011913203847369047
1/10,0.00011913203847369047
short,0.00011913203847369047
one-tenth,0.00011913203847369047
Adequate,0.00011913203847369047
replace,0.00011913203847369047
BE,0.00011913203847369047
Analogues,0.00011913203847369047
Nucleoside,0.00011913203847369047
WHEN,0.00011913203847369047
WITH,0.00011913203847369047
continued,0.00011913203847369047
methotrexate-related,0.00011913203847369047
1/3,0.00011913203847369047
1/4,0.00011913203847369047
Potentiation,0.00011913203847369047
third,0.00011913203847369047
caffeine-containing,0.00011913203847369047
needs,0.00011913203847369047
SHOULD,0.00011913203847369047
alternatives,0.00011913203847369047
Agonists,0.00011913203847369047
iron,0.00011913203847369047
notably,0.00011913203847369047
ofthe,0.00011913203847369047
releaser,0.00011913203847369047
Usage,0.00011913203847369047
seem,0.00011913203847369047
dictate,0.00011913203847369047
5-HT1B/1D,0.00011913203847369047
orthostatic,0.00011897746326017256
further,0.00011892603475849306
epoxide,0.00011876581557412891
cortical,0.00011876581557412891
assays,0.00011876581557412891
chromatography,0.00011876581557412891
glucuronidation,0.00011876581557412891
Metabolized,0.00011876581557412891
1.3,0.00011876581557412891
periods,0.00011876581557412891
meals,0.00011876581557412891
structurally,0.00011876581557412891
immune,0.00011876581557412891
schizoaffective,0.0001181052658467685
magnitude,0.0001181052658467685
converted,0.0001181052658467685
hydroxylation,0.0001181052658467685
median,0.0001181052658467685
duodenal,0.0001181052658467685
catabolism,0.0001181052658467685
slowly,0.0001181052658467685
metabolizing,0.0001181052658467685
competition,0.0001181052658467685
disorder,0.0001181052658467685
contraceptive,0.00011803521457753874
positive,0.00011797483523434682
Prior,0.0001175127631597439
failed,0.0001175127631597439
Parkinsons,0.0001175127631597439
attenuating,0.0001175127631597439
prolonging,0.0001175127631597439
vs,0.00011744174825945031
methods,0.00011736936283790467
done,0.00011736936283790467
International,0.0001167478247985354
0.05,0.0001167478247985354
inhibitory,0.00011599152854568917
GI,0.00011573206564330363
comparison,0.00011511408494491171
attenuate,0.00011511408494491171
adenocarcinomas,0.00011511408494491171
combinations,0.00011511408494491171
impeding,0.00011501170724914633
extend,0.00011501170724914633
4-6,0.00011501170724914633
mixed,0.00011325838216746931
H1,0.00011265490335499173
atropinization,0.00011265490335499173
nose,0.00011265490335499173
upper,0.00011265490335499173
skin,0.00011265490335499173
amlodipine/valsartan,0.00011265490335499173
Ampicillin/Amoxicillin,0.00011265490335499173
Hypertension,0.00011265490335499173
mydriasis,0.00011265490335499173
dryness,0.00011265490335499173
Altered,0.00011265490335499173
<,0.00011265490335499173
children,0.00011265490335499173
displayed,0.00011265490335499173
0.09-0.13,0.00011265490335499173
novel,0.00011265490335499173
adrenal,0.00011265490335499173
rash,0.00011265490335499173
antiviral,0.00011265490335499173
antibacterial,0.00011265490335499173
InsP,0.00011265490335499173
earlier,0.00011265490335499173
improved,0.0001123500106923192
mental,0.0001123500106923192
anti-depressants,0.0001123500106923192
Pediatric,0.00011144966964105052
measured,0.00011097680149751987
skills,0.00011001996807835646
250,0.00010990482321804329
intramuscular,0.00010990482321804329
tuberculosis,0.00010990482321804329
glucuronide,0.00010990482321804329
Intravenous,0.00010990482321804329
Another,0.00010990482321804329
limit,0.00010990482321804329
p.o,0.00010949504168134006
dysrhythmias,0.00010949504168134006
OH,0.00010936561417529411
"1,25",0.00010936561417529411
vasoconstrictor,0.00010936561417529411
2D3,0.00010936561417529411
humans,0.00010923173248467144
useful,0.00010886611463511997
>,0.00010886611463511997
subtypes,0.00010886611463511997
voltage-dependent,0.00010886611463511997
DNA,0.00010886611463511997
0.15,0.00010886611463511997
depressive,0.00010886611463511997
future,0.00010886611463511997
intravitreal,0.00010886611463511997
Many,0.00010886611463511997
diagnostic,0.00010886611463511997
ER,0.00010886611463511997
double-blind,0.00010886611463511997
unexpected,0.00010886611463511997
regular,0.00010886611463511997
descending,0.00010886611463511997
package,0.00010844929899134215
cycle,0.00010844929899134215
CGS,0.00010818017731528684
anxiogenic,0.00010818017731528684
CNS-Active,0.00010818017731528684
21680,0.00010818017731528684
account,0.00010818017731528684
dosed,0.00010818017731528684
vasodilating,0.00010818017731528684
fixed,0.00010818017731528684
lyase,0.00010818017731528684
conditions,0.00010766832073749733
Potassium-Sparing,0.00010734236534903907
cohort,0.00010734236534903907
HEY,0.00010734236534903907
chondroitin,0.00010689857510837175
heparinase,0.00010689857510837175
ABC,0.00010689857510837175
metastasis,0.00010663989869574841
DSST,0.00010636272825670368
msec,0.00010636272825670368
pyridine,0.00010636272825670368
deaths,0.00010636272825670368
stimulant,0.00010636272825670368
1.0,0.00010625832144006697
appeared,0.00010625786476603505
screen,0.00010617366110554638
cross-reactivity,0.00010617366110554638
practice,0.00010617366110554638
adolescent,0.00010617366110554638
tetracycline,0.00010617366110554638
asparagine,0.00010617366110554638
consciousness,0.00010617366110554638
overdose,0.00010594591261281483
poisoning,0.00010594591261281483
side-effects,0.00010594591261281483
insulin,0.00010568345841066584
maintenance,0.00010552919186057608
100-300,0.00010479613076352923
halved,0.00010479613076352923
extremely,0.00010479613076352923
CNS-active,0.00010479613076352923
forevidence,0.00010479613076352923
non-linear,0.00010479613076352923
controlled-release,0.00010416449662831173
article,0.00010416449662831173
P-glycoprotein,0.00010416449662831173
7-fold,0.00010416449662831173
600-mg,0.00010416449662831173
94.8,0.00010416449662831173
60-mg,0.00010416449662831173
16-fold,0.00010416449662831173
microsomes,0.00010416449662831173
96.3,0.00010416449662831173
dosages,0.00010402209719662103
regularly,0.00010199260952226119
involvement,0.00010199260952226119
kept,0.00010199260952226119
GIVEN,0.0001018398146207522
hormonal,0.00010087517575652072
fashion,0.0001008344391303373
percentage,0.0001008344391303373
lesser,0.0001008344391303373
forms,0.0001008344391303373
tumor,0.00010020438266722387
types,0.00010020438266722387
over,0.00010017985968324705
With,9.977471320898879e-05
insert,9.975568064735096e-05
Anticoagulant,9.933694881858468e-05
All,9.933694881858468e-05
Nicardipine,9.933694881858468e-05
conclusion,9.933694881858468e-05
nonetheless,9.933694881858468e-05
inadvisable,9.933694881858468e-05
mind,9.933694881858468e-05
79,9.933694881858468e-05
qid,9.933694881858468e-05
chemical,9.933694881858468e-05
resemblance,9.933694881858468e-05
interrupt,9.933694881858468e-05
achieved,9.933694881858468e-05
Standard,9.933694881858468e-05
co-administer,9.933694881858468e-05
green,9.89668774122876e-05
hyaluronan,9.89668774122876e-05
promoter,9.89668774122876e-05
fluorescent,9.89668774122876e-05
cDNA,9.89668774122876e-05
SSRIs,9.89668774122876e-05
encoding,9.89668774122876e-05
delivered,9.89668774122876e-05
GFP,9.89668774122876e-05
chicken,9.89668774122876e-05
convert,9.89668774122876e-05
-actin,9.89668774122876e-05
U251,9.89668774122876e-05
progesterone,9.89668774122876e-05
recommended.Levetiracetam,9.89668774122876e-05
levodopa/dopa-decarboxylase,9.89668774122876e-05
MAO-B,9.89668774122876e-05
n=29,9.89668774122876e-05
L-type,9.89668774122876e-05
ischemia,9.89668774122876e-05
Persons,9.89668774122876e-05
submaximal,9.89668774122876e-05
bolus-IFL,9.89668774122876e-05
extremities,9.89668774122876e-05
connection,9.89668774122876e-05
invalidate,9.89668774122876e-05
mmol/day,9.89668774122876e-05
IVA,9.89668774122876e-05
GVIA,9.89668774122876e-05
hot-plate,9.89668774122876e-05
minimize,9.89668774122876e-05
16-34,9.89668774122876e-05
technique,9.89668774122876e-05
maybe,9.89668774122876e-05
hydrophilic,9.89668774122876e-05
peroral,9.89668774122876e-05
8-23,9.89668774122876e-05
Conjugation,9.89668774122876e-05
HeLa,9.89668774122876e-05
HepG2,9.89668774122876e-05
pheochromocytoma,9.89668774122876e-05
vanillylmandelic,9.89668774122876e-05
induces,9.89668774122876e-05
complicated,9.89668774122876e-05
uncomplicated,9.89668774122876e-05
documented,9.89668774122876e-05
naloxone-sensitive,9.89668774122876e-05
elicit,9.89668774122876e-05
saline,9.89668774122876e-05
heparin-induced,9.89668774122876e-05
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle",9.89668774122876e-05
experimental,9.89668774122876e-05
0.2-0.5,9.89668774122876e-05
repeat,9.89668774122876e-05
ethinylestradiol/levonorgestrol,9.89668774122876e-05
prostatitis,9.89668774122876e-05
luteinizing,9.89668774122876e-05
lipid-lowering,9.89668774122876e-05
query,9.89668774122876e-05
planned,9.89668774122876e-05
guardians,9.89668774122876e-05
hypnotic,9.89668774122876e-05
non-CYP3A4,9.89668774122876e-05
Weekly,9.89668774122876e-05
n=24,9.89668774122876e-05
bosentan-,9.89668774122876e-05
light/dark,9.89668774122876e-05
n=18,9.89668774122876e-05
adenosine,9.89668774122876e-05
belladonna,9.89668774122876e-05
Prednisone/prednisolone,9.89668774122876e-05
parallel,9.89668774122876e-05
half-,9.89668774122876e-05
Repeated,9.89668774122876e-05
-warfarin,9.89668774122876e-05
6-MP/AZA,9.89668774122876e-05
besides,9.89668774122876e-05
supporting,9.879507162258161e-05
provide,9.879507162258161e-05
P450IID6,9.872212866268715e-05
125-mg,9.872212866268715e-05
poor,9.872212866268715e-05
T,9.872212866268715e-05
subsequently,9.839157655400221e-05
Antagonists,9.838152700858416e-05
bepridil,9.813676594405685e-05
volume,9.807535245520693e-05
synthesis,9.639833366925643e-05
tolerated,9.632454239305588e-05
drowsiness,9.617276250883933e-05
confirmed,9.617276250883933e-05
congeners,9.617276250883933e-05
immunization,9.617276250883933e-05
protective,9.617276250883933e-05
experiencing,9.617276250883933e-05
endotoxin-induced,9.617276250883933e-05
persistent,9.617276250883933e-05
injury,9.617276250883933e-05
coumaphos/kg,9.617276250883933e-05
Distinct,9.617276250883933e-05
cure,9.617276250883933e-05
factors,9.617276250883933e-05
Abl,9.617276250883933e-05
preclinical,9.617276250883933e-05
-mediated,9.617276250883933e-05
neuron,9.617276250883933e-05
flow,9.617276250883933e-05
noradrenergic,9.617276250883933e-05
symptomatic,9.617276250883933e-05
Most,9.617276250883933e-05
recognized,9.617276250883933e-05
Myocardial,9.617276250883933e-05
breakthrough,9.617276250883933e-05
kinases,9.617276250883933e-05
Src,9.617276250883933e-05
iatrogenic,9.617276250883933e-05
cocaine-induced,9.617276250883933e-05
drops,9.617276250883933e-05
symptomatology,9.617276250883933e-05
paclitaxel-induced,9.617276250883933e-05
E2,9.617276250883933e-05
hand,9.617276250883933e-05
pathway,9.604800483009601e-05
pharmacological,9.560195767344126e-05
265,9.538629009386845e-05
Clearance,9.538629009386845e-05
milk,9.538629009386845e-05
190,9.538629009386845e-05
andCmin,9.538629009386845e-05
non-matched,9.538629009386845e-05
historicalcontrol,9.538629009386845e-05
0.013,9.538629009386845e-05
DITROPAN,9.538629009386845e-05
competing,9.538629009386845e-05
Orlistat-Orlistat,9.538629009386845e-05
50-mg,9.538629009386845e-05
269,9.538629009386845e-05
matched,9.538629009386845e-05
0.022,9.538629009386845e-05
totally,9.538629009386845e-05
XL,9.538629009386845e-05
ages,9.538629009386845e-05
5-,9.538629009386845e-05
oxybutynin,9.538629009386845e-05
possibilities,9.538629009386845e-05
evidenced,9.538629009386845e-05
alternate-day,9.538629009386845e-05
1984,9.538629009386845e-05
hydroxylated,9.538629009386845e-05
biologic,9.538629009386845e-05
leave,9.538629009386845e-05
~36,9.538629009386845e-05
Aldehyde,9.538629009386845e-05
0-8,9.538629009386845e-05
elimination.14,9.538629009386845e-05
albumin,9.538629009386845e-05
University,9.538629009386845e-05
Rimmer,9.538629009386845e-05
H2-Receptor,9.538629009386845e-05
Richens,9.538629009386845e-05
consequent,9.538629009386845e-05
threatening,9.538629009386845e-05
Wales,9.538629009386845e-05
Drs,9.538629009386845e-05
life-,9.538629009386845e-05
"1,000",9.538629009386845e-05
479,9.538629009386845e-05
20-mg,9.538629009386845e-05
12-fold,9.538629009386845e-05
nonfunctioning,9.538629009386845e-05
10-fold,9.538629009386845e-05
accelerate,9.538629009386845e-05
minute,9.538629009386845e-05
uric,9.538629009386845e-05
hypoxanthine,9.538629009386845e-05
S.D,9.538629009386845e-05
reflects,9.538629009386845e-05
251,9.538629009386845e-05
averaged,9.538629009386845e-05
142,9.538629009386845e-05
302,9.538629009386845e-05
detoxification,9.538629009386845e-05
allopurinol,9.538629009386845e-05
delaying,9.538629009386845e-05
3.8-fold,9.538629009386845e-05
1.34-fold,9.538629009386845e-05
oral-dose,9.538629009386845e-05
~28,9.538629009386845e-05
accompany,9.538629009386845e-05
emptying,9.538629009386845e-05
sulfide,9.538629009386845e-05
1-,9.538629009386845e-05
representing,9.538629009386845e-05
97.5,9.538629009386845e-05
gritty,9.538629009386845e-05
Boric,9.538629009386845e-05
preservative,9.538629009386845e-05
99.2,9.538629009386845e-05
substance,9.538629009386845e-05
20-33,9.538629009386845e-05
Piperacillin,9.538629009386845e-05
fell,9.538629009386845e-05
methadone-maintenance,9.538629009386845e-05
useof,9.538629009386845e-05
clinician,9.538629009386845e-05
points,9.538629009386845e-05
denotes,9.538629009386845e-05
Pediatrics,9.538629009386845e-05
nc,9.538629009386845e-05
-19,9.538629009386845e-05
AUC0-120hr,9.538629009386845e-05
lactulose-induced,9.538629009386845e-05
drop,9.538629009386845e-05
1-week,9.538629009386845e-05
60mg,9.538629009386845e-05
chewable/dispersible,9.538629009386845e-05
15-fold,9.538629009386845e-05
37,9.538629009386845e-05
2.3,9.538629009386845e-05
marketed,9.538629009386845e-05
See,9.538629009386845e-05
102,9.538629009386845e-05
ml/min,9.538629009386845e-05
354,9.538629009386845e-05
73,9.538629009386845e-05
dolasetron,9.538629009386845e-05
rabbit,9.538629009386845e-05
slices,9.538629009386845e-05
co-treatment,9.538629009386845e-05
68,9.538629009386845e-05
conclusive,9.538629009386845e-05
performance,9.518028637878206e-05
psychomotor,9.518028637878206e-05
growth,9.397334029248583e-05
component,9.397334029248583e-05
parkinsonian,9.397334029248583e-05
mechanisms,9.397334029248583e-05
82,9.380686306947883e-05
6.6,9.362361445808265e-05
bioavailabillty,9.362361445808265e-05
Possible,9.362361445808265e-05
conjugation,9.362361445808265e-05
200-mg,9.362361445808265e-05
Metabolism,9.362361445808265e-05
meclofenamate,9.351720047978684e-05
Supplements,9.327053913366079e-05
neutrophil,9.307920391110613e-05
derived,9.307920391110613e-05
diabetics,9.307920391110613e-05
cause-and-effect,9.307920391110613e-05
demonstrate,9.268391620143035e-05
vs.,9.10538668386085e-05
dogs,9.094236609663575e-05
pulmonary,9.064264894753649e-05
cefditoren,9.053280396287278e-05
Treatment,9.041365245121558e-05
excluded,9.028635097907411e-05
variable,8.942587032034766e-05
literature,8.908219021397379e-05
warrant,8.906810386211106e-05
equipotent,8.906810386211106e-05
dissolution,8.906810386211106e-05
stereoisomers,8.906810386211106e-05
subcutaneous,8.906810386211106e-05
mode,8.906810386211106e-05
S-,8.906810386211106e-05
QRS,8.906810386211106e-05
NPH,8.906810386211106e-05
Such,8.906810386211106e-05
o,8.906810386211106e-05
smoking,8.906810386211106e-05
comprehensive,8.906810386211106e-05
0-24,8.906810386211106e-05
false-positive,8.906810386211106e-05
CMC-Cys7.3,8.906810386211106e-05
isolates,8.906810386211106e-05
R-value,8.906810386211106e-05
tid,8.892637078039556e-05
maintain,8.892637078039556e-05
1-mg,8.892637078039556e-05
measurable,8.892637078039556e-05
USP,8.8893007699542e-05
kg,8.797231988011411e-05
conversion,8.797231988011411e-05
negatively,8.797231988011411e-05
Clinically,8.797231988011411e-05
mL/min,8.75299180440603e-05
megestrol,8.75299180440603e-05
probably,8.743302890446003e-05
bile,8.742551122764564e-05
detected,8.742551122764564e-05
Effects,8.738282946008091e-05
intervals,8.732124289190235e-05
g,8.583623032354382e-05
NS,8.569459662965961e-05
STADOL,8.569459662965961e-05
Day5,8.470355061152013e-05
exchange,8.470355061152013e-05
absorbed,8.470355061152013e-05
sensitive,8.470355061152013e-05
anionic,8.470355061152013e-05
AUC0-24hr,8.470355061152013e-05
glutathione,8.470355061152013e-05
colonic,8.410127100377807e-05
RESULTS,8.410127100377807e-05
1-2,8.410127100377807e-05
considerable,8.410127100377807e-05
scintigraphy,8.410127100377807e-05
meal,8.410127100377807e-05
clearances,8.410127100377807e-05
cyclosporine-treated,8.410127100377807e-05
become,8.410127100377807e-05
displacing,8.410127100377807e-05
color,8.410127100377807e-05
later,8.410127100377807e-05
treatment-resistant,8.410127100377807e-05
oxypurines,8.410127100377807e-05
double,8.410127100377807e-05
indeed,8.410127100377807e-05
eye,8.410127100377807e-05
inter-patient,8.410127100377807e-05
0.025,8.410127100377807e-05
followed,8.39937277902214e-05
hypotension.Cimetidine,8.242791272572436e-05
blunts,8.242791272572436e-05
bumetanide-induced,8.242791272572436e-05
preparation,8.242791272572436e-05
depletion,8.242791272572436e-05
natriuresis,8.242791272572436e-05
mesylate,8.239643271223951e-05
safe,8.223199329038255e-05
phenelzine,8.223199329038255e-05
epinephrine,8.223199329038255e-05
problem,8.223199329038255e-05
alternate,8.223199329038255e-05
tranylcypromine,8.223199329038255e-05
Non-selective,8.223199329038255e-05
110-200,8.223199329038255e-05
sequence,8.223199329038255e-05
mixing,8.223199329038255e-05
myelosuppression,8.223199329038255e-05
HC1,8.223199329038255e-05
direct,8.220016423299281e-05
150,8.136584945095393e-05
15.1,8.105038238381823e-05
ORAL,8.105038238381823e-05
g/h/mL,8.105038238381823e-05
multidose,8.105038238381823e-05
4.55,8.105038238381823e-05
T1/2,8.105038238381823e-05
LNG,8.105038238381823e-05
EE,8.105038238381823e-05
hr/mL,8.105038238381823e-05
AUC0-12,8.105038238381823e-05
12.08,8.105038238381823e-05
10th,8.105038238381823e-05
magnesium-aluminum,8.105038238381823e-05
17.8,8.105038238381823e-05
5.4,8.105038238381823e-05
Basis,8.105038238381823e-05
Demonstrated,8.105038238381823e-05
Significance,8.105038238381823e-05
q24h,8.105038238381823e-05
C12hr,8.105038238381823e-05
stered,8.105038238381823e-05
completion,8.105038238381823e-05
230,8.105038238381823e-05
admini,8.105038238381823e-05
Involving,8.105038238381823e-05
3.3-fold,8.105038238381823e-05
2.3-fold,8.105038238381823e-05
"4,8",8.105038238381823e-05
threefold,8.105038238381823e-05
10-day,8.105038238381823e-05
170,8.105038238381823e-05
ng,8.105038238381823e-05
12-hour,8.105038238381823e-05
OBJECTIVE,7.916979394118062e-05
improve,7.916979394118062e-05
psychopathology,7.916979394118062e-05
overload,7.916979394118062e-05
HPLC,7.916979394118062e-05
red,7.916979394118062e-05
liquid,7.916979394118062e-05
0.6,7.916979394118062e-05
antifungal,7.898973354381056e-05
CYP2A6,7.824686114243917e-05
preliminary,7.824686114243917e-05
years,7.824686114243917e-05
estrogen,7.824686114243917e-05
By,7.824686114243917e-05
published,7.824686114243917e-05
1500,7.824686114243917e-05
aldehyde,7.824686114243917e-05
repeated,7.824686114243917e-05
Induce,7.824686114243917e-05
seven,7.80940662410412e-05
QID,7.80940662410412e-05
catalyzed,7.80940662410412e-05
kidney,7.80940662410412e-05
means,7.678962532464695e-05
traditional,7.678962532464695e-05
activation,7.678962532464695e-05
strains,7.678962532464695e-05
phase,7.678962532464695e-05
lines,7.678962532464695e-05
randomized,7.678962532464695e-05
sufficient,7.674744960917135e-05
conflicting,7.674744960917135e-05
toxicology,7.674744960917135e-05
properties,7.670473508891718e-05
minimal,7.668857743414748e-05
first-pass,7.600993226763997e-05
81,7.600993226763997e-05
recipients,7.600993226763997e-05
N=18,7.559120043876266e-05
2.2,7.559120043876266e-05
p-glycoprotein,7.559120043876266e-05
subject,7.559120043876266e-05
B2,7.559120043876266e-05
74,7.559120043876266e-05
area-under-the-curve,7.559120043876266e-05
0-,7.559120043876266e-05
ten-subject,7.559120043876266e-05
8.1,7.559120043876266e-05
7.2,7.559120043876266e-05
twice-daily,7.559120043876266e-05
94,7.559120043876266e-05
members,7.559120043876266e-05
-hydroxy,7.559120043876266e-05
mainly,7.559120043876266e-05
Conversely,7.559120043876266e-05
concomitan,7.559120043876266e-05
Therophylline,7.559120043876266e-05
remained,7.559120043876266e-05
5.4-fold,7.559120043876266e-05
49-fold,7.559120043876266e-05
13-fold,7.559120043876266e-05
psychiatric,7.559120043876266e-05
transport-related,7.559120043876266e-05
98,7.559120043876266e-05
N=16,7.559120043876266e-05
mineral,7.559120043876266e-05
111,7.559120043876266e-05
3.5-fold,7.559120043876266e-05
steady-,7.559120043876266e-05
lessened,7.559120043876266e-05
sublingual,7.559120043876266e-05
middle-aged,7.559120043876266e-05
lowers,7.559120043876266e-05
Day9,7.559120043876266e-05
114,7.559120043876266e-05
Calcium,7.559120043876266e-05
375-mg,7.559120043876266e-05
14-day,7.559120043876266e-05
Oil-Concomitant,7.559120043876266e-05
leads,7.559120043876266e-05
theophylline-containing,7.559120043876266e-05
primate,7.559120043876266e-05
11-fold,7.559120043876266e-05
nonsteroial,7.559120043876266e-05
88,7.559120043876266e-05
sequestrants,7.559120043876266e-05
CLcr=15,7.559120043876266e-05
urate,7.559120043876266e-05
Discontinuation,7.559120043876266e-05
Uricosuric,7.559120043876266e-05
physiologic,7.559120043876266e-05
Cholestyramine-Concomitant,7.559120043876266e-05
Colestipol-Concomitant,7.559120043876266e-05
impairs,7.559120043876266e-05
endotoxin-treated,7.559120043876266e-05
marked,7.538256484485029e-05
biliary,7.504932324275959e-05
tacrolimus-treated,7.504932324275959e-05
Suspension,7.504932324275959e-05
mL/h,7.504932324275959e-05
property,7.410498769333529e-05
cells.14,7.345378675593928e-05
intracranial,7.345378675593928e-05
persists,7.345378675593928e-05
Tissue,7.345378675593928e-05
almost,7.345378675593928e-05
Veratrum,7.345378675593928e-05
coeruleus/A5/A7,7.345378675593928e-05
hydroxylase,7.345378675593928e-05
striatal,7.345378675593928e-05
hydroxylase-positive,7.345378675593928e-05
3.0+/-0.9,7.345378675593928e-05
reversing,7.345378675593928e-05
aBased,7.345378675593928e-05
tomography,7.345378675593928e-05
heartbeat,7.345378675593928e-05
preclude,7.345378675593928e-05
Lotensin,7.345378675593928e-05
anti-,7.345378675593928e-05
irregular,7.345378675593928e-05
intravascular,7.345378675593928e-05
wistar,7.345378675593928e-05
Suppression,7.345378675593928e-05
Experience,7.345378675593928e-05
rate-decreasing,7.345378675593928e-05
non-comparative,7.345378675593928e-05
1400,7.345378675593928e-05
Efficacy,7.345378675593928e-05
bombesin-enhanced,7.345378675593928e-05
diminution,7.345378675593928e-05
Medroxyprogesterone,7.345378675593928e-05
Pharmacological/Pharmacodynamic,7.345378675593928e-05
kinetics,7.345378675593928e-05
provoke,7.345378675593928e-05
predisposing,7.345378675593928e-05
prevention,7.345378675593928e-05
Weakness,7.345378675593928e-05
367,7.345378675593928e-05
369,7.345378675593928e-05
Blocking,7.345378675593928e-05
exacerbation,7.345378675593928e-05
administer,7.345378675593928e-05
Warfarin-Vitamin,7.345378675593928e-05
Acetate,7.345378675593928e-05
Coumarin-Derivative,7.345378675593928e-05
perioperative,7.345378675593928e-05
Iodinated,7.345378675593928e-05
knockdown,7.345378675593928e-05
siRNA,7.345378675593928e-05
behavioural,7.345378675593928e-05
opioid-induced,7.345378675593928e-05
protect,7.345378675593928e-05
coenzyme,7.345378675593928e-05
theophylline-quinolone,7.345378675593928e-05
stereological,7.345378675593928e-05
peripherally,7.345378675593928e-05
immunoreactivity,7.345378675593928e-05
emission,7.345378675593928e-05
positron,7.345378675593928e-05
Anabolic,7.345378675593928e-05
stimulatory,7.345378675593928e-05
Lithium,7.345378675593928e-05
lithium,7.345378675593928e-05
successive,7.345378675593928e-05
17-day-old,7.345378675593928e-05
Acute,7.345378675593928e-05
87,7.345378675593928e-05
7.7,7.345378675593928e-05
e.w,7.345378675593928e-05
bactercidal,7.345378675593928e-05
organisms,7.345378675593928e-05
But,7.345378675593928e-05
diminishing,7.345378675593928e-05
quicker,7.345378675593928e-05
5.8+/-2.3,7.345378675593928e-05
hyperreninemia,7.345378675593928e-05
self,7.345378675593928e-05
2.5+/-0.6,7.345378675593928e-05
Hyperpyrexia,7.345378675593928e-05
Delayed,7.345378675593928e-05
Media,7.345378675593928e-05
allowing,7.345378675593928e-05
appropriateness,7.345378675593928e-05
iodinated,7.345378675593928e-05
12.6,7.345378675593928e-05
inhospital,7.345378675593928e-05
radiographic,7.345378675593928e-05
501,7.345378675593928e-05
11-28,7.345378675593928e-05
Contrast,7.345378675593928e-05
-blocking,7.345378675593928e-05
necessitating,7.345378675593928e-05
imaging,7.345378675593928e-05
midbrain,7.345378675593928e-05
abolish,7.345378675593928e-05
post-mortem,7.345378675593928e-05
leukopenia,7.345378675593928e-05
Angiotensln,7.345378675593928e-05
contractile,7.345378675593928e-05
measurements,7.345378675593928e-05
2.7,7.345378675593928e-05
11.5,7.345378675593928e-05
egg,7.345378675593928e-05
scores,7.345378675593928e-05
0.8,7.345378675593928e-05
9.2+/-1.8,7.345378675593928e-05
residual,7.345378675593928e-05
aggravating,7.345378675593928e-05
13.7,7.345378675593928e-05
13.8,7.345378675593928e-05
c,7.188958980441917e-05
amplifies,7.188958980441917e-05
approx,7.188958980441917e-05
massively,7.188958980441917e-05
Anti-Inflammatory,7.185620929361924e-05
incubation,7.16911111202645e-05
MCF7,7.16911111202645e-05
HCT116,7.16911111202645e-05
molecular,7.16911111202645e-05
schedules,7.16911111202645e-05
part,7.16911111202645e-05
variability,7.16911111202645e-05
step,7.16911111202645e-05
0.03,7.16911111202645e-05
fluoride,7.16911111202645e-05
citrate,7.16911111202645e-05
-1,7.16911111202645e-05
above,6.933345553128412e-05
non-human,6.933345553128412e-05
ND,6.927194760553146e-05
sampling,6.927194760553146e-05
long-acting,6.927194760553146e-05
TBg,6.927194760553146e-05
'',6.927194760553146e-05
METHODS,6.927194760553146e-05
iron-fortified,6.927194760553146e-05
deleterious,6.927194760553146e-05
fasting,6.927194760553146e-05
differently,6.927194760553146e-05
dependence,6.927194760553146e-05
saponins,6.927194760553146e-05
rabbits,6.927194760553146e-05
humoral,6.927194760553146e-05
particles,6.927194760553146e-05
samples,6.927194760553146e-05
MCF-7,6.927194760553146e-05
ginseng,6.927194760553146e-05
circulating,6.927194760553146e-05
arteries,6.927194760553146e-05
``,6.927194760553146e-05
HMGCoA,6.927194760553146e-05
25-mg,6.927194760553146e-05
stem-and-leaf,6.927194760553146e-05
basal,6.927194760553146e-05
constant,6.927194760553146e-05
dietary-obese,6.927194760553146e-05
3.5,6.927194760553146e-05
desirable,6.927194760553146e-05
ERMBT,6.927194760553146e-05
renally,6.927194760553146e-05
Pregnancy,6.927194760553146e-05
testing,6.86003006249436e-05
This,6.82986231324012e-05
second,6.771838292130017e-05
Ca,6.699386744246638e-05
too,6.699386744246638e-05
NAD+-dependent,6.699386744246638e-05
Moreover,6.699386744246638e-05
atypical,6.699386744246638e-05
contraceptives,6.699386744246638e-05
2+,6.699386744246638e-05
little,6.657705179846651e-05
postural,6.657705179846651e-05
Serum,6.613326155802124e-05
0.1,6.571676358313461e-05
dependent,6.277104727359095e-05
divided,6.277104727359095e-05
light,6.277104727359095e-05
tissues,6.274865103983451e-05
p,6.222826059221198e-05
IP,6.216876766573787e-05
consistent,6.216876766573787e-05
approach,6.216876766573787e-05
reducing,6.216876766573787e-05
disorders,6.216876766573787e-05
intraperitoneal,6.216876766573787e-05
selectively,6.216876766573787e-05
Twelve,6.216876766573787e-05
stimulation,6.216876766573787e-05
mask,6.216876766573787e-05
Digitalis,6.216876766573787e-05
implicated,6.216876766573787e-05
collapse,6.216876766573787e-05
abolished,6.216876766573787e-05
Thyroid,6.216876766573787e-05
sex,6.216876766573787e-05
MRSA,6.216876766573787e-05
0.7,6.216876766573787e-05
Adverse,6.216876766573787e-05
antinociception,6.216876766573787e-05
restricted,6.216876766573787e-05
tended,6.216876766573787e-05
occasional,6.216876766573787e-05
long-,6.216876766573787e-05
Meclofenamate,6.216876766573787e-05
achievement,6.216876766573787e-05
requiring,5.985480456671688e-05
Increases,5.985480456671688e-05
submitted,5.937456481230896e-05
250-mg,5.937456481230896e-05
edema,5.937456481230896e-05
protocol,5.937456481230896e-05
methicillin-resistant,5.937456481230896e-05
28-week,5.937456481230896e-05
distilled,5.937456481230896e-05
proved,5.937456481230896e-05
unique,5.937456481230896e-05
appetite,5.937456481230896e-05
absolute,5.937456481230896e-05
bodyweight,5.937456481230896e-05
1.00,5.937456481230896e-05
gonadotropin,5.937456481230896e-05
SH/DA,5.937456481230896e-05
hydroalcoholic,5.937456481230896e-05
SH/FA,5.937456481230896e-05
0.94,5.937456481230896e-05
comparative,5.937456481230896e-05
-associated,5.937456481230896e-05
inhalational,5.937456481230896e-05
purification,5.937456481230896e-05
375,5.937456481230896e-05
non-smoking,5.937456481230896e-05
29-40,5.937456481230896e-05
proportions,5.937456481230896e-05
2.5-,5.937456481230896e-05
Cohort,5.937456481230896e-05
Adrenal,5.937456481230896e-05
event,5.937456481230896e-05
442,5.937456481230896e-05
General,5.937456481230896e-05
l50,5.937456481230896e-05
Index,5.937456481230896e-05
0.91,5.937456481230896e-05
benzodiazepines,5.937456481230896e-05
zinc-chelating,5.937456481230896e-05
Exposed,5.937456481230896e-05
ratios,5.937456481230896e-05
Narrow,5.937456481230896e-05
-blockers,5.937456481230896e-05
occurrences,5.937456481230896e-05
unconjugated,5.937456481230896e-05
hydroxides,5.937456481230896e-05
HOUR,5.937456481230896e-05
CONCURRENTLY,5.937456481230896e-05
IMPEDING,5.937456481230896e-05
THAT,5.937456481230896e-05
INTERVAL,5.937456481230896e-05
BEFORE,5.937456481230896e-05
AN,5.937456481230896e-05
HOURS,5.937456481230896e-05
BIND,5.937456481230896e-05
IT,5.937456481230896e-05
THEIR,5.937456481230896e-05
25-O-desacetyl,5.937456481230896e-05
PATIENTS,5.937456481230896e-05
DRUGS,5.937456481230896e-05
GREAT,5.937456481230896e-05
kappa,5.937456481230896e-05
fluorescence,5.937456481230896e-05
sigma-2,5.937456481230896e-05
high-performance,5.937456481230896e-05
rocuronium,5.937456481230896e-05
prefrontal,5.937456481230896e-05
AT,5.937456481230896e-05
MAY,5.937456481230896e-05
ABSORPTION,5.937456481230896e-05
SINCE,5.937456481230896e-05
OTHER,5.937456481230896e-05
TAKE,5.937456481230896e-05
AS,5.937456481230896e-05
fermented,5.937456481230896e-05
2.0,5.937456481230896e-05
polymer/,5.937456481230896e-05
acids,5.937456481230896e-05
empiric,5.937456481230896e-05
i.e,5.937456481230896e-05
estimates,5.937456481230896e-05
exploited,5.937456481230896e-05
Congenital,5.937456481230896e-05
76,5.937456481230896e-05
formally,5.937456481230896e-05
Erythromycin,5.937456481230896e-05
age,5.937456481230896e-05
1.14,5.937456481230896e-05
refer,5.937456481230896e-05
MAO-Is,5.937456481230896e-05
app,5.937456481230896e-05
Formulation,5.937456481230896e-05
labelled,5.937456481230896e-05
457,5.937456481230896e-05
new,5.937456481230896e-05
Talk,5.937456481230896e-05
901,5.937456481230896e-05
318,5.937456481230896e-05
723,5.937456481230896e-05
POSSIBLE,5.937456481230896e-05
RECOMMENDED,5.937456481230896e-05
irinotecan/5-FU/leucovorin,5.937456481230896e-05
colorectal,5.937456481230896e-05
cellular,5.937456481230896e-05
respect,5.937456481230896e-05
Unmodified,5.937456481230896e-05
Strong,5.937456481230896e-05
rate-limiting,5.937456481230896e-05
Fifteen,5.937456481230896e-05
volatile,5.937456481230896e-05
M.C,5.937456481230896e-05
antiretroviral,5.937456481230896e-05
Comparison,5.937456481230896e-05
g/day,5.937456481230896e-05
hypercholesterolemia,5.937456481230896e-05
CYP3A5,5.937456481230896e-05
subgroup,5.937456481230896e-05
anti,5.937456481230896e-05
absent,5.937456481230896e-05
psoriatic,5.937456481230896e-05
0.075,5.937456481230896e-05
0.35,5.937456481230896e-05
202.5,5.937456481230896e-05
pregnancy,5.937456481230896e-05
hypercholesterolemic,5.937456481230896e-05
noninsulin,5.937456481230896e-05
Hypoglycemic,5.937456481230896e-05
dramatically,5.937456481230896e-05
49.1,5.937456481230896e-05
organogenesis,5.937456481230896e-05
sympatholytic,5.937456481230896e-05
comparatively,5.937456481230896e-05
resistances,5.937456481230896e-05
whole-cell,5.937456481230896e-05
monomeric,5.937456481230896e-05
disintegrin,5.937456481230896e-05
Differential,5.937456481230896e-05
16.6,5.937456481230896e-05
microg/mL,5.937456481230896e-05
statin,5.937456481230896e-05
Acquired,5.937456481230896e-05
patch-clamp,5.937456481230896e-05
applicable,5.937456481230896e-05
i.,5.937456481230896e-05
LEAST,5.937456481230896e-05
Gel,5.937456481230896e-05
blot,5.937456481230896e-05
US,5.937456481230896e-05
affinities,5.937456481230896e-05
sequestered,5.937456481230896e-05
Serial,5.937456481230896e-05
optimal,5.937456481230896e-05
inositol,5.937456481230896e-05
fura-2,5.937456481230896e-05
IS,5.937456481230896e-05
sensitizers,5.937456481230896e-05
childbearing,5.937456481230896e-05
slow-release,5.937456481230896e-05
"1,4,5-trisphosphate",5.937456481230896e-05
seriraline,5.937456481230896e-05
neurotoxin,5.937456481230896e-05
Initiating,5.937456481230896e-05
tightly,5.937456481230896e-05
-A,5.937456481230896e-05
antiarrhythrnics,5.937456481230896e-05
entry,5.937456481230896e-05
Dosage,5.937456481230896e-05
digestion,5.937456481230896e-05
TO,5.937456481230896e-05
AFTER,5.937456481230896e-05
AVOID,5.937456481230896e-05
bromide,5.937456481230896e-05
propatenone,5.937456481230896e-05
definite,5.937456481230896e-05
warfarin-like,5.937456481230896e-05
histidines,5.937456481230896e-05
More,5.937456481230896e-05
=1,5.937456481230896e-05
5-HT,5.937456481230896e-05
antianginal,5.937456481230896e-05
Dose-time,5.937456481230896e-05
R+,5.937456481230896e-05
scale,5.937456481230896e-05
1.09,5.937456481230896e-05
1.04,5.937456481230896e-05
0-infinity,5.937456481230896e-05
biopharmaceutical,5.937456481230896e-05
distinct,5.937456481230896e-05
adefovir,5.937456481230896e-05
men,5.937456481230896e-05
perchlorate,5.937456481230896e-05
1.10,5.937456481230896e-05
fixed-interval,5.937456481230896e-05
squirrel,5.937456481230896e-05
fixed-ratio,5.937456481230896e-05
fractions,5.937456481230896e-05
-treated,5.937456481230896e-05
12-week,5.937456481230896e-05
digoxin/placebo,5.937456481230896e-05
field,5.937456481230896e-05
interest,5.937456481230896e-05
microfluorometry,5.937456481230896e-05
recording,5.937456481230896e-05
NMDA,5.937456481230896e-05
ruthenium,5.937456481230896e-05
geometric,5.937456481230896e-05
1.02,5.937456481230896e-05
holed,5.937456481230896e-05
lenalidomide-CCI-779,5.937456481230896e-05
relapsed,5.937456481230896e-05
aim,5.937456481230896e-05
antinonciceptive,5.937456481230896e-05
peptides,5.937456481230896e-05
varying,5.937456481230896e-05
mcg/,5.937456481230896e-05
estrogenic,5.937456481230896e-05
surfactant,5.937456481230896e-05
intracisternal,5.937456481230896e-05
fexofenadine,5.937456481230896e-05
9.9-g/m2,5.937456481230896e-05
permit,5.937456481230896e-05
desethylzaleplon,5.937456481230896e-05
sum,5.937456481230896e-05
-enantiomers,5.937456481230896e-05
lung,5.937456481230896e-05
paper,5.937456481230896e-05
embolism,5.937456481230896e-05
P-glycoprotein-mediated,5.937456481230896e-05
0.125,5.937456481230896e-05
pesticide,5.937456481230896e-05
disintegrins,5.937456481230896e-05
homodimeric,5.937456481230896e-05
aPTT,5.937456481230896e-05
myeloma,5.937456481230896e-05
dipivoxil,5.937456481230896e-05
Northern,5.937456481230896e-05
RNA,5.937456481230896e-05
heparins,5.937456481230896e-05
transiently,5.937456481230896e-05
erectile,5.937456481230896e-05
whenever,5.937456481230896e-05
going,5.937456481230896e-05
cessation,5.937456481230896e-05
substitution,5.911787904577803e-05
0.75,5.911787904577803e-05
ruled,5.911787904577803e-05
Nicotinic,5.911787904577803e-05
vasoactive,5.911787904577803e-05
balance,5.911787904577803e-05
copying,5.911787904577803e-05
attention,5.911787904577803e-05
symbol,5.911787904577803e-05
digit,5.911787904577803e-05
aureus,5.911787904577803e-05
CNS-impairing,5.911787904577803e-05
short-acting,5.911787904577803e-05
DPCPX-induced,5.911787904577803e-05
0.53,5.911787904577803e-05
0.81,5.911787904577803e-05
.014,5.911787904577803e-05
cm3,5.911787904577803e-05
0.28,5.911787904577803e-05
spent,5.911787904577803e-05
zone,5.911787904577803e-05
prophylactic,5.911787904577803e-05
0.62,5.911787904577803e-05
0.44,5.911787904577803e-05
xenograft-bearing,5.911787904577803e-05
B3,5.911787904577803e-05
toxin,5.911787904577803e-05
competitive,5.911787904577803e-05
PR,5.911787904577803e-05
application,5.911787904577803e-05
theophylline-induced,5.911787904577803e-05
9,5.725232207065556e-05
buspirone,5.703907976795097e-05
pronounced,5.703907976795097e-05
mild,5.657754674903703e-05
A375,5.6314357804509996e-05
injected,5.6314357804509996e-05
weak,5.6314357804509996e-05
neuronal,5.6314357804509996e-05
metabotropic,5.6314357804509996e-05
melanoma,5.6314357804509996e-05
glutamate,5.6314357804509996e-05
extracellular,5.6314357804509996e-05
Inhibition,5.6314357804509996e-05
chickens,5.616156290288998e-05
suppressed,5.616156290288998e-05
applied,5.616156290288998e-05
Prolongation,5.616156290288998e-05
Laboratory,5.616156290288998e-05
Tests,5.616156290288998e-05
schedule,5.616156290288998e-05
review,5.616156290288998e-05
Staphylococcus,5.616156290288998e-05
dysfunction,5.616156290288998e-05
plate,5.616156290288998e-05
contraction,5.616156290288998e-05
subsequent,5.4952237409366944e-05
times,5.458444419403907e-05
alcoholic,5.407742892959977e-05
shortly,5.407742892959977e-05
megakaryocytes,5.407742892959977e-05
locomotion,5.407742892959977e-05
beverages,5.407742892959977e-05
tolerance,5.407742892959977e-05
necessitate,5.407742892959977e-05
infarction,5.407742892959977e-05
intrathecal,5.407742892959977e-05
resistant,5.407742892959977e-05
reversal,5.365869710072246e-05
eliminate,5.365869710072246e-05
"1,3-difluoro-2-propanol-intoxicated",5.365869710072246e-05
antidotal,5.365869710072246e-05
establish,5.365869710072246e-05
causation,5.365869710072246e-05
experiment,5.365869710072246e-05
attempt,5.365869710072246e-05
microalbuminuria,5.365869710072246e-05
DRUG,5.365869710072246e-05
Nalidixic,5.365869710072246e-05
diflunisal/acetaminophen,5.365869710072246e-05
length,5.365869710072246e-05
our,5.365869710072246e-05
cyclic,5.365869710072246e-05
haemorrhagic,5.365869710072246e-05
neurotoxicity,5.365869710072246e-05
minus,5.365869710072246e-05
Vaccinations,5.365869710072246e-05
Thiazide,5.365869710072246e-05
organism,5.365869710072246e-05
nonlethal,5.365869710072246e-05
neuropsychiatric,5.365869710072246e-05
IV/IM,5.365869710072246e-05
A1-selective,5.365869710072246e-05
normovolemic,5.365869710072246e-05
Glycosides,5.365869710072246e-05
Fosinopril,5.365869710072246e-05
A2-selective,5.365869710072246e-05
0.70,5.365869710072246e-05
neutropenic,5.365869710072246e-05
drug/drug,5.365869710072246e-05
ineffective,5.365869710072246e-05
immunocompromised,5.365869710072246e-05
INTERACTIONS,5.365869710072246e-05
thiazide-like,5.365869710072246e-05
hypoprothrombinemic,5.365869710072246e-05
ulceration,5.365869710072246e-05
EA,5.365869710072246e-05
limits,5.365869710072246e-05
Infusion,5.365869710072246e-05
none,5.365869710072246e-05
precipitous,5.365869710072246e-05
restriction,5.365869710072246e-05
6.25,5.365869710072246e-05
committed,5.365869710072246e-05
derive,5.365869710072246e-05
Neuromuscular,5.365869710072246e-05
suxamethonium,5.365869710072246e-05
inactivation,5.365869710072246e-05
identify,5.3116819904830415e-05
AI,5.3116819904830415e-05
concerning,5.3116819904830415e-05
TIVA,5.3116819904830415e-05
receptors,5.3116819904830415e-05
presentation,5.3116819904830415e-05
attenuation,5.3116819904830415e-05
PCP-induced,5.3116819904830415e-05
Among,5.3116819904830415e-05
5.5,5.3116819904830415e-05
analogue,5.3116819904830415e-05
accentuate,5.3116819904830415e-05
reviewed,5.3116819904830415e-05
contrast,5.3116819904830415e-05
open,5.3116819904830415e-05
capacity,5.3116819904830415e-05
gain,5.3116819904830415e-05
cyclosporine-induced,5.300170122946035e-05
prostacyclin,5.300170122946035e-05
impairment,5.051825357649253e-05
lack,4.947764551765932e-05
genetically,4.947764551765932e-05
fraction,4.947764551765932e-05
lean,4.947764551765932e-05
calcium-containing,4.947764551765932e-05
differential,4.947764551765932e-05
uptake-1,4.947764551765932e-05
far,4.947764551765932e-05
1-year,4.947764551765932e-05
generation,4.947764551765932e-05
discrimination,4.947764551765932e-05
ulcerans,4.947764551765932e-05
infant,4.947764551765932e-05
monthly,4.947764551765932e-05
randomly,4.947764551765932e-05
edetate,4.814384142470818e-05
disodium,4.814384142470818e-05
degrees,4.814384142470818e-05
chelating,4.814384142470818e-05
Edetate,4.814384142470818e-05
overall,4.783894876214667e-05
12.5,4.783894876214667e-05
dihydroergotamine,4.6298552781154356e-05
D.H.E,4.6298552781154356e-05
accompanied,4.485455224512158e-05
gram,4.485455224512158e-05
hepatitis,4.2831303418644495e-05
per,4.281432202590807e-05
formed,4.185166632642012e-05
transporter,4.185166632642012e-05
much,4.174725950978342e-05
kidneys,3.9581189677839745e-05
subjective,3.9581189677839745e-05
osteoporosis,3.9581189677839745e-05
allograft,3.9581189677839745e-05
DRL,3.9581189677839745e-05
compatibility,3.9581189677839745e-05
cumulative,3.9581189677839745e-05
Further,3.9581189677839745e-05
pyrocarbonate,3.9581189677839745e-05
Mycobacterium,3.9581189677839745e-05
resemble,3.9581189677839745e-05
Drug-drug,3.9581189677839745e-05
regulation,3.9581189677839745e-05
novo,3.9581189677839745e-05
year,3.9581189677839745e-05
proven,3.9581189677839745e-05
gel,3.9581189677839745e-05
Prevention,3.9581189677839745e-05
V,3.9581189677839745e-05
formula,3.9581189677839745e-05
morning,3.9581189677839745e-05
Concomitantly,3.9581189677839745e-05
designed,3.9581189677839745e-05
Influence,3.9581189677839745e-05
evoked,3.9581189677839745e-05
greatly,3.9581189677839745e-05
micromol/l,3.9581189677839745e-05
Poor,3.9581189677839745e-05
allow,3.9581189677839745e-05
assigned,3.9581189677839745e-05
volunteer,3.9581189677839745e-05
drawn,3.9581189677839745e-05
young,3.9581189677839745e-05
Affect,3.9581189677839745e-05
radiation,3.9581189677839745e-05
systemically,3.9581189677839745e-05
value,3.9581189677839745e-05
polyene,3.9581189677839745e-05
globulin,3.9581189677839745e-05
syringe,3.9581189677839745e-05
CYP2E1,3.9581189677839745e-05
support,3.9581189677839745e-05
n=12,3.9581189677839745e-05
psychoses,3.9581189677839745e-05
times/day,3.9581189677839745e-05
2C9,3.9581189677839745e-05
extract,3.9581189677839745e-05
Addition,3.9581189677839745e-05
Lack,3.9581189677839745e-05
surgery,3.9581189677839745e-05
seen,3.6611226219784854e-05
6-mg,2.968519724988461e-05
coffee,2.968519724988461e-05
cups,2.968519724988461e-05
hundred,2.968519724988461e-05
thrombolytic,2.968519724988461e-05
Compromised,2.968519724988461e-05
producing,2.968519724988461e-05
addictive,2.968519724988461e-05
habituating,2.968519724988461e-05
5-35,2.968519724988461e-05
aminocaproic,2.968519724988461e-05
antifibrinolytic,2.968519724988461e-05
metab-olizers,2.968519724988461e-05
lag,2.968519724988461e-05
characteristic,2.968519724988461e-05
528,2.968519724988461e-05
12-month,2.968519724988461e-05
873,2.968519724988461e-05
30-40,2.968519724988461e-05
androgen,2.968519724988461e-05
supplementation,2.968519724988461e-05
tranexamic,2.968519724988461e-05
IU/ml,2.968519724988461e-05
defined,2.968519724988461e-05
provides,2.968519724988461e-05
adjuvants,2.968519724988461e-05
last,2.968519724988461e-05
uncertain,2.968519724988461e-05
R-,2.968519724988461e-05
P450-based,2.968519724988461e-05
150-mg,2.968519724988461e-05
ingredient,2.968519724988461e-05
Thrombolytic,2.968519724988461e-05
colon,2.968519724988461e-05
systematic,2.968519724988461e-05
ge,2.968519724988461e-05
nerally,2.968519724988461e-05
2C19,2.968519724988461e-05
Beta-Blocking,2.968519724988461e-05
erythromycin,2.968519724988461e-05
fenofibric,2.968519724988461e-05
proliferates,2.968519724988461e-05
American,2.968519724988461e-05
enantiomer,2.968519724988461e-05
biochemical,2.968519724988461e-05
METHOD,2.968519724988461e-05
45.7,2.968519724988461e-05
43.4,2.968519724988461e-05
aqueous,2.968519724988461e-05
relaxation,2.968519724988461e-05
preconstricted,2.968519724988461e-05
2000,2.968519724988461e-05
August,2.968519724988461e-05
Pharmaceutical,2.968519724988461e-05
MEDLINE,2.968519724988461e-05
water-miscible,2.968519724988461e-05
commentaries,2.968519724988461e-05
1999,2.968519724988461e-05
PREMEDLINE,2.968519724988461e-05
January,2.968519724988461e-05
Analysis,2.968519724988461e-05
equilibration,2.968519724988461e-05
ultracentrifugation,2.968519724988461e-05
pointes-type,2.968519724988461e-05
tartrate,2.968519724988461e-05
hydrolysis,2.968519724988461e-05
consisting,2.968519724988461e-05
international,2.968519724988461e-05
Antibiotics-Broad-spectrum,2.968519724988461e-05
75-mg,2.968519724988461e-05
lunch,2.968519724988461e-05
searches,2.968519724988461e-05
terms,2.968519724988461e-05
mmol/l,2.968519724988461e-05
calling,2.968519724988461e-05
Registry,2.968519724988461e-05
enroll,2.968519724988461e-05
1-866-263-8483,2.968519724988461e-05
meaningfully,2.968519724988461e-05
0.375,2.968519724988461e-05
immobilised,2.968519724988461e-05
1.8,2.968519724988461e-05
nonclinical,2.968519724988461e-05
comparisons,2.968519724988461e-05
implies,2.968519724988461e-05
stronger,2.968519724988461e-05
nonmatched,2.968519724988461e-05
activated,2.968519724988461e-05
Enzymes,2.968519724988461e-05
preventing,2.968519724988461e-05
fetal,2.968519724988461e-05
21.7,2.968519724988461e-05
multicenter,2.968519724988461e-05
transplantation,2.968519724988461e-05
2-adamantyl,2.968519724988461e-05
hexamethylenimine,2.968519724988461e-05
anti-parkinsonian,2.968519724988461e-05
harmonic,2.968519724988461e-05
101,2.968519724988461e-05
Kit,2.968519724988461e-05
Lithium-A,2.968519724988461e-05
iron/6,2.968519724988461e-05
micrograms/ml,2.968519724988461e-05
precipitation,2.968519724988461e-05
7-day,2.968519724988461e-05
washout,2.968519724988461e-05
49.9,2.968519724988461e-05
2.6,2.968519724988461e-05
7.73,2.968519724988461e-05
Pseudomonas,2.968519724988461e-05
aeruginosa,2.968519724988461e-05
dropped,2.968519724988461e-05
assumed,2.968519724988461e-05
underlies,2.968519724988461e-05
oz,2.968519724988461e-05
binding-based,2.968519724988461e-05
beta-receptor,2.968519724988461e-05
ectopy,2.968519724988461e-05
spectrophotometrically,2.968519724988461e-05
indanedione,2.968519724988461e-05
confirm,2.968519724988461e-05
levofloxacin/oxycodone,2.968519724988461e-05
48.59,2.968519724988461e-05
9.93,2.968519724988461e-05
1.6,2.968519724988461e-05
unaltered,2.968519724988461e-05
8.52,2.968519724988461e-05
posed,2.968519724988461e-05
differential-reinforcement-of-low-rates,2.968519724988461e-05
lethal,2.968519724988461e-05
Escherichia,2.968519724988461e-05
alpha-,2.968519724988461e-05
CYP-450,2.968519724988461e-05
two-lever,2.968519724988461e-05
signalled-unsignalled,2.968519724988461e-05
tend,2.968519724988461e-05
thyroxine-binding,2.968519724988461e-05
1.1,2.968519724988461e-05
reflecting,2.968519724988461e-05
mixed-function,2.968519724988461e-05
Initial,2.968519724988461e-05
Hemostasis,2.968519724988461e-05
puncture,2.968519724988461e-05
Until,2.968519724988461e-05
Uncontrolled,2.968519724988461e-05
habituation,2.968519724988461e-05
sterilize,2.968519724988461e-05
Broad-Spectrum,2.968519724988461e-05
serotonin2-receptors,2.968519724988461e-05
contribution,2.968519724988461e-05
glycemia,2.968519724988461e-05
rt-PA,2.968519724988461e-05
propoxyphene,2.968519724988461e-05
intoxication,2.968519724988461e-05
episode,2.968519724988461e-05
Spray,2.968519724988461e-05
medium,2.968519724988461e-05
Prostatic,2.968519724988461e-05
3.7,2.968519724988461e-05
ng/ml,2.968519724988461e-05
microflora,2.968519724988461e-05
dopamine2-,2.968519724988461e-05
replaced,2.968519724988461e-05
swine,2.968519724988461e-05
anesthetized,2.968519724988461e-05
a-chloralose,2.968519724988461e-05
4-hour,2.968519724988461e-05
person,2.968519724988461e-05
cereals,2.968519724988461e-05
antiaddictive,2.968519724988461e-05
RIA,2.968519724988461e-05
INN,2.968519724988461e-05
Nasal,2.968519724988461e-05
Interferences,2.968519724988461e-05
alkaline,2.968519724988461e-05
red-orange,2.968519724988461e-05
monooxygenase,2.968519724988461e-05
mono-oxidases,2.968519724988461e-05
intubation,2.968519724988461e-05
tracheal,2.968519724988461e-05
mixture,2.968519724988461e-05
succinylcholine-facilitated,2.968519724988461e-05
Digi-,2.968519724988461e-05
Serotonergic,2.968519724988461e-05
OA,2.968519724988461e-05
2400,2.968519724988461e-05
ulcers,2.968519724988461e-05
Known,2.968519724988461e-05
microg/kg,2.968519724988461e-05
homocysteine,2.968519724988461e-05
rationalized,2.968519724988461e-05
"1,200",2.968519724988461e-05
routinely,2.968519724988461e-05
delta,2.968519724988461e-05
concentration-dependent,2.968519724988461e-05
broadly,2.968519724988461e-05
early-phase,2.968519724988461e-05
Improvements,2.968519724988461e-05
aimed,2.968519724988461e-05
Antipsychotic,2.968519724988461e-05
Then,2.968519724988461e-05
nd,2.968519724988461e-05
yeast,2.968519724988461e-05
coated,2.968519724988461e-05
gastroduodenal,2.968519724988461e-05
endoscopic,2.968519724988461e-05
quality,2.968519724988461e-05
Numerous,2.968519724988461e-05
"1,25-Dihydroxycholecalciferol",2.968519724988461e-05
opioids,2.968519724988461e-05
hyperpolarized,2.968519724988461e-05
mu-,2.968519724988461e-05
kappa-selective,2.968519724988461e-05
superiority,2.968519724988461e-05
21-day,2.968519724988461e-05
concentrating,2.968519724988461e-05
organs,2.968519724988461e-05
endoscopy,2.968519724988461e-05
ameliorate,2.968519724988461e-05
recommend,2.968519724988461e-05
document,2.968519724988461e-05
extrarenal,2.968519724988461e-05
agranulocytosis,2.968519724988461e-05
hyperprolactinaemia,2.968519724988461e-05
extrapyramidal,2.968519724988461e-05
choice,2.968519724988461e-05
relapses,2.968519724988461e-05
Long,2.968519724988461e-05
Acting,2.968519724988461e-05
ClO-4-,2.968519724988461e-05
routes,2.968519724988461e-05
clinically-,2.968519724988461e-05
TDM,2.968519724988461e-05
employing,2.968519724988461e-05
characterize,2.968519724988461e-05
exogenous,2.968519724988461e-05
coli,2.968519724988461e-05
enrolled,2.968519724988461e-05
anti-peptic,2.968519724988461e-05
3500,2.968519724988461e-05
recur,2.968519724988461e-05
historical,2.968519724988461e-05
1:1:1,2.968519724988461e-05
parameter,2.968519724988461e-05
Valproic,2.968519724988461e-05
Acid,2.968519724988461e-05
Physiological,2.968519724988461e-05
treating,2.968519724988461e-05
Tab,2.968519724988461e-05
calcineurin,2.968519724988461e-05
cohorts,2.968519724988461e-05
inhibitor-free,2.968519724988461e-05
Proton,2.968519724988461e-05
7.4,2.968519724988461e-05
fo,2.968519724988461e-05
From,2.968519724988461e-05
mGluR,2.968519724988461e-05
123,2.968519724988461e-05
RR,2.968519724988461e-05
sessions,2.968519724988461e-05
Skeletal,2.968519724988461e-05
"15,000",2.968519724988461e-05
hrs,2.968519724988461e-05
excreted,2.968519724988461e-05
Estimates,2.968519724988461e-05
breakfast,2.968519724988461e-05
fortified,2.968519724988461e-05
Ten,2.968519724988461e-05
lactulose,2.968519724988461e-05
thienobenzodiazepine,2.968519724988461e-05
derivative,2.968519724988461e-05
Antiinflammatory,2.968519724988461e-05
substrates/inhibitors,2.968519724988461e-05
irbesartan,2.968519724988461e-05
oxidized,2.968519724988461e-05
superior,2.968519724988461e-05
pumps,2.968519724988461e-05
source,2.968519724988461e-05
Antidiabetic,2.968519724988461e-05
cross-over,2.968519724988461e-05
blind,2.968519724988461e-05
compassionate,2.968519724988461e-05
program,2.968519724988461e-05
wthionamide,2.968519724988461e-05
esterases,2.968519724988461e-05
rivastigmine,2.968519724988461e-05
pectoris,2.968519724988461e-05
zinc,2.968519724988461e-05
crystalline,2.968519724988461e-05
transferase,2.968519724988461e-05
predominant,2.968519724988461e-05
acidity,2.968519724988461e-05
Literature,2.968519724988461e-05
balanced,2.968519724988461e-05
anti-asthma,2.968519724988461e-05
mellitus,2.968519724988461e-05
line,2.968519724988461e-05
Aspirin/Nonsteroidal,2.968519724988461e-05
manufacturers,2.968519724988461e-05
Dopamine-induced,2.968519724988461e-05
TCAplasma,2.968519724988461e-05
Note,2.968519724988461e-05
Coagulation,2.968519724988461e-05
thrombocyte,2.968519724988461e-05
captopril-digoxin,2.968519724988461e-05
N=180,2.968519724988461e-05
alpha-2,2.968519724988461e-05
exhibiting,2.968519724988461e-05
Decreasing,2.968519724988461e-05
external,2.968519724988461e-05
m/m,2.968519724988461e-05
ocular,2.968519724988461e-05
display,2.968519724988461e-05
Animals,2.968519724988461e-05
2-3,2.968519724988461e-05
introduced,2.968519724988461e-05
',2.968519724988461e-05
newly,2.968519724988461e-05
Quetiapine,2.968519724988461e-05
'Seroquel,2.968519724988461e-05
diluent,2.968519724988461e-05
7.3,2.968519724988461e-05
1-866-AMEVIVE,2.968519724988461e-05
encouraged,2.968519724988461e-05
pregnant,2.968519724988461e-05
providers,2.968519724988461e-05
UDP-glucuronyl,2.968519724988461e-05
Approximately,2.968519724988461e-05
unfractionated,2.968519724988461e-05
units/day,2.968519724988461e-05
Cimetidine,2.968519724988461e-05
Investigations,2.968519724988461e-05
Affecting,2.968519724988461e-05
ca,2.968519724988461e-05
microgram/ml,2.968519724988461e-05
non-specific,2.968519724988461e-05
actively,2.968519724988461e-05
22.0,2.968519724988461e-05
28.9,2.968519724988461e-05
30.7,2.968519724988461e-05
first-line,2.968519724988461e-05
option,2.968519724988461e-05
synthesis-inhibiting,2.968519724988461e-05
TORADOLIV/IM,2.968519724988461e-05
QHS,2.968519724988461e-05
Beta-blocking,2.968519724988461e-05
prostatectomy,2.968519724988461e-05
Abstracts,2.968519724988461e-05
editorials,2.968519724988461e-05
recorded,2.968519724988461e-05
15.0,2.968519724988461e-05
potentials,2.968519724988461e-05
bar-press,2.968519724988461e-05
margin,2.968519724988461e-05
alcohol-related,2.968519724988461e-05
Haemodynamic,2.968519724988461e-05
Biogen,2.968519724988461e-05
prospective,2.968519724988461e-05
8-fold,2.968519724988461e-05
Itraconazole,2.968519724988461e-05
6-,2.968519724988461e-05
next,2.968519724988461e-05
collected,2.968519724988461e-05
aldosterone,2.968519724988461e-05
mM,2.968519724988461e-05
maintaining,2.968519724988461e-05
alkyating,2.968519724988461e-05
pro-oxidant,2.968519724988461e-05
six-healthy-male,2.968519724988461e-05
based,2.471706157813891e-05
Considering,1.9789668189607035e-05
Interval,1.9789668189607035e-05
Confidence,1.9789668189607035e-05
cyclooxygenase-2,1.9789668189607035e-05
intramuscularly,1.9789668189607035e-05
CYP450,1.9789668189607035e-05
endothelial,1.9789668189607035e-05
Activity,1.9789668189607035e-05
verified,1.9789668189607035e-05
factor,1.9789668189607035e-05
diethyl,1.9789668189607035e-05
residues,1.9789668189607035e-05
histidine,1.9789668189607035e-05
vas,1.9789668189607035e-05
prepared,1.9789668189607035e-05
antibodies,1.9789668189607035e-05
immunoreactive,1.9789668189607035e-05
Interferon,1.9789668189607035e-05
measure,1.9789668189607035e-05
appreciably,1.9789668189607035e-05
determination,1.9789668189607035e-05
psychostimulant,1.9789668189607035e-05
bred,1.9789668189607035e-05
parathyroid,1.9789668189607035e-05
relationships,1.9789668189607035e-05
PSA,1.9789668189607035e-05
hospitalized,1.9789668189607035e-05
guinea-pig,1.9789668189607035e-05
deferens,1.9789668189607035e-05
concentrates,1.9789668189607035e-05
Coombs,1.9789668189607035e-05
authors,1.9789668189607035e-05
nursing,1.9789668189607035e-05
pathways,1.9789668189607035e-05
serotype,1.9789668189607035e-05
O11,1.9789668189607035e-05
non-diabetic,1.9789668189607035e-05
neutralized,1.9789668189607035e-05
carcinogenicity,1.9789668189607035e-05
isoforms,1.9789668189607035e-05
mucosal,1.9789668189607035e-05
fasted,1.9789668189607035e-05
gene,1.9789668189607035e-05
hydrolase,1.9789668189607035e-05
rapidly,1.9789668189607035e-05
Ethinyl,1.9789668189607035e-05
respiration,1.9789668189607035e-05
104-week,1.9789668189607035e-05
exert,1.9789668189607035e-05
drug-metabolizing,1.9789668189607035e-05
depth,1.9789668189607035e-05
Induction,1.9789668189607035e-05
linked,1.9789668189607035e-05
substituted,1.9789668189607035e-05
create,1.9789668189607035e-05
Changes,1.9789668189607035e-05
8-week,1.9789668189607035e-05
measuring,1.9789668189607035e-05
acquisition,1.9789668189607035e-05
costs,1.9789668189607035e-05
Renal,1.9789668189607035e-05
Candida,1.9789668189607035e-05
older,1.9789668189607035e-05
65,1.9789668189607035e-05
wide,1.9789668189607035e-05
spectrum,1.9789668189607035e-05
carbodiimide,9.89460245404139e-06
date,9.89460245404139e-06
covalently,9.89460245404139e-06
Drug/,9.89460245404139e-06
ii,9.89460245404139e-06
membrane,9.89460245404139e-06
ergosterol,9.89460245404139e-06
acinar,9.89460245404139e-06
tool,9.89460245404139e-06
photic,9.89460245404139e-06
bioequivalent,9.89460245404139e-06
progestogen,9.89460245404139e-06
5-methyltetrahydro-folate,9.89460245404139e-06
reproductive,9.89460245404139e-06
gavage,9.89460245404139e-06
thoracic,9.89460245404139e-06
sterol,9.89460245404139e-06
emergence,9.89460245404139e-06
repeatedly,9.89460245404139e-06
oncology,9.89460245404139e-06
CSF,9.89460245404139e-06
fertility,9.89460245404139e-06
3.4,9.89460245404139e-06
cardiotoxicity,9.89460245404139e-06
Female,9.89460245404139e-06
criteria,9.89460245404139e-06
interpreted,9.89460245404139e-06
stereotyped,9.89460245404139e-06
ribs,9.89460245404139e-06
extra,9.89460245404139e-06
1mg,9.89460245404139e-06
900,9.89460245404139e-06
retrospectively,9.89460245404139e-06
consulting,9.89460245404139e-06
variables,9.89460245404139e-06
Five,9.89460245404139e-06
scales,9.89460245404139e-06
negligible,9.89460245404139e-06
45-52,9.89460245404139e-06
45-51,9.89460245404139e-06
CONCLUSION,9.89460245404139e-06
62,9.89460245404139e-06
Supraventricular,9.89460245404139e-06
K-dependent,9.89460245404139e-06
Little,9.89460245404139e-06
records,9.89460245404139e-06
carcinogenesis,9.89460245404139e-06
histologic,9.89460245404139e-06
STUDY,9.89460245404139e-06
mammary,9.89460245404139e-06
Green,9.89460245404139e-06
glucocorticoid-induced,9.89460245404139e-06
tea,9.89460245404139e-06
polyphenols,9.89460245404139e-06
66,9.89460245404139e-06
gallate,9.89460245404139e-06
crude,9.89460245404139e-06
Volunteers,9.89460245404139e-06
6.0,9.89460245404139e-06
Relaxants,9.89460245404139e-06
Nondepolarizing,9.89460245404139e-06
Similar,9.89460245404139e-06
Monitoring,9.89460245404139e-06
disruption,9.89460245404139e-06
Grapefruit,9.89460245404139e-06
14-57,9.89460245404139e-06
documenting,9.89460245404139e-06
Molecular,9.89460245404139e-06
attacks,9.89460245404139e-06
5000,9.89460245404139e-06
tannic,9.89460245404139e-06
Ames,9.89460245404139e-06
dipstick,9.89460245404139e-06
sulfosalicylic,9.89460245404139e-06
readings,9.89460245404139e-06
maximize,9.89460245404139e-06
lysing,9.89460245404139e-06
share,9.89460245404139e-06
duodenum,9.89460245404139e-06
Muscle,9.89460245404139e-06
volume-depleted,9.89460245404139e-06
11.4,9.89460245404139e-06
vascularity,9.89460245404139e-06
6.4,9.89460245404139e-06
U,9.89460245404139e-06
mix,9.89460245404139e-06
orders,9.89460245404139e-06
enter,9.89460245404139e-06
remain,9.89460245404139e-06
neuropathy,9.89460245404139e-06
Neuropathy,9.89460245404139e-06
REACTIONS,9.89460245404139e-06
ADVERSE,9.89460245404139e-06
postoperative,9.89460245404139e-06
efficiently,9.89460245404139e-06
template,9.89460245404139e-06
endocrine,9.89460245404139e-06
15-20,9.89460245404139e-06
avian,9.89460245404139e-06
Enhancement,9.89460245404139e-06
Newcastle,9.89460245404139e-06
aerobic,9.89460245404139e-06
P-,9.89460245404139e-06
stroke,9.89460245404139e-06
reinfarction,9.89460245404139e-06
Anticoagulation,9.89460245404139e-06
people,9.89460245404139e-06
Healthy,9.89460245404139e-06
10-monohydroxy,9.89460245404139e-06
CYP3A4/5,9.89460245404139e-06
CYP4A9,9.89460245404139e-06
CYP4A11,9.89460245404139e-06
exception,9.89460245404139e-06
ADMINISTRATION-Dosage,9.89460245404139e-06
sections,9.89460245404139e-06
Intermediate,9.89460245404139e-06
aminoglycosidic,9.89460245404139e-06
osteoarthritis,9.89460245404139e-06
hormone-binding,9.89460245404139e-06
cigarettes,9.89460245404139e-06
Repeating,9.89460245404139e-06
detect,9.89460245404139e-06
injectables,9.89460245404139e-06
implants,9.89460245404139e-06
progestational,9.89460245404139e-06
Thirty,9.89460245404139e-06
mg/kg/ml,9.89460245404139e-06
Fischer-344,9.89460245404139e-06
equal,9.89460245404139e-06
agonist/antagonist,9.89460245404139e-06
3A4/5,9.89460245404139e-06
presented,9.89460245404139e-06
reinforcer,9.89460245404139e-06
nondrug,9.89460245404139e-06
unlike,9.89460245404139e-06
stereotypic,9.89460245404139e-06
morphine-experienced,9.89460245404139e-06
copper,9.89460245404139e-06
Clinistix,9.89460245404139e-06
Under,9.89460245404139e-06
summarized,9.89460245404139e-06
adjuvant,9.89460245404139e-06
placebo/day,9.89460245404139e-06
Subjects,9.89460245404139e-06
CYP-2C19,9.89460245404139e-06
Prospective,9.89460245404139e-06
intensified,9.89460245404139e-06
phenotype,9.89460245404139e-06
Jaffe,9.89460245404139e-06
Adjustment,9.89460245404139e-06
v/v,9.89460245404139e-06
contents,9.89460245404139e-06
coexisting,9.89460245404139e-06
dexmedetomidine-induced,9.89460245404139e-06
bacteria,9.89460245404139e-06
metabolizer,9.89460245404139e-06
CBG,9.89460245404139e-06
measures,9.89460245404139e-06
phosphorous,9.89460245404139e-06
aggression,9.89460245404139e-06
beta-blocker,9.89460245404139e-06
cardioselective,9.89460245404139e-06
Postoperatively,9.89460245404139e-06
pupil,9.89460245404139e-06
constriction,9.89460245404139e-06
rating,9.89460245404139e-06
improvements,9.89460245404139e-06
Male,9.89460245404139e-06
Table,9.89460245404139e-06
anxiety/depressive,9.89460245404139e-06
anti-platelet,9.89460245404139e-06
ex,9.89460245404139e-06
TXB2,9.89460245404139e-06
substitute,9.89460245404139e-06
serial,9.89460245404139e-06
Response,9.89460245404139e-06
just,9.89460245404139e-06
otherwise,9.89460245404139e-06
MI,9.89460245404139e-06
450,9.89460245404139e-06
pass,9.89460245404139e-06
prophylaxis,9.89460245404139e-06
several-fold,9.89460245404139e-06
despite,9.89460245404139e-06
Compared,9.89460245404139e-06
Radioligand,9.89460245404139e-06
cost,9.89460245404139e-06
first-episode,9.89460245404139e-06
relapse,9.89460245404139e-06
rehospitalisation,9.89460245404139e-06
stock,9.89460245404139e-06
DOSAGE,9.89460245404139e-06
AND,9.89460245404139e-06
PHARMACOLOGY-Pharmacokinetics-Drug-Drug,9.89460245404139e-06
Pharmacoeconomic,9.89460245404139e-06
transfer,9.89460245404139e-06
benzyl,9.89460245404139e-06
remains,9.89460245404139e-06
transferred,9.89460245404139e-06
preventive,9.89460245404139e-06
permeability,9.89460245404139e-06
infants,9.89460245404139e-06
Digoxin,9.89460245404139e-06
Tacrolimus,9.89460245404139e-06
survive,9.89460245404139e-06
SIDE,9.89460245404139e-06
8.5,9.89460245404139e-06
explain,9.89460245404139e-06
~20,9.89460245404139e-06
Carcinogenesis,9.89460245404139e-06
discontinue,9.89460245404139e-06
SG,9.89460245404139e-06
N-Multistix,9.89460245404139e-06
menopause,9.89460245404139e-06
linear,9.89460245404139e-06
antistress,9.89460245404139e-06
ml,9.89460245404139e-06
distinctive,9.89460245404139e-06
EFFECTS,9.89460245404139e-06
gly-buride,9.89460245404139e-06
ligated,9.89460245404139e-06
1/,9.89460245404139e-06
alleles,9.89460245404139e-06
females,9.89460245404139e-06
~7,9.89460245404139e-06
micrograms/mL,9.89460245404139e-06
Jaff,9.89460245404139e-06
antiepilepsy,9.89460245404139e-06
non-enzyme,9.89460245404139e-06
delayed-release,9.89460245404139e-06
contributed,9.89460245404139e-06
homogenates,9.89460245404139e-06
preceded,9.89460245404139e-06
radiolabeled,9.89460245404139e-06
breaks,9.89460245404139e-06
thiol,9.89460245404139e-06
Isoenzymes,9.89460245404139e-06
Epoxide,9.89460245404139e-06
Antidepressant-warfarin,9.89460245404139e-06
sought,9.89460245404139e-06
"407,370",9.89460245404139e-06
"430,455",9.89460245404139e-06
person-years,9.89460245404139e-06
10-63,9.89460245404139e-06
incisive,9.89460245404139e-06
longterm,9.89460245404139e-06
encountered,9.89460245404139e-06
teratogenic,9.89460245404139e-06
Category,9.89460245404139e-06
Mothers,9.89460245404139e-06
lam,9.89460245404139e-06
full,9.89460245404139e-06
illustrated,9.89460245404139e-06
flu-like,9.89460245404139e-06
interferons,9.89460245404139e-06
interresponse,9.89460245404139e-06
failures,9.89460245404139e-06
training,9.89460245404139e-06
Nursing,9.89460245404139e-06
aged,9.89460245404139e-06
narrower,9.89460245404139e-06
Again,9.89460245404139e-06
behaviors,9.89460245404139e-06
focus,9.89460245404139e-06
investigation,9.89460245404139e-06
Combinations,9.89460245404139e-06
psychotomimetic,9.89460245404139e-06
alpha,9.89460245404139e-06
septic,9.89460245404139e-06
task,9.89460245404139e-06
Salicylates-Salicylates,9.89460245404139e-06
lethality,9.89460245404139e-06
decision,9.89460245404139e-06
estimation,9.89460245404139e-06
streptozotocin-induced,9.89460245404139e-06
156,9.89460245404139e-06
cefotaxime,9.89460245404139e-06
successfully,9.89460245404139e-06
undesirable,9.89460245404139e-06
often,9.89460245404139e-06
numbers,9.89460245404139e-06
survival,9.89460245404139e-06
187,9.89460245404139e-06
PRA,9.89460245404139e-06
shift,9.89460245404139e-06
Antimicrobial,9.89460245404139e-06
achieving,9.89460245404139e-06
Advantages,9.89460245404139e-06
antiglaucoma,9.89460245404139e-06
Quantitative,9.89460245404139e-06
difficulty,9.89460245404139e-06
antidiuretic,9.89460245404139e-06
respond,9.89460245404139e-06
sub-G1,9.89460245404139e-06
42.5,9.89460245404139e-06
wethers,9.89460245404139e-06
Sublingual,9.89460245404139e-06
discernible,9.89460245404139e-06
nitrate,9.89460245404139e-06
miconazole,9.89460245404139e-06
Isoenzyme,9.89460245404139e-06
Few,9.89460245404139e-06
assessments,9.89460245404139e-06
Expected,9.89460245404139e-06
pharmaco-dynamics,9.89460245404139e-06
multidrug-resistant,9.89460245404139e-06
AIMS/HYPOTHESIS,9.89460245404139e-06
declines,9.89460245404139e-06
6-deoxy,9.89460245404139e-06
situ,9.89460245404139e-06
Systems,9.89460245404139e-06
Transport,9.89460245404139e-06
undergoes,9.89460245404139e-06
Pgp,9.89460245404139e-06
Bound,9.89460245404139e-06
Highly,9.89460245404139e-06
manifested,9.89460245404139e-06
3.2,9.89460245404139e-06
5.1,9.89460245404139e-06
apoptotic,9.89460245404139e-06
location,9.89460245404139e-06
Likewise,9.89460245404139e-06
obstruction,9.89460245404139e-06
Duloxetine-treated,9.89460245404139e-06
bilirubin,9.89460245404139e-06
affects,9.89460245404139e-06
alternatively,9.89460245404139e-06
bolus,9.89460245404139e-06
nick-end,9.89460245404139e-06
24.7,9.89460245404139e-06
.017,9.89460245404139e-06
antiprothrombinemic,9.89460245404139e-06
wild-type,9.89460245404139e-06
Felodipine,9.89460245404139e-06
n-dodecyl,9.89460245404139e-06
hence,9.89460245404139e-06
triazo,9.89460245404139e-06
CONCLUSIONS/INTERPRETATION,9.89460245404139e-06
20.1,9.89460245404139e-06
dasatinib-,9.89460245404139e-06
22.4,9.89460245404139e-06
TORADOLORAL,9.89460245404139e-06
"10,11-epoxide",9.89460245404139e-06
Hydrolase,9.89460245404139e-06
carbamazepine,9.89460245404139e-06
younger,9.89460245404139e-06
trans-diol,9.89460245404139e-06
Rat,9.89460245404139e-06
ATP,9.89460245404139e-06
oxaloacetate,9.89460245404139e-06
Mg2+,9.89460245404139e-06
xenografts,9.89460245404139e-06
contains,9.89460245404139e-06
96,9.89460245404139e-06
shock,9.89460245404139e-06
Depression,9.89460245404139e-06
flushes,9.89460245404139e-06
always,9.89460245404139e-06
strategies,9.89460245404139e-06
norfluoxe-tine,9.89460245404139e-06
Decreased,9.89460245404139e-06
Metabolizing,9.89460245404139e-06
logarithmic,9.89460245404139e-06
2946,9.89460245404139e-06
NIDDM,9.89460245404139e-06
insignificant,9.89460245404139e-06
Fertility,9.89460245404139e-06
Mutagenesis,9.89460245404139e-06
Impairment,9.89460245404139e-06
offered,9.89460245404139e-06
transferase-mediated,9.89460245404139e-06
transfection,9.89460245404139e-06
albicans,9.89460245404139e-06
embryocidal,9.89460245404139e-06
mutagenic,9.89460245404139e-06
work,9.89460245404139e-06
levonorgestrel-treated,9.89460245404139e-06
declining,9.89460245404139e-06
Recommendations,9.89460245404139e-06
cytometry,9.89460245404139e-06
TUNEL,9.89460245404139e-06
roles,9.89460245404139e-06
vectors,9.89460245404139e-06
deoxynucleotidyl,9.89460245404139e-06
dUTP,9.89460245404139e-06
Food,9.89460245404139e-06
80-95,9.89460245404139e-06
genotoxic,9.89460245404139e-06
essentially,9.89460245404139e-06
lumen,9.89460245404139e-06
diffusible,9.89460245404139e-06
follow,9.89460245404139e-06
growing,9.89460245404139e-06
broad,9.89460245404139e-06
Month,9.89460245404139e-06
pergolide,9.89460245404139e-06
crushed,9.89460245404139e-06
self-injection,9.89460245404139e-06
misused,9.89460245404139e-06
mortality,9.89460245404139e-06
cerebrovascular,9.89460245404139e-06
obstetric,9.89460245404139e-06
table,9.89460245404139e-06
thrombopenia,9.89460245404139e-06
purpura,9.89460245404139e-06
accidents,9.89460245404139e-06
ascertain,9.89460245404139e-06
immunoanalytical,9.89460245404139e-06
Care,9.89460245404139e-06
continuous,9.89460245404139e-06
divergently,9.89460245404139e-06
thought,9.89460245404139e-06
switched,9.89460245404139e-06
physiological,9.89460245404139e-06
vasopressor,9.89460245404139e-06
Commonly,9.89460245404139e-06
Longitudinal,9.89460245404139e-06
Hyaluronan,9.89460245404139e-06
Electroretinograms,9.89460245404139e-06
survived,9.89460245404139e-06
Medical,9.89460245404139e-06
existing,9.89460245404139e-06
phosphatase,9.89460245404139e-06
abundance,9.89460245404139e-06
Conversion,9.89460245404139e-06
phosphatases,9.89460245404139e-06
precede,9.89460245404139e-06
Behavioral,9.89460245404139e-06
persist,9.89460245404139e-06
borne,9.89460245404139e-06
Mice,9.89460245404139e-06
long-sedation,9.89460245404139e-06
benign,9.89460245404139e-06
rodent,9.89460245404139e-06
smallest,9.89460245404139e-06
contributing,9.89460245404139e-06
Drug/LaboratoryTest,9.89460245404139e-06
bioassay,9.89460245404139e-06
hyperplasia,9.89460245404139e-06
supplemental,9.89460245404139e-06
defect,9.89460245404139e-06
mimicked,9.89460245404139e-06
vasculature,9.89460245404139e-06
disturbing,9.89460245404139e-06
20th,9.89460245404139e-06
transit-enhancing,9.89460245404139e-06
intraluminally,9.89460245404139e-06
pentobarbital-induced,9.89460245404139e-06
adequately,9.89460245404139e-06
beta-glucuronidase,9.89460245404139e-06
CYP450s,9.89460245404139e-06
cortisol,9.89460245404139e-06
1.13,9.89460245404139e-06
6.13,9.89460245404139e-06
80-85,9.89460245404139e-06
3-hydroxy-3-methylglutaryl,9.89460245404139e-06
1986,9.89460245404139e-06
approved,9.89460245404139e-06
cysteine,9.89460245404139e-06
Ontario,9.89460245404139e-06
alcoholics,9.89460245404139e-06
"16,16-dimethylprostaglandin",9.89460245404139e-06
Via,9.89460245404139e-06
5.5-fold,9.89460245404139e-06
s.c,9.89460245404139e-06
depletor,9.89460245404139e-06
SST,9.89460245404139e-06
Samples,9.89460245404139e-06
OBJECTIVES,9.89460245404139e-06
four-session,9.89460245404139e-06
within-subject,9.89460245404139e-06
ileocecal,9.89460245404139e-06
cecum,9.89460245404139e-06
resecting,9.89460245404139e-06
junction,9.89460245404139e-06
failing,9.89460245404139e-06
allergic,9.89460245404139e-06
HACA,9.89460245404139e-06
LST,9.89460245404139e-06
estimated,9.89460245404139e-06
outer,9.89460245404139e-06
ketones,9.89460245404139e-06
necrolysis,9.89460245404139e-06
epidermal,9.89460245404139e-06
consequently,9.89460245404139e-06
hydrogen-3,9.89460245404139e-06
density,9.89460245404139e-06
carrier,9.89460245404139e-06
titers,9.89460245404139e-06
PDA,9.89460245404139e-06
Shimadzu,9.89460245404139e-06
Here,9.89460245404139e-06
oxygen,9.89460245404139e-06
pesticides,9.89460245404139e-06
pyrethroid,9.89460245404139e-06
reactive,9.89460245404139e-06
antigen,9.89460245404139e-06
18-41,9.89460245404139e-06
toxicokinetic,9.89460245404139e-06
prostate-specific,9.89460245404139e-06
Stroke,9.89460245404139e-06
accordance,9.89460245404139e-06
internal,9.89460245404139e-06
86,9.89460245404139e-06
cardiology,9.89460245404139e-06
tolerability,9.89460245404139e-06
again,9.89460245404139e-06
bwt,9.89460245404139e-06
gentamycin/kg,9.89460245404139e-06
formulary,9.89460245404139e-06
indications,9.89460245404139e-06
n=43,9.89460245404139e-06
Glucose,9.89460245404139e-06
39.1,9.89460245404139e-06
SD,9.89460245404139e-06
micrograms/120,9.89460245404139e-06
violations,9.89460245404139e-06
MPTP-evoked,9.89460245404139e-06
Rates,9.89460245404139e-06
faecalis,9.89460245404139e-06
"3,7-dihydroxyflavone",9.89460245404139e-06
Enterococcus,9.89460245404139e-06
underlying,9.89460245404139e-06
acromegaly,9.89460245404139e-06
departments,9.89460245404139e-06
nephrosis,9.89460245404139e-06
applying,9.89460245404139e-06
N=17,9.89460245404139e-06
selected,9.89460245404139e-06
235.1,9.89460245404139e-06
palytoxin-induced,9.89460245404139e-06
Dual,9.89460245404139e-06
228.2,9.89460245404139e-06
30.8,9.89460245404139e-06
detector,9.89460245404139e-06
clotibrate,9.89460245404139e-06
Toxicologic,9.89460245404139e-06
Decreases,9.89460245404139e-06
appearance,9.89460245404139e-06
slows,9.89460245404139e-06
lome-floxacin,9.89460245404139e-06
Comet,9.89460245404139e-06
limb,9.89460245404139e-06
tension,9.89460245404139e-06
post-transplant,9.89460245404139e-06
conventional,9.89460245404139e-06
cream,9.89460245404139e-06
butenafine,9.89460245404139e-06
Cream,9.89460245404139e-06
hospital,9.89460245404139e-06
Ganoderma,9.89460245404139e-06
end-stage,9.89460245404139e-06
Improved,9.89460245404139e-06
BPH,9.89460245404139e-06
hy-per-parathyroidism,9.89460245404139e-06
gram-positive,9.89460245404139e-06
masking,9.89460245404139e-06
prohibited,9.89460245404139e-06
NINDS,9.89460245404139e-06
symptom,9.89460245404139e-06
t-PA,9.89460245404139e-06
Trial,9.89460245404139e-06
lucidum,9.89460245404139e-06
corresponded,9.89460245404139e-06
Rate,9.89460245404139e-06
93,9.89460245404139e-06
faecium,9.89460245404139e-06
Strip,9.89460245404139e-06
Enzymatic,9.89460245404139e-06
Fehlings,9.89460245404139e-06
Benedicts,9.89460245404139e-06
Clinitest,9.89460245404139e-06
radiotherapy,9.89460245404139e-06
Local,9.89460245404139e-06
Subsequent,9.89460245404139e-06
vancomycin-sensitive,9.89460245404139e-06
digital,9.89460245404139e-06
Evoked,9.89460245404139e-06
hind,9.89460245404139e-06
extensor,9.89460245404139e-06
i.v,9.89460245404139e-06
cardiopulmonary,9.89460245404139e-06
arrest,9.89460245404139e-06
toxicologic,9.89460245404139e-06
assessment,9.89460245404139e-06
exposure-response,9.89460245404139e-06
C57BL/6,9.89460245404139e-06
conscious,9.89460245404139e-06
strand,9.89460245404139e-06
MTT,9.89460245404139e-06
Palythoa,9.89460245404139e-06
mu,9.89460245404139e-06
facilitates,9.89460245404139e-06
goal-directed,9.89460245404139e-06
pointer,9.89460245404139e-06
C129H223N3O54,9.89460245404139e-06
COX-2,9.89460245404139e-06
representations,9.89460245404139e-06
neural,9.89460245404139e-06
deletion,9.89460245404139e-06
trace,9.89460245404139e-06
generalized,9.89460245404139e-06
left,9.89460245404139e-06
correlated,9.89460245404139e-06
metabolizes,9.89460245404139e-06
tolerant,9.89460245404139e-06
FDA,9.89460245404139e-06
respectto,9.89460245404139e-06
needing,9.89460245404139e-06
instead,9.89460245404139e-06
trimethyl,9.89460245404139e-06
help,9.89460245404139e-06
30-fold,9.89460245404139e-06
aminotransferases,9.89460245404139e-06
in-vivo,9.89460245404139e-06
chemosensitizer,9.89460245404139e-06
hematopoiesis,9.89460245404139e-06
restored,9.89460245404139e-06
Folinic,9.89460245404139e-06
differed,9.89460245404139e-06
.002,9.89460245404139e-06
manufacturer,9.89460245404139e-06
nonopioid,9.89460245404139e-06
estrogen-dependent,9.89460245404139e-06
investigates,9.89460245404139e-06
origins,9.89460245404139e-06
predict,9.89460245404139e-06
domestic,9.89460245404139e-06
uncontrolled,9.89460245404139e-06
Controlled,9.89460245404139e-06
monoclonal,9.89460245404139e-06
47,9.89460245404139e-06
marine,9.89460245404139e-06
vitamin-D-mediated,9.89460245404139e-06
emphasize,9.89460245404139e-06
signalling,9.89460245404139e-06
mg/l,9.89460245404139e-06
Lopinavir/Ritonavir,9.89460245404139e-06
incombination,9.89460245404139e-06
opioid-dependent,9.89460245404139e-06
N-demethylated,9.89460245404139e-06
treatpatients,9.89460245404139e-06
co-infected,9.89460245404139e-06
mayuse,9.89460245404139e-06
andusing,9.89460245404139e-06
d,9.89460245404139e-06
BW,9.89460245404139e-06
phasic,9.89460245404139e-06
17.0,9.89460245404139e-06
promising,9.89460245404139e-06
SHBG,9.89460245404139e-06
corticosteroid,9.89460245404139e-06
personality,9.89460245404139e-06
user,9.89460245404139e-06
seeking,9.89460245404139e-06
1602,9.89460245404139e-06
tobacco,9.89460245404139e-06
ataxia,9.89460245404139e-06
genotypes,9.89460245404139e-06
homozygous,9.89460245404139e-06
poultry,9.89460245404139e-06
8.0,9.89460245404139e-06
SC,9.89460245404139e-06
urticaria,9.89460245404139e-06
EC50,9.89460245404139e-06
.13,9.89460245404139e-06
.76,9.89460245404139e-06
patterns,9.89460245404139e-06
rendered,9.89460245404139e-06
stimulus,9.89460245404139e-06
heat,9.89460245404139e-06
epsilon,9.89460245404139e-06
angioedema,9.89460245404139e-06
sensation,9.89460245404139e-06
E-strain,9.89460245404139e-06
disrupts,9.89460245404139e-06
A-strain,9.89460245404139e-06
tuberculosa,9.89460245404139e-06
coelenterates,9.89460245404139e-06
translocation,9.89460245404139e-06
translocating,9.89460245404139e-06
oleate,9.89460245404139e-06
transferring,9.89460245404139e-06
phosphohydrolase,9.89460245404139e-06
aggressive,9.89460245404139e-06
impulsivity,9.89460245404139e-06
off,9.89460245404139e-06
wear,9.89460245404139e-06
cleared,9.89460245404139e-06
Ambulatory,9.89460245404139e-06
compatible,9.89460245404139e-06
Supplements/Antacids,9.89460245404139e-06
accounts,9.89460245404139e-06
lasma,9.89460245404139e-06
esmolol,9.89460245404139e-06
18-27,9.89460245404139e-06
wshow,9.89460245404139e-06
Cyclosporine,9.89460245404139e-06
ANOVA,9.89460245404139e-06
context,9.89460245404139e-06
.82,9.89460245404139e-06
temporal,9.89460245404139e-06
Aerosol,9.89460245404139e-06
singly,9.89460245404139e-06
0.1-0.8,9.89460245404139e-06
degrading,9.89460245404139e-06
adeno-associated,9.89460245404139e-06
effected,9.89460245404139e-06
expanders,9.89460245404139e-06
succinylcholine-induced,9.89460245404139e-06
retina,9.89460245404139e-06
layer,9.89460245404139e-06
low-molecular,9.89460245404139e-06
virus-2,9.89460245404139e-06
Diethyl,9.89460245404139e-06
RBC,9.89460245404139e-06
sensitization,9.89460245404139e-06
chemically,9.89460245404139e-06
7.0,9.89460245404139e-06
ROS,9.89460245404139e-06
Zn-Sepharose,9.89460245404139e-06
vice,9.89460245404139e-06
molecules,9.89460245404139e-06
-diethyl,9.89460245404139e-06
labelling,9.89460245404139e-06
b,9.89460245404139e-06
NO,9.89460245404139e-06
characterization,9.89460245404139e-06
dried,9.89460245404139e-06
impinger,9.89460245404139e-06
cascade,9.89460245404139e-06
impactor,9.89460245404139e-06
equilibrium,9.89460245404139e-06
versa,9.89460245404139e-06
Modification,9.89460245404139e-06
Specific,9.89460245404139e-06
EIA,9.89460245404139e-06
in-vitro,9.89460245404139e-06
2C8,9.89460245404139e-06
2E1,9.89460245404139e-06
0.012,9.89460245404139e-06
0.1-0.4,9.89460245404139e-06
Vasodilator,9.89460245404139e-06
nerves,9.89460245404139e-06
Having,9.89460245404139e-06
renin-angiotensin-aldosterone,9.89460245404139e-06
494,9.89460245404139e-06
Sympathetic,9.89460245404139e-06
copper-reduction,9.89460245404139e-06
piperacillin/tazobactam,9.89460245404139e-06
Platelia,9.89460245404139e-06
Aspergillus,9.89460245404139e-06
Bio-Rad,9.89460245404139e-06
superimposed,9.89460245404139e-06
concentration-responses,9.89460245404139e-06
smooth,9.89460245404139e-06
potency,9.89460245404139e-06
ration,9.89460245404139e-06
3:1,9.89460245404139e-06
activate,9.89460245404139e-06
treatment-emergent,9.89460245404139e-06
sub-,9.89460245404139e-06
time-dependent,9.89460245404139e-06
XI,9.89460245404139e-06
APTT,9.89460245404139e-06
Nonclinical,9.89460245404139e-06
VIII,9.89460245404139e-06
one-stage,9.89460245404139e-06
IX,9.89460245404139e-06
solubility,9.89460245404139e-06
solubilization,9.89460245404139e-06
size,9.89460245404139e-06
Alter,9.89460245404139e-06
Excretion,9.89460245404139e-06
noradrenaline-precontracted,9.89460245404139e-06
independent,9.89460245404139e-06
denudation,9.89460245404139e-06
endothelium,9.89460245404139e-06
Disintegrating,9.89460245404139e-06
Orally,9.89460245404139e-06
drug-metab-olizing,9.89460245404139e-06
generated,9.89460245404139e-06
conclusions,9.89460245404139e-06
sample,9.89460245404139e-06
dodecyl,9.89460245404139e-06
